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Abstract 
There is a need for vectors that, with high efficiency, can deliver small and 
macromolecular therapeutics into cells and defined intracellular locations.  
Extracellular vesicles (EVs), including exosomes, are naturally derived nanovesicles 
generated in and released by numerous cell types. As extracellular entities they 
have the capacity to interact with neighbouring cells and distant tissues and affect 
physiological processes as well as being implicated in numerous diseases including 
tumorigenesis and neurodegeneration. They are also under intense investigation as 
delivery vectors for biotherapeutics. The ways in which EVs interact with recipient 
cells to influence cell physiology and deliver a macromolecular payload are at the 
early stages of exploration, but are believed to involve endocytosis. For endocytic 
characterisation a significant challenge is having the ability to label exosomes 
directly or indirectly with fluorescent probes to qualitatively and quantitatively 
monitor exosome-cell interaction and uptake without compromising functionality.  
In this thesis, techniques to inhibit different pathways of endocytosis were 
investigated and further developed order to establish high content in vitro 
platforms to study the uptake mechanisms of potential drug delivery vectors 
focusing here exosomes as a model system. These techniques involved siRNA 
depletion of prospective endocytic proteins and chemical inhibitors of endocytosis. 
A simple and rapid method for fluorescent labelling purified Du145 exosomes 
covalently was for the first time utilised to allow comprehensive analysis of the 
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cellular uptake of differentiation competent prostate cancer derived EVs in live cells 
using confocal microscopy.   
For endocytosis analyses, depletion of key endocytic proteins and the use of 
chemical inhibitors (Dynasore, EIPA, Rottlerin and IPA-3) indicated that a fluid-
phase endocytosis and/or macropinocytosis-like mechanism dependent on 
dynamin were involved in exosome internalisation. Over a period of six hours 
exosomes were observed to increasingly co-localise with lysosomes, indicating a 
possible intracellular terminus with significance with respects to utilisation of 
exosomes as drug delivery vectors.  Overall this labelling method, when used in 
conjunction with established models of endocytic inhibition, provides new 
opportunities for analysing the cellular dynamics of exosomes and other 
extracellular vesicles as biological entities affecting cell and whole body physiology 
as well as investigating their potential as drug delivery vectors.  The work also 
further enhances our ability to study multiple endocytic pathways as potential 
routes for entry of other drug delivery vectors to gain important information 
towards the design of more efficient formulations targeting a number of diseases. 
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1 Introduction 
The intracellular environment is regarded by many to be a vault full of therapeutic 
targets for disease intervention. Hundreds of proteins residing within the cell could be 
potential targets for entities defined as macromolecular therapeutics; these include 
proteins, peptides (Cleal et al., 2013; Ye et al., 2016) and nucleotides (Khvorova and 
Watts, 2017). Unfortunately, there are a number of major obstacles that need to be 
overcome if these therapeutics are to reach their intracellular targets and be of clinical 
value (Agrahari et al., 2016). One of these is effective crossing of biological barriers 
that stand between a therapeutic and its target including the plasma membrane and 
the endolysosomal network (Cerrato et al., 2017; Cleal et al., 2013; Dowdy, 2017; 
Saffari et al., 2016; Yang et al., 2017).  
1.1 Macromolecular Therapeutics 
The functional outcome of therapeutic macromolecules that act within the cell relies 
upon their protection from extracellular degradation once administered inside the 
body. Following this, they must cross the plasma membrane and then reach their 
intracellular destination without degradation at the lysosome that contained 
hydrolases that will degrade biotherapeutics described above. The fate of internalised 
cargo depends upon cell type and physiological context within the endocytosis remit: 
endosomal escape to the cytosol, lysosomal delivery, recycling back to the plasma 
membrane and cellular escape via exosomes are common journeys taken by 
endocytosed materials. Therapeutic efficiency of endocytosed macromolecules require 
escape from the endosomal sorting machinery, or remain in the lysosome yet avoid 
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degradation (Cleal et al., 2013). Functional outcome of therapeutic molecules does 
indeed depend on several other processes. For instance, the use of monoclonal 
antibodies often results in the instigation of a natural immunoregulatory response; the 
ability to circumvent the activation of an immune response is therefore essential (Tyagi 
and Santos, 2018). Metabolic stability is also necessary for a functional outcome, 
whereby clearance of the therapeutic from the bloodstream is reduced and an 
extended half-life are necessary in order to improve its bioavailability (Masimirembwa 
et al., 2003). 
 Drug delivery systems need to surpass a number of obstacles in order to transfer a 
macromolecule efficiently to its therapeutic target, where it can then perform 
processes such as inhibition or silencing of aberrant proteins or genes at the functional 
and expression level. Before identifying potential vectors, the biochemical nature of 
one of these obstacles, the plasma membrane, must be considered. Many therapeutic 
macromolecules, such as nucleic acids, are hydrophilic, and this polarity together with 
their large size negates the possibility that they can diffuse through the membrane 
directly into the cytosol. A number of studies have now shown that by conjugating or 
encapsulating a biotherapeutic with a variety of different vector types, they are able to 
cross this barrier via endocytosis or direct translocation (Kristensen et al., 2016; 
Veldhoen et al., 2008; Zylberberg and Matosevic, 2016). Vectors can be developed 
from a variety of sources. Those of viral origin, for instance, have previously provided 
efficient cell specific gene delivery; they are acknowledged however as highly 
immunogenic, meaning efforts to avoid activation of the immune response are 
required (Manjila et al., 2013). Viral vectors with low toxicity in vitro exist, such as the 
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adeno-associated virus compounds, which demonstrate promise as carriers for DNA-
delivery systems (Skubis-Zegadlo et al., 2013). However, in vivo studies and clinical 
trials have demonstrated the high immunogenicity of these compounds, exemplifying 
a major obstacle in the application of viral based delivery systems (Mingozzi and High, 
2011; Mingozzi and High, 2013; Zaiss and Muruve, 2005). Unwanted integration of viral 
DNA into the host genome has also been described (Thomas et al., 2003).  
1.2 The Plasma Membrane: A Biological Barrier to Macromolecular Therapeutics 
The plasma membrane is a dynamic barrier that lies between the internal and external 
milieu of a eukaryotic cell and is composed of phospholipids, sphingolipids, 
cholesterol, carbohydrates and membrane proteins and glycoproteins such as heparin 
sulphate proteoglycans (HSPGs) (Doherty and McMahon, 2009). The equilibrium of 
small molecules, such as ions and hormones, and larger particles, such as cell debris 
and pathogens, across the interior and exterior of the cell is tightly regulated by this 
structure. For these reasons, the membrane is paramount for homeostatic control of 
not just the individual cell, but of the whole cellular population and the tissue to which 
it belongs. 
A phospholipid bilayer provides the foundation of the plasma membrane, creating a 
barrier between the aqueous regions either side. The hydrophobic head of each 
phospholipid lies in the inner layer, meaning that water-soluble particles, a group that 
includes many biological molecules, are incapable of passing the membrane. The 
flexibility of these hydrophobic fatty acid tails also provides a structural fluidity to the 
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membrane, exemplified by the plasma membrane fluid mosaic model (Cooper, 2000). 
Cholesterol is also a key part in the dynamics of fluidity via its interaction with the fatty 
acid tails, but also through its association with sphingolipids in distinct regions of the 
membrane commonly referred to as ‘lipid-rafts’ (Frank et al., 2006). The fluid mosaic 
model also describes the dynamic lateral movement of membrane proteins. 
Functionally, the membrane relies upon these proteins, which include transmembrane 
receptors, cytoskeletal components, ion channels and adhesion proteins, amongst 
numerous others. With regards to endocytosis however several proteins are key. The 
essential interaction between the different classes of membrane constituents is 
exemplified by glycosylphosphatidylinositol (GPI)-linked proteins. The C-terminus of 
these transmembrane proteins associates with a glycolipid anchor termed a GPI at the 
endoplasmic reticulum, and following transport to the plasma membrane are exposed 
either within or outside of the cell (Alberts et al., 2008). GPI-linked proteins are 
generally organised within the membrane as rafts, but also have extensive 
physiological roles outside of endocytosis such as acting as adhesion molecules, within 
immune regulation and as receptors (Kinoshita et al., 2008). The GPI-linked proteins 
CD59 and CD55, for instance are involved in the regulation of the complement cascade 
(Ruiz-Argüelles and Llorente, 2007) and T-cadherin is a significant regulator of 
vascularisation (Parker-Duffen et al., 2013). 
An endocytic event, whereby an external entity is internalised by encapsulation in a 
plasma-membrane derived vesicle, relies upon the interaction of several membrane 
components. Different components and cargo molecules result in diverse interactions 
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at this interface that ultimately necessitate distinct pathways of endocytosis to 
operate with a variety of physiological functions (Doherty and McMahon, 2009).  
1.3 Mechanisms of Endocytosis  
One natural mechanism allowing extracellular molecules can gain access to the 
intracellular region of the cell is termed endocytosis. This phenomenon involves the 
envelopment of materials from the exterior region of the cell by the plasma 
membrane, eventually forming an internal structure consisting of membrane-bound 
cargo and a portion of the detached membrane, otherwise termed a vesicle (Doherty 
and McMahon, 2009; Robinson, 2015). The constituents of these vesicles vary 
depending on the endocytic pathway utilised and one termed macropinocytosis 
involves an initial outward projection of the membrane before engulfment is initiated. 
Endocytosis is extremely important for both the individual cell and for communication 
with adjacent cells and the surrounding extracellular environment. A number of 
endocytic mechanisms/pathways, resulting from the interactions between different 
membrane and cytosolic components, are performed by eukaryotic cells. These are 
generally divided into phagocytosis and pinocytosis, the former being implicated in the 
uptake of larger molecules, pathogens and cell debris as performed by specialised cell 
types, such as dendritic cells and macrophages (Aderem and Underhill, 1999). This 
mechanism is responsible for pathogen, microbial, and apoptotic cell clearance 
(Maderna and Godson, 2003; Underhill and Ozinsky, 2002), although some phagocytic 
components are also involved in autophagy (Mehta et al., 2014; Romao and Munz, 
2014). Pinocytic mechanisms, of which there may be several are, aside from clathrin 
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mediated endocytosis (CME), more difficult to characterise due to the lack of 
information regarding their requirements for specific proteins and unique endocytic 
probes to study their function.  Different physiological and environmental contexts 
also make it difficult to characterise the different pathways, in addition to differing 
endocytic profiles between cell-types. A high level of the molecular mechanisms 
governing CME has allowed greater exploration of its role in physiology. The less well 
defined mechanisms that are deemed to exist independent of clathrin, have been 
show to require regulation by the proteins: caveolin-1, flotillin-1, Arf-6, GRAF-1 
(Bastiani and Parton, 2010; Hansen and Nichols, 2009), and more recently endophilin-
A2 (Boucrot et al., 2015; Renard et al., 2015). All of these pathways and examples of 
the methods used to study them in this thesis are presented in Figure 1.1, and will be 
discussed later in this Chapter.  
The capacity of these pathways to act as portals for various drug delivery vectors 
requires further investigation, as many of the context dependent mechanisms involved 
still require characterisation. Additionally the fate of the drug delivery vector and its 
therapeutic cargo within the cell may also be dependent on the uptake mechanism. 
For these reasons, the established mechanisms and physiological functions of each 
pathway, including their potential as portals for drug delivery systems, will be 
discussed in this introduction. Methods for exploring the molecular mechanisms 
involved in each pathway will also be discussed, particularly through the use of high 
content technologies. The hunt for specific inhibitory methods and cargoes remains a 
principle challenge in the characterisation of the different endocytic pathways.  
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1.3.1 Clathrin Mediated Endocytosis (CME) 
Clathrin mediated endocytosis is by far the most well defined and widely studied 
endocytic system, and can be performed by all known eukaryotic cells to date, with the 
possible exception of red blood cells (McMahon and Boucrot, 2011). A variety of 
extracellular materials can be internalised at membrane localised clathrin coated pits 
(CCPs), where pinching into clathrin coated vesicles (CCVs) occurs. The molecular 
events involved are part of a complex regulatory network and was in part initially 
determined through the use of Saccharomyces cerevisiae as a model organism 
(Boettner et al., 2012; Myers and Payne, 2013). The physiological flexibility of CME is 
demonstrated by its ability to internalise a vast number of molecules including the iron 
Dynasore 
Fig 1.1 Key Endocytic Mechanisms and methods of endocytic inhibition utilised 
in this thesis  Key examples of entities that have been shown to gain 
intracellular access via these routes are presented. Courtesy of Dr Edd Sayers.
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transporter, transferrin. The uptake of this protein via binding to the transferrin 
receptor has been extensively studied and involves a variety of different proteins 
(Collinet et al., 2010) that will be further discussed in this chapter. The actions of 
clathrin and the other proteins involved in CME are vital for physiological regulation. 
The integrity of the plasma membrane also relies upon this process, and CME is 
operational in signal transduction, nutrient selection and uptake, in addition to the 
maintenance of cellular and tissue homeostasis (Godlee and Kaksonen, 2013; 
McMahon and Boucrot, 2011).  
The structure of the clathrin molecule, composed of the clathrin heavy chain (CHC) 
isoforms and clathrin light chain (CLC) has been studied extensively, and is responsible 
for CCP formation and receptor endocytosis. Endosomal sorting and recycling are also 
dependant on clathrin, demonstrating a cell-wide role for clathrin in processes 
regulating cellular homeostasis (Brodsky, 2012). Clathrin also operates at the trans-
Golgi network (TGN), and together with adaptor complexes (AP1/3) regulate secretion 
into the endocytic pathway and to lysosomes (cathepsins) (Shiba et al., 2013) or to the 
plasma membrane for secreted proteins (Ponnambalam and Baldwin, 2003). Effective 
endocytosis however begins with the recruitment of specific proteins such those 
forming the AP2 adaptor complex to the plasma membrane, this initiates formation of 
the clathrin triskelia and formation of the CCP (Takei and Haucke, 2001). Early CCP 
budding has been shown to rely on the activities of F-BAR domain containing proteins 
(FCHo proteins), resulting in recruitment of the scaffold proteins, intersectin and 
eps15, to the site (Henne et al., 2010). Investigations in zebrafish have suggested a 
more cargo-specific relationship between FCHo proteins and CCP formation, 
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exemplifying the complexity of the relationship between specific adaptor proteins and 
different cargoes in CME (Umasankar et al., 2012). Otherwise characterised as clathrin 
pit nucleation, this phenomenon allows CCP formation to occur, the processes of 
which illustrated in Figure 1.2.  
The core AP2 adaptor provides the essential linkage between clathrin and plasma 
membrane regions rich in phosphatidylinositol-4,5-bisphosphates (PIP2). AP2 is 
characterised as a 200kDa core, composed of four subunits of varying size and 
function: the α and β2 trunks, the µ2 subunit, and the σ2 unit (Collins et al., 2002).  
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Plasma membrane receptors 
Fig 1.2 Mechanism of Clathrin-Mediated Endocytosis CPP formation begins with 
recruitment of accessory proteins, before invagination and dynamin recruitment. 
Following membrane curvature, dynamin mediated scission removes the budding 
structure from the plasma membrane, resulting in an intracellular clathrin coated 
vesicle. This coat is removed and the resulting vesicle merges with the early 
endosome. Adapted from (Doherty and McMahon, 2009).     
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Via cargo, clathrin, PIP2 and further accessory protein binding, AP2 regulates cargo 
anchoring to the CCP and, following scission, clathrin coated vesicle (CCV) formation 
(Jackson et al., 2010). Scission is carried out by the 100kDa GTPase dynamin. Helical 
dynamin arrays result in the formation of a dynamin collar around the neck of the CCP, 
facilitating GTP hydrolysis and removal of the pit complex and its cargo from the 
plasma membrane.  
Characterisation of these events was performed using dynamin mutants deficient in 
vital biochemical abilities such as GTPase binding (S45N mutant) (Chappie and Dyda, 
2013; Liu et al., 2013). The implication of dynamin II in CCP scission is well established, 
though its involvement at early stages of clathrin lattice recruitment and importance in 
CCP stabilisation has also been demonstrated, suggesting both mechanical and 
regulatory roles (Mettlen et al., 2009). Subsequent detachment of the scission 
machinery, adaptor proteins and clathrin from the internalised vesicle primarily 
involves the chaperone Hsc70 (70kDa heat-shock cognate protein) and auxilin, where 
an ATP-dependent interaction lifts the clathrin lattice to allow recruitment of further 
chaperones for further vesicle trafficking (Xing et al., 2010; Young et al., 2013). These 
proteins demonstrate a role additional to that of their involvement in clathrin 
disassembly, further exemplifying the duplicate roles of the numerous proteins 
involved in CME regulation. Clathrin pit invagination is also reliant on the hsc70-auxilin 
relationship, in addition to clathrin recycling back to the plasma membrane (Eisenberg 
and Greene, 2007). 
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Bitsikas et al. explored, in HeLa cells, the importance of different pathways in 
endocytic flux, concluding that CME is solely responsible for endocytic entry in this cell 
line (Bitsikas et al., 2014). This contentious observation needs further proof but raised 
interesting questions regarding thousands of papers focusing on clathrin independent 
endocytosis, in HeLa cells and others, within the context of cell biology and drug 
delivery. 
1.3.2 Caveolin Mediated Endocytosis 
Internalisation of structures called caveolae at membrane regions of high sphingolipid 
and cholesterol density, termed lipid rafts, occurs during Caveolin-1 (Cav1) mediated 
endocytosis (Cheng and Nichols, 2016; Lajoie and Nabi, 2007; Nichols, 2003). Definition 
of the mechanistic processes involved in this pathway are less clear than those defined 
in CME, yet knowledge of the pathway has escalated in recent years mainly due to a 
greater range of molecular research technologies. The involvement of caveolae is not 
restricted to endocytosis, and comparable to CME, is implicated in exocytosis, 
transcytosis and signal transduction.  
Caveolae formation relies on the small 20kDa caveolin proteins, caveolin-1, -2 and -3, 
which have variable expression patterns based on cell and tissue type (Parton and 
Simons, 2007; Williams and Lisanti, 2004). Caveolin-1 and -2 are expressed in most 
non-skeletal muscle cell types, whereas caveolin-3 resides solely in striated and cardiac 
muscle tissue (Bastiani and Parton, 2010). Cav1 is most commonly investigated for its 
involvement in caveolae formation and internalisation at lipid rafts, where the protein 
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interacts with up to two cholesterol molecules (Murata et al., 1995) and anchors itself 
to the membrane via a hydrophobic loop (Kiss and Botos, 2009). Cav1 derived vesicles 
are primarily composed of caveolin, cavins and cholesterol. The interaction between 
these proteins at lipid rafts is performed by up to 200 Cav1 molecules per caveolae, 
creating structures of approximately 60-80 nm in diameter (Parton and del Pozo, 
2013). Caveolae are lacking in cells that do not express Cav1 protein, such as 
leukocytes (Doherty and McMahon, 2009). Scission of the caveolae derived vesicle is 
also reliant upon the GTPase activity of dynamin (Henley et al., 1998; Oh et al., 2012) 
again demonstrating one of the numerous commonalities between mechanisms in the 
endocytic regulatory network.  
Much of the information available regarding the internalisation and trafficking capacity 
of caveolae has been provided through exploration of possible caveolin-dependant 
endocytic probes, such as cholera toxin B (CTxB), GPI-linked proteins, Simian-Virus 40 
(SV40) and albumin (Nichols, 2002). More recently, evidence of caveolae dependent 
internalisation of oxidised low density lipoprotein in endothelial cells has been 
described (Sun et al., 2010). The internalisation mechanism of the glycosphingolipid 
lactosylceramide (LacCer) is also demonstrated to be caveolin related, but this uptake 
displays a certain level of context dependence, whereby uptake mechanism used is 
dependent upon Cav1 expression levels (Singh et al., 2003). Here, caveolin dependent 
uptake of CTxB was also shown to be heavily context dependent. This work went on to 
further describe how caveolin dependent LacCer uptake results in its merging with the 
CME early endosome (Sharma et al., 2003). 
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SV40 internalisation has suggested one possible trafficking route of caveolae derived 
vesicles. This virus most commonly localises at multivesicular bodies of neutral pH, 
which are locations distinct from the endosomal transport of CME markers such as 
transferrin. Termed caveosomes, these distinct vesicles do not travel via the lysosomal 
system, providing the virus with an escape from intracellular degradation (Pelkmans et 
al., 2001). However, subsequent studies have indicated that internalisation of this virus 
is cholesterol and lipid-raft dependant, yet independent of clathrin, caveolin and the 
scission events controlled by dynamin II. The pH neutral vesicles positive for the virus 
were found to be devoid of caveolin (Damm et al., 2005), which could either suggest 
an entirely different uptake route or removal of the protein from these vesicles during 
downstream trafficking. Cav1 positive caveosomes have been demonstrated to traffic 
to the late endosomal compartments, suggesting that cargo are trafficked to the 
lysosome (Hayer et al., 2010; Parton and Howes, 2010). The lack of pathway specificity 
of distinct cargo is exemplified here.  
Notably, the endocytic functions of Cav1 are not isolated to caveolae formation and 
internalisation. For instance, observation of greater apoptotic cell accumulation in 
Cav1 knockout mice when compared with wildtype indicates a lack of clearance by 
phagocytic macrophages, suggesting the involvement of this protein in phagocytosis (Li 
et al., 2005). Cav1 is also has a regulatory role in other cellular processes such as 
cholesterol homeostasis. Via interaction with the ATP binding cassette transporter, G1, 
Cav1 has been demonstrated to be a prime regulatory element in cholesterol efflux, 
particularly in macrophages (Frank et al., 2006; Gu et al., 2014). Findings such as these 
have identified Cav1 as a possible target for preventative treatment against diseases 
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aberrant in cholesterol homeostasis, atherosclerosis and cardiovascular disease (Frank 
et al., 2007) and also demonstrate the existence of diverse regulatory and mechanical 
roles of this protein. 
1.3.3 Clathrin-Independent Carriers with GPI-linked proteins enriched in early 
endosomal compartments (CLIC-GEEC) Endocytosis 
Other clathrin-independent pathways with distinct regulatory mechanisms have been 
proposed. Interest in these pathways initially arose due to the ability of cells depleted 
of clathrin and Cav1 dependant events to internalise cargoes originally thought to gain 
cellular access only by these mechanisms. CLIC-GEEC endocytosis is one such 
mechanism, determined by the involvement of clathrin independent carriers (CLIC) 
with GPI-linked proteins enriched in early endosomal compartments (GEEC). In regions 
of potential endocytosis, GPI-linked proteins within the plasma membrane are more 
enriched than in the comparable regions of CCPs and caveolae, and result in tubular, 
rather than pit-shaped invagination. Suggested cargoes include a number of GPI-linked 
proteins, such as the alpha subunit of the folate receptor (FRα). Previous studies 
indicate that internalisation of GPI-linked proteins requires cross-linked Cav1 
(Fujimoto, 1996); however, during caveolae endocytosis cross-linking is not always 
evident, suggesting that a large amount of FRα gains intracellular access by a different 
route. Investigations utilising the detergent-insoluble nature of caveolae indicate that 
a vast number of FRα subunits can circumvent caveolae in order to internalise 
(Rijnboutt et al., 1996).  
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During and following internalisation, the fate of cargo via CLIC-GEEC may be 
dependent on the actin cytoskeleton (Doherty and McMahon, 2009). The actin-
associated small RhoGTPase Cdc42 was shown to be directed to GEECs on the plasma 
membrane via N-terminal BAR domains, where it co-localised with the protein GRAF1 
(GTPase regulator associated with focal adhesion kinase-1) (Lundmark et al., 2008). 
GRAF1 has therefore been suggested as a chief regulatory factor of the CLIC/GEEC 
pathway, meaning that this pathway is also referred to as the GRAF1-dependent 
pathway. Following GRAF1 depletion, CLIC domain formation is prevented and cell 
migration was also affected, demonstrating the association between cytoskeletal 
dynamics, the CLIC/GEECs and GRAF1 (Doherty et al., 2011; Doherty and Lundmark, 
2009). 
1.3.4 Flotillin-Dependant Endocytosis 
Uptake mechanisms which demonstrate dependence upon Flotillin-1 and flotillin-2 
have also been described. Endocytosis of anti-CD59, an antibody involved in 
complement activation, has been linked to this pathway (Doherty and McMahon, 
2009; Sugita and Masuho, 1995). In hepatocytes the process of GPI-linked protein 
uptake demonstrates dependency on Flot2, a finding identified by depleting this 
protein via transfection with an anti Flot2 siRNA (Ait-Slimane et al., 2009). Flot1 
dependency during prion protein endocytosis has also been demonstrated in 
neuroblastoma cells (Ren et al., 2013).  
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1.3.5 Endophilin-A2 and Arf6 dependent endocytosis 
The discovery of an uncharacterised endocytic pathway has recently been described. 
The BAR-domain containing protein, EndophilinA2, was found in endocytic structures 
positive for the supposed activators of this pathway, Shiga-toxin and Cholera-toxin. 
Furthermore, these membrane tubulations were not associated with CME associated 
markers, yet required dynamin for scission (Renard et al., 2015). The observations 
made here are further supported by a lack of established endocytic cargoes, such as 
transferrin, within these structures yet clathrin-independent cargoes, such as the IL-2R, 
were internalised via this route. This pathway has subsequently been given the name: 
fast-endophilin-mediated endocytosis (FEME) (Boucrot et al., 2015). 
ADP-ribosylation factor 6 (Arf6) is a GTPase binding protein that has demonstrated 
involvement in its own regulatory pathway (Radhakrishna and Donaldson, 1997), 
shown to be responsible for the uptake of growth factor receptors (Pellon-Cardenas et 
al., 2013) and in the uptake of fibrinogen (Rondina and Weyrich, 2016). It has also 
been linked with the regulation of other pathways including macropinocytosis (Tang et 
al., 2015) and via its activation by dynamin II in CME (Okada et al., 2015).   
1.3.6 Fluid-Phase Endocytosis vs Macropinocytosis 
Fluid and associated small molecules will conceivably enter the cytoplasm of cells via 
all described endocytic pathways and it still largely remains to be determined whether 
there exists a constitutive pinocytosis pathway that only function to internalise fluid. 
Larger molecules of up to 1 µm in size and much higher volumes of fluid can enter via a 
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phenomenon that is absolutely reliant on the dynamics of actin. This is 
macropinocytosis and although described as separate processes, definitive distinction 
of the molecular mechanisms dividing fluid-phase endocytosis and macropinocytosis 
remain elusive. A reliance on actin for the latter may be one deciding factor together 
with the fact that macropinocytosis is initiated by outward projection of the plasma 
membrane in the form of lamellapodia, circular ruffles or blebs. For macropinocytosis 
to manifest itself prominently cells often need to be serum starved and activated by 
growth factors such as EGF or PDGF (Kerr and Teasdale, 2009). The extent to which 
constitutive macropinocytosis occurs in any cell type remains to be determined. 
As noted, extensive folding and protrusion of the plasma membrane characterise 
macropinocytosis, resulting in cargo and fluid engulfment following fusion of distinct 
membrane protrusions (Figure 1.3). These widespread membrane modifications are 
dependent upon cytoskeletal activity, and particularly that of actin. Formation of the 
intracellular macropinosome has two stages that are dependent upon meticulous 
organisation of the actin cytoskeleton. The process begins with the formation of 
membrane ruffles, which then fuse at their distal margins to create circular ruffles. A 
second closure of the ruffles forms the macropinocytic cup, which is pinched from the 
membrane to form a macropinosome (Buckley and King, 2017; Swanson, 2008). Any 
extracellular fluids or proteins caught within these ruffles are internalised, creating an 
endocytic pathway with relatively little cargo specificity. Nevertheless, any membrane 
receptor bound ligands present at the region of membrane ruffling, and the receptors 
themselves will be internalised. This process shares many characteristics with the 
mechanism of phagosome formation (Lim and Gleeson, 2011).  
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Macropinocytosis results in much larger uncoated vesicles than other pinocytic 
pathways which result from growth factor stimulation. Activation of growth factor 
receptors results in a cell-wide increase in cytoskeletal activity, rather than the 
endocytic organisation at specific membrane regions seen in other pinocytic 
mechanisms (Kerr and Teasdale, 2009). 
 Following scission of the macropinocytic cup from the membrane, suggested to occur 
via a brefeldin A ADP-ribosylated substrate (CtBP1/BARS) dependant mechanism 
(Liberali et al., 2008; Valente et al., 2013),  the recruitment of pinocytic regulators was 
shown to occur (Feliciano et al., 2011). These include the early endocytic marker Rab5 
and CtBP1/BARS, which is responsible for several cytoplasmic fission events including 
trans-Golgi network (TGN) vesicle scission and macropinosome excision from the 
plasma membrane (Valente et al., 2013). Although comparable with phagocytosis, 
EGF 
EGF 
Fig 1.3 Macropinocytic Cup Formation and Closure Growth factor stimulation 
induces circular ruffle formation and closure followed by cup closure viewed from 
above and laterally. Adapted from (Swanson, 2008).    
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macropinocytosis can be carried out by cells that are not professional phagocytes. Cell 
lines such as A431s that express high levels of epidermal growth factor receptor (EGFR) 
demonstrate an increased level of cell-wide plasma membrane ruffling and 
macropinosome formation when subjected to epidermal growth factor (EGF) 
stimulation (Araki et al., 2007; Araki et al., 2006). As previously stated, actin-
dependant membrane ruffling is recognised as a characteristic feature of 
macropinocytosis. Macropinocytosis in response to growth factor stimulation is often 
measured as an increase in the uptake of the fluid phase endocytic probe dextran (Al 
Soraj et al., 2012; Haigler et al., 1979).  
A number of major actin regulatory proteins have demonstrated involvement in 
macropinocytosis. Primary investigation indicated the importance of phosphoinositide 
3-kinase (PI3K) and phospholipase C (PLC) interaction, which are proteins involved in 
actin remodelling, actin polymerisation, and focal contact turnover during chemokine 
directed migration (Kolsch et al., 2008; Kortholt et al., 2007). These studies were 
performed in Dictyostelium, a model organism in the study of phagocytosis and 
macropinocytosis, thereby indicating a role for PI3K, PLC and related factors in actin 
dynamics during these processes. Actin reorganisation involved in motility of classically 
phagocytic leukocytes is also reliant on these proteins, particularly with regards to 
RhoGTPases such as Rac1 (Alon and Shulman, 2011). It must be noted however that 
chemotactic events are distinct from macropinocytic events. The non-phagocytic cell 
line, A431, with high EGFR expression, is recognised for high levels of macropinosome 
formation and membrane ruffling following EGF stimulation, indicating the importance 
of PI3K and its binding partners in this phenomenon. Ruffling in regions of 
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macropinocytic cup formation is accompanied by phosphatidylinositol 4,5-
bisphosphate (PIP2) accumulation and a simultaneous surge in  phosphatidylinositol 
(3,4,5)-trisphosphate (PIP3) before closure and scission (Araki et al., 2007). 
Compositional organisation of these processes suggests PI3K-dependance, establishing 
a possible role in the macropinocytic events of A431 cells. Fusion of macropinosomes 
with early endocytic compartments, as indicated by co-localisation with early 
endosomal antigen 1 (EEA1) in A431 cells, is reliant on PI3K (Araki et al., 2006), 
indicating the further involvement of this kinase in downstream trafficking events. 
These observations provide both evidence for the importance of PI3K in the events 
following internalisation, and indicate association with the early endocytic pathway 
where trafficking of the macropinosome joins vesicles from other pinocytic pathways.  
P21-activated kinase 1 (PAK1), a downstream serine-threonine kinase targeted by the 
small RhoGTPase actin regulators, has been defined as a chief regulator of 
macropinocytic events (Dharmawardhane et al., 2000; Liberali et al., 2008; Redelman-
Sidi et al., 2013). Regions of ruffling are often accompanied by membrane localised 
PAK1, providing a binding platform for other actin regulators such as Cdc42, Rac1 and 
RhoA. The role of this kinase was initially delineated through the use of PAK1 mutants 
in a study that demonstrated its role in both macropinocytosis, and during cellular 
motility through its involvement in actin dynamics (Dharmawardhane et al., 2000). 
PAK1 has been shown to coordinate a variety of cellular processes through its 
upstream effectors Cdc42 and Rac1, particularly at the cell periphery (Delorme-Walker 
et al., 2011). These aspects of cytoskeletal regulation further support the importance 
of PAK1 in the regulation of the actin dynamics associated with macropinocytosis. 
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Increased levels of the PAK1 effector, Rac1, synchronise with regions of PIP3 
accumulation at late ruffling events, activating closure of the macropinocytic cup 
following deactivation in macrophages (Fujii et al., 2013; Yoshida et al., 2009). The 
events following ruffling and downstream macropinosome formation are further 
indicated as Rac-dependent in dendritic cells (West et al., 2000). It must be noted here 
that constitutive events are most likely distinct from growth factor stimulated events. 
Although linked to membrane ruffling through its association with Rac1 in leukocytes 
(Cox et al., 1997), and constitutive endocytosis for antigen presentation in dendritic 
cells (Garrett et al., 2000) the role of Cdc42 in growth factor stimulated 
macropinocytosis requires further delineation. In the absence of Rac1, Cdc42 and 
RhoG (another small GTPase) fibroblasts were unable to initiate actin lamellipodia 
(extensions that incorporate ruffling) at the plasma membrane. The action of these 
small GTPases however can activate filopodia independent of Rac1, perhaps through 
interaction with other signalling molecules (Steffen et al., 2013). It must be considered 
that much of this work is cell-type dependant, suggesting that effects may be cell-line 
specific and cannot be applied universally. A number of endocytic probes and their 
suggested mechanisms of entry are presented in Table 1.1, which nicely demonstrates 
this cell-type dependency.   
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Table 1.1 – Endocytic Pathways involved in the cellular uptake of different probes 
*Macropinocytosis is most extensively characterised as an increase in uptake of this 
probe following growth factor activation 
Entity Endocytic 
Pathway(s) 
Cell type Reference 
Transferrin 
Receptor (TfR) 
CME Rat reticulocytes (Harding et al., 1983; 
Pearse and Robinson, 
1990) 
Dextran Fluid-phase 
Macropinocytosis*  
 
HeLa, coelomocytes 
Dendritic cells 
 
(Li et al., 2015) 
(Falcone et al., 2006) 
Albumin Caveolae HRGEC (Moriyama et al., 2017) 
Low density 
Lipoprotein (LDL) 
CME 
 
Fluid-phase 
K562 erythroleukemia 
cells 
Macrophages 
(Bos et al., 1995) 
 
(Barthwal et al., 2013) 
Cholera Toxin B 
(CTxB) 
Caveolae/CME  
CME/Caveolae 
HeLa 
HeLa, Baby hamster 
kidney (BHK), Caco-2 
(Singh et al., 2003) 
(Torgersen et al., 2001) 
GPI-linked 
proteins 
CLIC-GEEC 
Flotillin-1 
HeLa, NIH 3T3 
HeLa 
(Lundmark et al., 2008) 
(Glebov et al., 2006) 
CD59 Flotillin-1 
Arf-6 
HeLa, A431 
HeLa 
(Al Soraj et al., 2012) 
(Naslavsky et al., 2004) 
Simian Virus 40 
(SV40) 
Caveolin-1 
 
 
CIE 
African Green 
Monkey Kidney 
Fibroblasts (CV-1), 
HeLa 
Fibroblasts 
(Anderson et al., 1996) 
 
 
(Damm et al., 2005) 
Lactosylceramide 
(LacCer) 
Caveolae 
CIE 
HeLa, A431 
HeLa 
(Al Soraj et al., 2012) 
(Singh et al., 2003) 
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1.4 Establishment of Endocytic Specific Models of Inhibition 
A collection of methods are available for studying endocytosis in in vitro models. These 
can largely be classified into two groups: chemical inhibitors and molecular biology.  
Chemical inhibitors of various types have been used for decades to study endocytic 
events. Experiments with these are relatively easy to perform involving simple 
incubations with cell culture models to assess uptake of a measurable probe and/or a 
plasma membrane protein. The main problem with these agents is their lack of 
selectivity for distinct endocytic pathways and other off target effects that could also 
influence viability and thus endocytosis (Dutta and Donaldson, 2012; Ivanov, 2008). In 
drug delivery research they have been extensively used to study uptake of drug 
delivery vectors with the aim of them providing information on uptake route of 
targeted and non-targeted formulations (Vercauteren et al., 2012). 
The birth of RNA interference technologies has allowed a much greater level of protein 
target specificity via silencing expression of key endocytic regulators of endocytosis. 
These techniques have been established for just over a decade and a half (Fire et al., 
1998), yet are utilised universally across the field of molecular biology. Small 
interfering RNA (siRNA) allows a more specific approach to understanding the 
involvement of distinct proteins during the various mechanisms of endocytosis. These 
technologies perform post-transcriptional gene silencing via the two short (~21-23) 
nucleotide sequences of the siRNA molecule, which are specific to a distinct mRNA 
sequence (Hamilton and Baulcombe, 1999). Silencing of transcription is facilitated 
following binding of the siRNA molecule to its target mRNA sequence, where the 
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sequence is cleaved and then degraded (Zamore et al., 2000). Due to the half-life of 
the proteins targeted using these technologies, longer incubation times of 24-72 hours 
are generally required, potentially affecting cellular homeostasis. From the cell biology 
literature, in some commonly used cell types (HeLa, A431, RPE) the Jones laboratory 
working in collaboration with the University of Ghent invested in developing siRNA 
models  of endocytosis for drug delivery research (Vercauteren et al., 2011; 
Vercauteren et al., 2010). Although beneficial for target specificity, the secondary 
effects on endocytic activity of the cell must be considered when using these 
technologies but in association with chemical inhibitors much information can be 
obtained regarding uptake mechanisms for a particular delivery formulation under 
consideration. 
1.4.1 Endocytic Probes 
Fluorescently labelled markers or probes such as transferrin can be utilised in flow 
cytometry or microscopy studies in order to observe and evaluate the onset, trafficking 
dynamics and terminus of a specific pathway. Labels commonly used to tag endocytic 
markers include the broad range of AlexaFluors (488, 647), BODIPY labels, Fluoresceine 
(FITC), Rhodamine, and Biotinylation, amongst others. When used in conjunction with 
inhibitory techniques such as those briefly discussed, the mechanics of a specific 
pathway and the regulatory proteins involved can be analysed by observing how the 
internalisation of a probe is different from its internalisation in cells where endocytosis 
has not been compromised. Co-localisation studies with different pathway specific 
probes can also be performed in order to characterise the trafficking events of 
49 
 
different endocytic mechanisms. Identification of pathway specific probes and 
selective methods of inhibition however is difficult due to the regulatory network that 
spans across the different endocytic mechanisms. One probe can be internalised by 
different pathways and the same endocytic protein can be involved in the regulation of 
more than one pathway. It is also likely that a protein required for endocytosis is also 
involved in other cellular processes. Pathway specific probes are much needed as are 
the identification of proteins that regulate only one pathway.  The current systems 
available for studying different endocytic pathways will now be discussed, highlighting 
the ways that the lack of specificity for these methods has been approached. 
1.4.2 Analyses of Clathrin-mediated Endocytosis (CME) 
The original inhibitors used to target CME include sucrose and chlorpromazine, to 
respectively remove or sequester clathrin and its adaptor proteins from the plasma 
membrane (Day et al., 2003; Heuser and Anderson, 1989; Ivanov, 2008). Other 
inhibitors include those which target dynamin, such as Dynasore (Macia et al., 2006) 
and dyngo-4a (McCluskey et al., 2013), although studies that use these generally refer 
to the uptake pathway that has been inhibited as dynamin dependent rather than CME 
(Fletcher et al., 2012; Harper et al., 2011; Wang et al., 2012). Dynasore is a GTPase 
inhibitor that reversibly prevents the GTPase scission activity of dynamin, thereby 
stopping scission of CCPs from the plasma membrane (Preta et al., 2015). These 
inhibitors obstruct clathrin stabilisation at, and scission of, CCPs at the plasma 
membrane, reducing the net occurrence of CME. The efficient nature of dynamin’s 
scission activity is not just utilised by the cell for CME however. Dynamin has been 
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implicated in mitochondrial fission (van der Bliek et al., 2013) and in the regulation of 
various cytoskeletal processes including cell-wide actomyosin organisation (Mooren et 
al., 2009) and remodelling of F-actin in lamellipodia (Menon et al., 2014; Menon and 
Schafer, 2013). Together with its involvement in other pinocytic mechanisms such as 
those dependant on the caveolin family (Henley et al., 1998), dynamin appears to be a 
relatively unspecific target for CME inhibition. In spite of their lack of specificity 
however, these inhibitors have proved useful for the elucidation of the distinct role of 
dynamin in CME, for example at the early steps of CCP formation (Nankoe and Sever, 
2006).  
The wider roles of clathrin (light and heavy chain) and dynamin that are independent 
of endocytosis suggest that non-specific effects are likely to be produced when these 
proteins are targeted by chemical inhibition or siRNA transfection. However, currently 
they remain the only viable methods to study CME endocytosis in detail and the 
dependence of this pathway for the uptake of any probe or drug delivery formulation.   
Using these approaches has identified an exclusive or joint role for CME in the uptake 
of plasma membrane localised receptors and their associated ligands.  These include 
the transferrin receptor (TfR)(Dautry-Varsat, 1986; Gammella et al., 2017), EGFR 
(Vieira et al., 1996) and the low-density lipoprotein receptor (LDLR)(Brown and 
Goldstein, 1979). Recent studies however have demonstrated that LDLR can also 
internalise via a clathrin-independent mechanisms (Ivaturi et al., 2014; Scotti et al., 
2013), indicating that this receptor is not a reliable marker for studying CME 
specifically. EGFR has also been shown to be internalised via a clathrin independent 
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mechanism that is dependent on the concentration of added EGF (Sigismund et al., 
2005). Constitutive internalisation of the transferrin receptor (TfR) is specifically 
dependent on CME and once internalised this and its ligand is sorted to recycling 
endosomes where the receptor and ligand are returned to the membrane (Mayle et 
al., 2012). During this endocytic cycle the iron bound to the transferrin is released into 
the cytosol for use in several different processes. There are similarities and differences 
in endocytic traffic between TfR, LDLR and EGFR highlighting that uptake via one route 
may lead to delivery of the receptor and ligand to different locations including delivery 
to lysosomes (EGFR, EGF and LDL) and recycling to the plasma membrane (TfR, Tf and 
LDLR).  
1.4.3 Analyses of Caveolin-Dependant Endocytosis 
Targeting cholesterol dynamics is classically used to prevent caveolae formation and 
internalisation, due to the essential nature of this sterol in these processes. 
Sequestration of cholesterol from the plasma membrane is directed by the 
cyclodextrin molecules, a group to which the widely utilised methyl-β cyclodextrin 
(MβCD) belongs. Typically pre-incubation of cells in culture with this agent is 
performed before assessing its effects on endocytic uptake. This method is useful in 
that depletion is reversible, meaning that cholesterol can be restored to the plasma 
membrane (Watkins et al., 2009). Evident effects on the structure of cells in the 
presence of this inhibitor are however apparent (Dutta and Donaldson, 2012), 
suggesting a range of secondary effects caused by MβCD. CME is also affected through 
the use of this inhibitor (Rodal et al., 1999), further reducing its specificity for targeting 
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caveolae. Additional inhibitors include those that prevent the synthesis of cholesterol, 
such as statins, and molecules that directly associate with the cholesterol molecule, 
such as nystatin (Cleal et al., 2013). Although effective for prevention of caveolin-
dependant endocytosis, all of these mechanisms cause secondary effects within the 
cell due to the universal depletion of cholesterol at the plasma membrane. Much of 
the information available regarding the internalisation and trafficking capacity of 
caveolae has been provided through exploration of caveolin-dependent endocytic 
probes, such as cholera toxin B (CtxB), GPI-linked proteins, Simian-Virus 40 (SV40) 
(Nichols, 2002) and albumin (Botos et al., 2008).  
siRNA depletion methods targeting Cav-1 have also been used as a means to prevent 
caveolin-1 mediated endocytosis by our group (Al Soraj et al., 2012) and others (Sun et 
al., 2010). In collaboration with the University of Ghent, previous members of the lab 
found that depletion of the protein resulted in a decrease in LacCer uptake, providing 
further evidence of caveolin-1 dependent endocytosis of this glycolipid (Vercauteren et 
al., 2011). Depletion of flot-1 however also resulted in reduced uptake of LacCer, 
demonstrating an ability to internalise via multiple CIE pathways. This has also been 
described through the investigation of its uptake in cells treated with chemical 
inhibitors of this process, which also indicated that the pathway used was cell type 
dependent (Vercauteren et al., 2010).    
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1.4.4 Analyses of Fluid-phase Endocytosis and Macropinocytosis 
Inhibitory methods that target the extensive actin remodelling that is indicative of 
macropinocytosis are most commonly used to study this pathway. Several inhibitors 
are currently in use for exploring these pathways. Amiloride and its more potent 
derivative 5-(N-ethyl-N-isopropyl) amiloride (EIPA), are Na+/H+ exchange inhibitors that 
obstruct macropinocytosis (Dowrick et al., 1993; Nakase et al., 2004), by acidifying 
sites of macropinocytic cup formation at the membrane. This process inhibits actin 
regulatory GTPases in this region, such as Cdc42 and Rac1, thereby preventing cup 
formation (Koivusalo et al., 2010).  
ML-7, a myosin light chain kinase inhibitor, has previously been used at concentrations 
identified as specific for targeting myosin II, a protein that localises to the region of 
macropinocytic cups in leukocytes (Araki et al., 2003). Myosin II uses its contractile 
capacity (Shutova et al., 2012) in association with actin to modulate actomyosin 
turnover (Even-Ram et al., 2007), which in this instance leads to cup closure. Here, ML-
7 was able to lower internalisation of a macropinocytic probe, dextran, in 
macrophages, whereby treated cells were unable to successfully close a shallower 
macropinocytic cup structure (Araki et al., 2003).  
Rottlerin is a commonly used inhibitor of fluid-phase endocytosis and 
macropinocytosis, though its mechanism of inhibition is currently unknown. Although 
little is known about this inhibitor, it was deemed appropriate for use in these studies 
due to its extensive use in previous endocytic studies. When Rottlerin was incubated 
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with dendritic cells, actin reorganisation following cytokine stimulation was found to 
be reduced (Sarkar et al., 2005). Rottlerin has also been shown to inhibit the uptake of 
Vaccinia virus in conjunction with EIPA in monocyte-derived dendritic cells, suggesting 
macropinocytosis as the mechanism of uptake used by this virus (Sandgren et al., 
2010).  
Vaccinia virus (Mercer et al., 2010), adenovirus (Kalin et al., 2010), herpes simplex and 
human immunodeficiency virus (HIV) have also been suggested to enter cells via 
macropinocytosis (Mercer and Helenius, 2009). Notably, entry is via clathrin-, caveolin- 
and dynamin-independent mechanisms, yet demonstrates reliance on PAK1 through 
uncoated vacuolar vesicles similar to macropinosomes. Widely utilised probes for the 
study of fluid-phase and macropinocytosis are the dextran molecules (Al Soraj et al., 
2012; Aleksandrowicz et al., 2011). These comprise of a group of glucan polymers of 
varying lengths linked by α-D-1,6-glucose bonds, do not have an identified receptor in 
mammalian cells and are therefore internalised into endosomes in the core fluid. The 
dextran molecules can be purchased in a range of chain lengths (1- 2,000,000 Da) 
though the differences between their hydrodynamic radii does not vary to the extent 
of their molecular weights (Armstrong et al., 2004). The difference in radii between 
10kDa and 70kDa dextran is approximately 3.5 nm, a relatively small difference 
considering the variance in chain length.  Unfortunately none of these probes has been 
able to segregate fluid phase endocytosis from macropinocytosis but the work in our 
laboratory showed that another myosin II inhibitor blebbistatin (Kovacs et al., 2004) 
was able to inhibit the increase in dextran uptake in serum starved A431 cells activated 
with EGF but had no effect on baseline uptake of dextran (Al Soraj et al., 2012).    
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In conclusion to this section it is fair to say that a wide range of chemical inhibitors are 
available to study endocytosis but that they all have drawbacks. Until the protein 
machinery of more endocytic pathways is identified we are currently in the situation 
that it is very difficult to specifically study endocytic pathways beyond CME using 
siRNA approaches. For both types of analysis new probes are also required that show a 
higher level of endocytic selectivity. 
1.5 Extracellular Vesicles (EVs) 
Extracellular vesicles are defined as ‘membrane-contained vesicles released in an 
evolutionally conserved manner by cells ranging from organisms such as prokaryotes 
to higher eukaryotes and plants’ (Yanez-Mo et al., 2015). They can be found in all 
bodily fluids including blood plasma, cerebrospinal fluid, urine, semen, breast milk and 
sweat (Keller et al., 2011; Zaborowski et al., 2015). Various types of EV have been 
described including three main groups: exosomes (30-150 nm), microvesicles (50-1000 
nm) and apoptotic bodies (50-5000 nm), all of which consist of a lumen encased by a 
lipid bilayer membrane. Other classifications include microparticles and ectosomes, 
however these subsets are less well defined (Raposo and Stoorvogel, 2013). The lumen 
contains proteins, lipids and nucleotides (mRNA, DNA) that are derived from their cell 
of origin (Penfornis et al., 2016). The ability of EVs to carry and transfer these 
functional materials between adjacent and distant cells as a form of intercellular 
communication suggests that they have a variety of roles in both normal physiology 
and disease pathology (Gopal et al., 2017; Tkach and Thery, 2016). Many studies 
initially focussed on delineating the pathological involvement of these vesicles in 
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diseases such as cancer and autoimmunity, rather than the possibility that they may 
actually have a physiological role. There has also been more recent studies on their 
putative use as disease biomarkers and biotherapeutics or vectors for drug delivery 
(Ha et al., 2016; Maas et al., 2017; van der Meel et al., 2014).  
The first evidence of EVs was suggested as early as 1946 (Chargaff and West, 1946), 
followed by visualisation of platelet derived lipid-based structures (Wolf, 1967) and 
matrix derived membrane bound vesicles via electron microscopy (Anderson, 1969). A 
small number of further observations of this type of entity were made in the decades 
following these studies, before vesicles involved in reticulocyte maturation were found 
to be released from multivesicular bodies (MVBs)(Johnstone et al., 1987).  Literature 
states that the term ‘Exosome’ for a type of these EVs was coined in 1981 (Trams et al., 
1981). The next significant observation of vesicular type structures came in 1996, when 
B lymphocyte derived exosomes were found to induce a functional effect via antigen 
presentation and membrane fusion in T cells (Raposo et al., 1996).  The capacity for 
functional intercellular communication between different cell types suggested by 
these observations accelerated research in the EV field, resulting in collection and 
isolation from different kinds of body fluids and cell culture media. The great 
heterogeneity between the structure, composition and lumen contents of the EVs 
collected indicated the existence of different types of vesicle, having been derived via 
different mechanisms and cell types. This variation has necessitated greater 
standardisation of what defines each class of EV, and the factors required in order for a 
population of isolated vesicles to fulfil their identity as a particular subset of vesicle: 
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exosomes or microvesicles, for instance (Gould and Raposo, 2013; Lotvall et al., 2014; 
Yanez-Mo et al., 2015).  
1.5.1 EV Collection, Purification and Characterisation 
Recommended isolation techniques to study vesicles across research groups have been 
established (Witwer et al., 2013) to ensure consistency between different reports, 
particularly due to the growing knowledge of their importance in disease 
pathogenesis. Consistency between techniques, particularly with regards to collection, 
isolation, and storage, ensure that the secreted vesicles being studied both fulfil the 
criteria as extracellular vesicles (Lotvall et al., 2014) and are from a pure vesicle 
preparation (Webber and Clayton, 2013). The range of membrane derived products 
(from shedding to debris) and types of vesicle contained in cell culture supernatant 
and bodily fluids can complicate the characterisation of isolated preparations of 
‘vesicles’ (Kreimer et al., 2015). This problem is exemplified in the ‘vesicle’ 
preparations obtained via commercial isolation kits, which can contain non-vesicular 
nucleotide carriers, such as lipo-proteins (Van Deun et al., 2014). Several distinct 
methods are used for EV collection, and enrichment including differential 
ultracentrifugation, density-gradient/sucrose-cushion ultracentrifugation and size 
exclusion chromatography, immunoaffinity-based purification methods and 
commercial precipitation methods such as ExoQuick™ (Szatanek et al., 2015; Thery et 
al., 2006; Van Deun et al., 2014). Differential ultracentrifugation is currently the most 
common technique used to isolate and purify vesicle preparations from cell culture 
supernatants and biofluids. This process is involves centrifugation and pelleting of the 
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sample at increasingly greater speeds (Figure 1.4). Microvesicles, other larger vesicles 
and cell debris are believed to pellet before exosomes at approximately 10,000-20,000 
x gravitational force (g), isolating the final EV pellet containing exosomes after two 
longer sequential centrifugation steps of 100,000 x g. Sucrose-cushion 
ultracentrifugation can be incorporated into this method, which separates exosomes 
from other vesicles/debris using a 30% sucrose/D2O cushion (approx. density 1.2 
g/cm3) (Zhang et al., 2014). Size exclusion chromatography methods also involve 
ultracentrifugation steps in conjunction with the use of a gel filtration column. This 
separates structures in the sample based on the theory that larger particles will elute 
through the column at a quicker rate than smaller particles, meaning that elutions 
collected at specified times will contain similar sized vesicles that can then be further 
characterised. 
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Affinity-based methods of vesicle isolation and purification are an additional method 
of isolating vesicles from cell culture supernatant or biofluids. These techniques 
generally involve the use of a commercial kit incorporating exosome specific 
antibodies that have been immobilised onto either specialised columns, ELISA plates, 
magnetic beads or microfluidic devices, for instance (Abramowicz et al., 2016).  
Antibody targeted proteins include CD63, CD9 and Annexin. This method is useful for 
the collection of vesicles from a specific cell type in a sample that contains vesicles 
from multiple cell types, resulting in vesicles with similar characteristics and 
Culture supernatant 
Supernatant 
Supernatant 
Supernatant 
Cell pellet 
Dead cell pellet 
Cell debris pellet 
Exosome pellet + contaminants 
Pure exosome pellet 
300 x g, 10 min 
2000 x g, 10 min 
10,000 x g, 30 min 
100,000 x g, 70 min 
100,000 x g, 70 min PBS wash 
Fig 1.4 Isolation of different EV subgroups via the different stages of differential 
ultracentrifugation Based on (Thery et al., 2006)   
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composition. For example, the colon epithelial specific protein A33 has been used to 
isolate exosomes specifically from this cell line in order to identify exosomal proteins 
that could be used as diagnostic markers for colon cancer (Mathivanan et al., 2010). 
The vesicle yield using affinity-based methods however is relatively low in comparison 
to other isolation techniques (Zaborowski et al., 2015). To remove large aggregates 
and cell debris, an extra filtration step can be performed prior to these isolation 
techniques. Filtration is often simply carried out by gently pushing the sample through 
a 0.22 µm filter, removing large aggregates and larger vesicles. These different 
methods of isolation produce vesicles with variable functionality with regards to both 
cargo and composition (Mol et al., 2017; Tauro et al., 2012; Taylor and Shah, 2015). 
Following collection and isolation, an established set of criteria needs to be fulfilled to 
ensure the collection of as pure an EV preparation as currently possible. Proteomic 
analysis has indicated that cytosolic-, cytoskeletal- and membrane-proteins are of 
particular abundance in exosomes, whereas intracellular proteins associated with 
organelles are not (Yanez-Mo et al., 2015). It is clear, however, that the proportion of 
these proteins varies between different vesicle populations, meaning that an 
abundance of one particular protein in a sample is not sufficient to confirm a pure 
vesicle/exosome population. An enrichment of several proteins is therefore required 
to define a preparation as containing mostly exosomes. For example, current protein 
markers that are abundant in exosomes include Alix, tetraspanins (e.g. CD63), Tumor 
susceptibility gene 101 (TSG101), Hsp70 and Major histocompatibility complex II 
(MHCII) (Kalra et al., 2012; Kreimer et al., 2015). Electron microscopy analysis of 
isolated samples can also be performed to ensure structures between 30-150nm 
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containing a bilayer enclosing a lumen are clearly defined. This analysis also indicates 
the presence of debris and non-vesicular structures that result in a ‘dirty’ preparation. 
Evaluation of the protein content of vesicle samples allows an approximate exosome 
concentration to be established, and is most commonly performed using a protein 
detection assay such as a BCA- or a Bradford assay (Thery et al., 2006). In conjunction 
with Nanoparticle tracking analysis (NTA), the purity of the sample can be further 
evaluated via calculation of a particle:protein (P/µg) ratio (Webber and Clayton, 2013). 
A high ratio value (>3x1010 P/µg) indicates that the majority of the sample protein is 
associated with the particles in the sample, here referring to vesicles. Hence, this is an 
indicator of the presence of proteins within the sample that are not associated with 
the EVs.     
Due to the variety of factors required to establish their identity as a particular type of 
vesicle, terminology can be loose.  Here, ‘EVs’ will be used to refer to vesicles not 
solely defined as either exosomes or microvesicles, but defined as a collection of both. 
From here on in the EV isolates will be referred to as exosomes due to the rigorous 
characterisation (discussed in Appendix B) performed by the team of collaborators at 
the Velindre Hospital lead by Professor Aled Clayton and Dr Jason Webber, who 
defined the samples as exosomes. 
1.6 Exosomes 
Exosomes are an EV subgroup derived from the multivesicular bodies (MVBs) of the 
endolysosomal system, and are expelled from numerous cell types (Edgar, 2016). To 
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date, exosomes have been established as essential components of numerous 
physiological processes, including intercellular communication and immune regulation 
via the transfer of functional proteins, lipids and nucleotides (DNAs, mRNAs, siRNAs) 
through the extracellular environment between cells and tissues (Mulcahy et al., 2014; 
Qin and Xu, 2014). Exosomes are 30-150 nm vesicles, composed of a single 
phospholipid bilayer encapsulating cargo from their cell of origin. This structure allows 
exosomes to effectively transport a variety of entities through the extracellular milieu, 
affording protection from degradation. This in a sense describes a form of drug 
delivery vector leading to interest in their potential use as carriers or therapeutics for 
the treatment of a variety of diseases (Keller et al., 2011; Simpson et al., 2009).  
1.6.1 Exosome Structure and Cargo 
1.6.1.1 Exosome RNA 
The exosome lumen also encompasses complex entities derived from the cell of origin, 
including cytosolic proteins and a subset of cellular RNAs (Yanez-Mo et al., 2015; 
Zaborowski et al., 2015). One may envisage that exosomes may also contain fluid 
internalised by the endocytic process that generated the MVBs.  Coding and non-
coding RNA species have been detected in EV isolates, including microRNAs, transfer 
RNAs, silencing RNAs, small nuclear RNAs and small cytoplasmic RNAs, amongst others. 
RNA sorting into exosomes is increasingly observed to be a regulated process 
(Villarroya-Beltri et al., 2014), indicating that transfer of RNA between cells by 
exosomes is pertinent to normal homeostasis, particularly with regards to immunity 
(Mittelbrunn et al., 2011; Nolte-'t Hoen et al., 2012), and possibly within disease onset 
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and pathogenesis (Kosaka et al., 2013; Takahashi et al., 2017). The sorting mechanism 
responsible for miRNA packaging had been shown to involve the heterogeneous 
nuclear ribonucleoprotein A2B1 (hnRNPA2B1), which binds to specific miRNA motifs, 
targeting them for exosome packaging (Villarroya-Beltri et al., 2013). These specific 
motifs have been termed EXOmotifs, which are GGAG tetranucleotides, found on the 
miRNA to be sorted (Yanez-Mo et al., 2015) However, the involvement of other 
mechanisms for different RNA species is still under investigation; other mRNA and 
miRNA motifs are also being studied for involvement in their sorting into exosomes. 
1.6.2.2 DNA 
Double stranded DNA fragments of a variety of sizes (100 base pairs to 2.5 kilobase 
pairs) have been identified in EV isolates, and have been given the title EV-DNAs 
(Thakur et al., 2014). Whether EV-DNA is homologous to genomic DNA remains to be 
fully established, and in comparison to EV-RNA, the functional impact of EV-DNA 
currently remains unknown. 
1.6.2.3 Proteins on EV membranes  
The protein signature of isolated EVs is shaped by the physiological context and cell-
type from which the vesicles are derived. As previously discussed, exosomes have 
several proteins that look to be universally enriched in exosomes, regardless of the 
identity of their cell of origin. These include a number of tetraspanins (CD37, CD53, 
CD63, CD81, and CD82) and MHCII proteins. Sorting of proteins into MVBs is 
dependent on the endosomal sorting complexes required for transport 
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(ESCRT)(Schmidt and Teis, 2012), which results in variants of these complexes being 
enriched on exosomes. These include Alix and TSG101, in addition to the protein 
chaperones, Hcs70 and Heat shock protein 90 (Hsp90). The use of this intraendosomal 
sorting machinery for packaging proteins into vesicles strongly suggests that exosomes 
generally have greater enrichment of these proteins than a standard cell lysate or 
other EV sample. However, enrichment of these proteins, including the heat shock 
proteins and MHCII, has recently been suggested to occur in all EV subtypes (Kowal et 
al., 2016), thereby questioning their exclusivity to exosomes alone. 
1.6.2 Function of Exosomes and Extracellular Vesicles 
Exosomes naturally shuttle cargo between adjacent and distant cells as a mode of 
communication, modulating important physiological and pathological processes such 
as cancer, cardiovascular diseases, and neurodegeneration, as well as transferring 
pathogenic virulence factors (Yanez-Mo et al., 2015). This natural ability to functionally 
transfer a spectrum of macromolecular cargo between cells also raises opportunities 
for exploiting exosomes as vectors for drug delivery (Batrakova and Kim, 2015; Vader 
et al., 2016; van Dommelen et al., 2012). 
1.6.2.1 Exosomes as Shuttles for Communication Between Cells 
The communicative abilities of extracellular vesicles have been widely studied with 
regards to both normal physiology and disease pathogenesis. Having been isolated 
from all human bodily fluids and from the biofluids of other organisms, including plants 
(Lange and Gagliardi, 2012), fungi (Rodrigues et al., 2011) and bacteria (Kim et al., 
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2014; Lefebvre and Lecuyer, 2017), it can be hypothesised that their roles are 
extensive. Transfer of a range of functional cargoes between adjacent and distant cells 
is apparent. However, little is known about the ways in which exosomes initially 
interact with the cell, gain intracellular access and are trafficked through the cell to 
their final destination. Even less is known about how intravesicular cargo is released 
and directed towards the intended target within the cytosol or other intracellular 
compartments. There is an abundance of information regarding the importance of EV 
mediated cargo transfer in the processes involved in an extensive range of 
physiological systems (Yanez-Mo et al., 2015; Zaborowski et al., 2015). For example, 
involvement within cardiovascular regulation, influence over sexual reproduction and 
importance for immune surveillance and activation has been suggested (S et al., 2013; 
Vlassov et al., 2012). There are many systems in which EVs have been found to have 
involvement and some of these are briefly described below.  
1.6.2.2 Cardiovascular Regulation 
With the earliest EV work having been performed with blood plasma isolates (Chargaff 
and West, 1946; Wolf, 1967), it is of no wonder that much work has been performed 
to characterise their roles within vascular homeostasis.  
The involvement of EVs in vascularisation has been extensively characterised with 
regards to their roles in angiogenesis but also with reference to vascular regeneration. 
Angiogenesis will be discussed below in the context of cancer. Vascular regeneration 
has been studied with exosomes derived from stem cells of endothelial nature in both 
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an in vitro and an in vivo setting. In both instances, endothelial progenitor cells (EPCs) 
were harvested from human umbilical cord samples, and exosomes isolated. After 
injury to the rat carotid artery, EPC exosomes were observed to accelerate the early 
regeneration of endothelial tissue of the injured artery. Further to this, these 
exosomes were found to increase proliferation of cultured endothelial cells in in vitro 
wound models (Li et al., 2016a; Li et al., 2016b). This remarkable ability has 
undoubtedly identified stem cell vesicle isolates as possible therapeutics for 
cardiovascular repair, targeting damaged tissues through localised engraftment or 
transplants (Huang et al., 2015; Lai et al., 2011). Inter-cell communication and 
regulation of the events following a myocardial infarction have also been associated 
with EV released from cardiomyocytes, indicating use of a variety of cell-derived 
vesicles for similar therapeutics (Yuan et al., 2016) or help to influence or aid these 
mechanisms to improve recovery (Sahoo and Losordo, 2014). 
1.6.2.3 Immunity 
EVs are released from a number of leukocytes of both the innate and activated 
immune system. These include macrophages, dendritic cells, natural killer (NK) cells, B 
cells, and T cells (Robbins and Morelli, 2014). The cellular system from which they are 
derived influences their immune associated activities, and cargoes shown to be 
associated with EV and exosome isolates from these cell types are diverse. For 
example, a great number of cytokines and chemokines have been designated as vesicle 
cargoes, with many of these believed to be involved in processes such as inflammation 
and antigen presentation (Benito-Martin et al., 2015; Thery et al., 2002). It must be 
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noted however that many of these studies investigate the involvement of the immune 
system in the context of cancer onset and progression. 
Cargoes associated with EVs also extend to those originating from pathogens such as 
viruses, and these could even play a role in prevention of pathogenesis (Kouwaki et al., 
2017). Hepatitis C viral RNA carried on the exosome surface from infected hepatocytes 
can be recognised by pattern recognition receptors on dendritic cells and 
macrophages, causing activation of an antiviral cascade (Dreux et al., 2012; Kouwaki et 
al., 2016). Similar actions have been demonstrated by exosomes released from 
Epstein-Barr virus infected cells, which carry small-RNAs from the virus. These 
exosomes transfer immunity to non-infected dendritic cells (Baglio et al., 2016). 
Pathogenic bacterial RNA has also been found in exosomes. For example, exosomes 
produced by Mycobacterium tuberculosis (M.Tb) infected macrophages contain M.Tb 
derived RNA that demonstrates functionality (Singh et al., 2015). These exosomes have 
the ability to recruit macrophages and other immune cells during tuberculosis 
granuloma formation, though the exact mechanism responsible for this is unknown 
(Singh et al., 2012). M.Tb derived protein cargo may well be responsible. Alternately, 
tumour-derived exosomes have been found to carry cargoes that can act to suppress 
the immune system (Whiteside, 2017). Increased rates of apoptosis and a reduction in 
proliferation of T cells (Wieckowski et al., 2009), in addition to a reduced cytotoxicity 
of natural killer cells (Szczepanski et al., 2011), are some other examples of how 
exosomes influence immune activity. These abilities are most likely due to their 
capacity to successfully transfer functional cargo and/or activate plasma membrane 
receptors.         
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1.6.2.4 Cancer 
Exosomes and other EVs have been extensively studied with regards to their 
involvement in cancer onset and progression (Whiteside, 2017; Zha et al., 2017). The 
tumour microenvironment is responsible for these activities, and has key influence 
over the behaviour of cancer cells (Fouad and Aanei, 2017; Pickup et al., 2014). EVs, 
including exosomes, have been found to be produced by cells within the cancer 
structure, indicating their involvement in the processes regulated by this environment 
(Meehan and Vella, 2016; Webber et al., 2015). Their roles in these processes are 
broad ranging, having relevance in angiogenesis, immune inactivation and evasion, 
alteration of cellular metabolism and transfer of metastatic factors to adjacent and 
distant tissues.  
Progressive diseases have the ability to generate their own vascular system (Hanahan 
and Weinberg, 2011). Angiogenic factors are often secreted by tumour cells, inducing 
angiogenesis from surrounding tissues, and it has been demonstrated that tumour 
derived exosomes have to the ability to induce this effect. Tetraspanins are one such 
angiogenic factor, harnessing the ability to activate branching of adjacent vessels. As 
previously discussed, these proteins are highly enriched in the membranes of 
exosomes and other EVs, suggesting a possibility for their interaction via tetraspanins 
with tumor vasculature to induce angiogenesis (Webber et al., 2015).  
The ability of tumour cells to evade clearance by the immune system is important for 
early disease progression and tumour growth. Tumour-derived exosomes have been 
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found to carry cargoes that can act to suppress the immune system at various different 
levels in a variety of ways (Whiteside, 2017). Effects include increased rates of 
apoptosis and a reduction in proliferation of T cells (Wieckowski et al., 2009), in 
addition to a reduced cytotoxicity of natural killer cells (Szczepanski et al., 2011). 
1.6.3 Exosomes as Diagnostics 
Via profiling methods commonly utilising PCR, a number of miRNAs have been 
identified in exosomes derived from a range of different biofluids, suggesting their use 
in the diagnosis of a variety of diseases, from gastrointestinal (Matsumura et al., 2015; 
Nedaeinia et al., 2017; Ogata-Kawata et al., 2014), pancreatic (Que et al., 2013) and 
cancers (Schwarzenbach, 2015), Alzheimer’s disease (Van Giau and An, 2016) and 
Multiple Sclerosis. Notably, it has been suggested that exosomal transfer between 
cancer cells is involved in the propagation of drug resistance in prostate (Corcoran et 
al., 2012), and other cancers (Chen et al., 2014). 
1.6.4 Exosomes as Drug Delivery Vectors  
The involvement of exosomes and other EVs within normal physiological processes and 
within a variety of diseases suggests they have ability to transfer bioactive cargo of 
different types between different cells as a form of cell-cell communication. Their 
proficiency here makes them promising vectors for small molecule and 
macromolecular drug delivery (Batrakova and Kim, 2015; Vader et al., 2016; van 
Dommelen et al., 2012). As more information about their involvement in different 
pathogeneses also increases, ways in which exosomes could be harnessed for 
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treatment and prevention is also promising.  The treatment of a variety of diseases 
could benefit from their use due to their ability to reach distant tissues that are 
oftentimes protected by highly specialised barriers that other drug delivery systems 
are unable to transgress, such as the BBB (Ha et al., 2016). These diseases include 
Alzheimer’s and other cerebrospinal diseases such as Parkinson’s disease (Rufino-
Ramos et al., 2017; Wu et al., 2017). Exosomes also possess a number of other factors 
that make them suitable for drug delivery, including the ability to genetically modify 
the cell of origin so that the exosomes produced express tissue specific targeting 
proteins (Batrakova and Kim, 2015). Additionally, some cell types such as dendritic 
cells produce a proportion of exosomes without T cell activators, such as MHCII, 
resulting in low levels of immunogenicity (Quah and O'Neill, 2005).    
Several studies have endeavoured to explore this function in a variety of contexts. For 
instance, functional delivery of siRNA to the brain has been demonstrated in vivo 
(Alvarez-Erviti et al., 2011). Here, siRNA targeting GAPDH and Beta-secretase 1 
(BACE1), a protein target for Alzheimer’s disease, was loaded into dendritic cell derived 
EVs loaded with siRNA by electroporation, before intravenous injection of the 
preparation into mice. Targeting to brain tissues was attempted via modification of 
exosomes with Rabies Virus Glycoprotein (RVG), a neuron-specific peptide for BBB 
targeting. A reduction in both GAPDH and BACE1 expression in excised brain tissue was 
presented using Western blot analysis, indicating successful delivery of functional 
cargo. Protein delivery by exosomes has also been demonstrated in neuronal cells, 
where loading of exosomes with catalase via sonication or permeabilisation was 
performed. Increased uptake of exosomes was observed in neuronal cells and via the 
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measurement of microglial activation in the mouse brain it was found that catalase 
loaded exosomes had a neuroprotective effect (Haney et al., 2015). Exosome delivery 
potential also extends to small molecule chemotherapeutics. Loading dendritic cell 
derived exosomes with doxorubicin resulted in the inhibition of tumour growth in mice 
in vivo (Tian et al., 2014b) and paclitaxel and doxorubicin encapsulated in exosomes 
derived from a number of brain tumour cell lines resulted in decreased viability of the 
same cell lines in vitro and a loss of cancer cells in the brains of a zebrafish model of 
brain cancer (Yang et al., 2015). 
Methods to improve the uptake of exosomes as a means of improving their delivery 
capacity for potential therapeutics will be discussed in the following section.  
1.6.5 Methods to study Endocytosis of Exosomes 
The ways in which exosomes and other EVs interact with and enter cells still remain 
largely undetermined. Increased knowledge on this is required to elucidate their roles 
in normal physiology, disease and also to determine how best to exploit them as drug 
delivery vectors. An array of endocytic inhibitors to target various endocytic pathways 
has previously been employed in exosomal uptake assays to identify potential routes 
of internalisation. Studies utilising inhibitors such as EIPA and Cytochalasin D suggest 
that macropinocytosis, an actin-dependent process, is involved in exosome 
internalisation (Escrevente et al., 2011), whereas the use of dynamin inhibitors such as 
dynasore suggests a role for clathrin- and caveolin-mediated endocytosis. Phagocytosis 
has also been suggested as a preferential uptake route in a study utilising both 
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phagocytic and non-phagocytic cell types, whereby exosomes were shown to be 
localised to phagosomal-like structures (Feng et al., 2010). Interestingly, it has also 
been suggested that exosomes are able to travel along cell filopodia to activate their 
own uptake (Heusermann et al., 2016). Here downstream of the plasma membrane 
they were trafficked to lysosomes.  
Exosome modification to improve cell uptake capacity has been explored. Exosome 
conjugation with GALA, a pH-sensitive peptide, and other cationic lipids results in 
increased uptake and cytosolic release of dextran molecules loaded into HeLa derived 
exosomes. This method also resulted in the increased cytosolic release of the ribosome 
inactivating protein, saporin (Nakase and Futaki, 2015). Loading with EGF induced 
uptake via activation of macropinocytosis  It is suggested that encapsulated EGF 
released to the cytosol following internalisation of a small proportion of exosomes 
travels back to the cellular plasma membrane to induce macropinocytosis and thereby 
increases internalisation of the extracellular exosomes not yet internalised (Nakase et 
al., 2015). Induction of macropinocytosis as an internalisation mechanism was further 
explored by modifying the exosome membrane with the cell penetrating peptide 
steryl-octaarginine, resulting in enhanced uptake. Improved cytosolic delivery of 
encapsulated saporin was again demonstrated (Nakase et al., 2017; Nakase et al., 
2016).  
Exploring how exosomes interact with in vitro cell models for high content analyses 
can be facilitated by fluorescently labelling them using several different methods. The 
quickest way of labelling a preparation of isolated exosomes is by using a lipophilic 
73 
 
dye. These dyes come in many different forms including the Di (DiI, DiO) and the PKH 
(PKH26, 27, etc) molecules (Jensen, 2012). These fluorescent molecules embed within 
the membrane bilayer of the exosome (Figure 1.5) following a simple incubation with a 
purified vesicle preparation, resulting in a fluorescently labelled sample. Another 
method includes the use of exosome permeable compounds including 
carboxyfluorescein succinimidyl ester (CFSE) and 5(6) carboxyfluorescein succinimidyl 
diacetate (CFDA) (Temchura et al., 2008). Both molecules are membrane permeable, 
yet their labelling mechanisms are different. CFSE associates with molecules within the 
lumen of the exosome via their succinimidyl group and is constitutively fluorescent, 
whereas the fluorescence of CFDA requires activation by exosomal esterases. Other 
more labour intensive methods of acquiring fluorescent exosomes include transfection 
of a cell line with a Green Fluorescent Protein (GFP)-tagged exosomally enriched 
protein, such as CD63-GFP. Exosomes isolated from these transfected cells are 
therefore already fluorescently tagged at the point of origin. Both stable and transient 
transfection have been utilised for this approach. Advantages and disadvantages exist 
for all of these methods, and discussed in the next section.        
1.6.5.1 Labelling Exosomes with Lipophilic Dyes  
A variety of lipophilic dyes have been utilised to generate fluorescently labelled 
extracellular vesicle populations, including exosomes, for many applications.  These 
dyes have also been used in the exploration of possible isolation and characterisation 
applications including microfluidic devices (Kanwar et al., 2014) and size exclusion 
chromatography (Xu et al., 2016). By embedding within the membrane bilayer, these 
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dyes enable qualitative and quantitative measurements of cell-exosome interactions, 
via microscopy and flow cytometry respectively. The lipophilic carbocyanine Di 
molecules, which include DiD, DiL and DiO, amongst others, have been used 
extensively for this purpose, the structure of which is presented in Figure 1.5.  
The PKH dyes utilise a similar mechanism to embed within the membrane bilayer to 
generate a fluorescently labelled whole cell or vesicle population, and this is also 
presented again in Figure 1.5. These molecules also provide a certain extent of 
flexibility with regards to colour of fluorescence, PKH26 having red fluorescence for 
instance and PKH67 green. This method has been used to label bladder cancer cell 
exosomes indicating that their uptake in the same cell line is time and dose dependent 
(Franzen et al., 2014).  
Labelling of exosomes using these methods is easy to perform but the literature does 
not disclose experiments that have been performed to characterise the functional 
integrity of these entities 
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1.6.5.2 Labelled Exosomes from Stable Cell Lines 
Transient transfection is a quick and efficient method of altering gene expression, and 
is most commonly used to perform this type of experiment. If expression with greater 
stability is required however, the generation of a stably transfected cell line is a better 
option, and are commonly utilised for a variety of applications (Bussow, 2015).  These 
Fig 1.5 Current methods used to produce fluorescently labelled exosome 
preparations Stable transfection of a GFP-tagged exosomally enriched protein 
(such as CD63) into a cell line from which exosomes will be collected, results in the 
subsequent production of GFP-labelled exosomes. Below, fluorescent hydrophilic 
dyes (Di/PKH molecules) non-covalently embed in the exosome membrane.   
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range from cells that do not express specific proteins to cells that express recombinant 
proteins, such as mutant proteins or tagged proteins. A sustained gene expression is 
provided using this method, rather than loss of expression following cell division 
(Assenberg et al., 2013; Dyson, 2016). Tagged proteins include proteins that have been 
engineered to express a fluorescent protein, such as GFP or mCherry, and has proved 
particularly useful in the generation of fluorescently labelled exosomes (Figure 1.5).  
Exosome profiling has identified proteins that are highly enriched in these vesicles 
(Duijvesz et al., 2013; Webber et al., 2014), generating a list of potential proteins that 
could be targeted for labelling. The most commonly used protein for this process is the 
tetraspanin CD63, which is commonly transfected as a GFP/mCherry recombinant. 
CD63 is also called LAMP3, a protein often labelled in cells for immunofluorescence 
microscopy identification of late endosomes and lysosomes. Exosomes that are 
collected from stably transfected CD63-GFP cells are therefore fluorescent due to their 
GFP enrichment and can be further used for analysis using methods such as 
microscopy or flow cytometry. For instance, exosomes collected from HeLa generated 
to stably express CD63-GFP have been utilised for exosome microscopy studies 
(Nakase et al., 2015; Suetsugu et al., 2013). Unfortunately these techniques can result 
in differential expression of tetraspanins in the structure of the vesicle, with 
overexpression potentially altering the composition of vesicles collected from such cell 
lines (Lin et al., 2008; Perez-Hernandez et al., 2013). 
These methods exemplify the ways in which exosomes have been labelled for 
subsequent analysis of cell uptake and intracellular traffic in different in vitro models. 
77 
 
The capacity of exosomes to enter via endocytosis has been suggested primarily 
through the proposition that entry requires an energy-dependent process (Escrevente 
et al., 2011; Mulcahy et al., 2014). In dendritic cells it has been shown that localisation 
of internalised exosomes is confined to endosomal sorting networks, further 
supporting a role for endocytosis as a portal for exosomal entry (Morelli et al., 2004). 
Studies by Tian et al (Tian et al., 2010; Tian et al., 2014a) used a combination of siRNA 
depletion of endocytic proteins and pharmacological inhibitors to study possible entry 
mechanisms of PC12 derived exosomes in PC12 cells.   
Once labelled, the cell-type specific endocytic profile of exosomes, and other discussed 
drug delivery systems, can be elucidated by using the techniques of pathway specific 
modelling previously discussed. As presented in Table 1.3 a combination of both flow 
cytometry and microscopy analysis can be used to determine exosome uptake and 
quantify fluorescence in in vitro models. Flow cytometry can provide quantification of 
intracellular fluorescence, if removal of cell surface fluorescence can be guaranteed. 
This process involves several trypsinisation steps, potentially altering the plasma 
membrane so to avoid this, intracellular fluorescence can be quantified from 
microscopy images and this process is described in Section 2.13.1.   
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Table 1.3 – Proposed uptake mechanisms of exosomes labelled using different probes 
Exosome 
derivation 
Label Recipient cell type Method – 
FACS/Microscopy 
Endocytic 
Pathway(s) 
Reference 
SW780 human 
bladder cancer 
PKH26 Human bladder cancer - SW780 and 
UMUC3 
Both Receptor-mediated (Franzen et al., 
2014) 
U87 MG human 
glioblastoma cells 
PKH67/26, 
cellvue midklaret  
HeLa, mouse embryonic fibroblasts (MEF) Both Lipid-raft mediated (Svensson et al., 
2013) 
U87 MG human 
glioblastoma cells 
PKH26 U87 MG, U118 MG and LN18 human 
glioblastoma, CHO hamster ovary 
Both HSPG-dependent (Christianson et 
al., 2013) 
K562 human 
lymphoblasts, MT-
4 human T-cell 
PKH67/26 Human – Macrophages (RAW 264.7, 
J774A.1, THP-1), Lymphocytes (Jurkat T 
cells), Kidney (293T cells, COS-7), HEL299 
lung fibroblast, Mouse - NIH-3T3 fibroblast 
Both Phagocytosis (Feng et al., 2010) 
PC12 rat 
embryonic brain 
DiD, CFSE PC12, Rat bone marrow stem cells  Both CME, 
macropinocytosis 
(Tian et al., 
2014a) 
SKOV3 human 
ovarian carcinoma 
CFSE SKOV3 Both Lipid-raft, 
macropinocytosis 
(Escrevente et al., 
2011) 
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1.7 Hypothesis 
High-content studies utilising the techniques of endocytic inhibition described will 
permit a greater level of characterisation of many drug delivery systems. Aiming to 
identify more specific endocytic probes and inhibitory mechanisms will be 
facilitated through a greater delineation of the molecular mechanisms involved in 
processes, particularly that of macropinocytosis. 
The hypothesis of this study is: 
Further identification of methods to attenuate different endocytic pathways will 
lead to higher level of evaluation of the cellular internalisation mechanisms 
utilised by established and novel drug delivery vectors such as exosomes.  
1.8 Objectives 
The overall aim of this project is to provide high content in vitro endocytic platforms 
using siRNA transfection of endocytic proteins and chemical inhibitors of 
endocytosis to analyse the uptake of potential drug delivery systems. Provide an in 
vitro platform for specific inhibition of Clathrin-mediated endocytosis   
- Further investigate the proteins involved in macropinocytosis to identify a 
more specific method of targeting this pathway 
- Use established and newly developed techniques of endocytic inhibition to 
better characterised the uptake of model prostate cancer derived exosomes   
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2 Materials and Methods 
2.1 Materials 
General materials and their suppliers are listed in Appendix A. All tissue culture 
plasticware was manufactured by Corning and purchased from Fisher Scientific 
(Loughborough, UK), as were laboratory disposables and organic solvents. General 
usage chemicals and reagents were supplied by Sigma-Aldrich (Poole, UK). Glass 
bottomed 35 mm MatTek imaging dishes were purchased from MatTek Corporation 
(MA, USA). Cell lines for in vitro barrier models were supplied by GSK through the 
COMPACT Consortium, the details of which are presented in Table 2.1. 
2.2 General cell culture 
2.2.1 Cell lines 
All cell lines were maintained as sub-confluent monolayers with 10% foetal bovine 
serum (FBS) supplemented growth media (details provided in Section 2.2.2). All 
were cultured in a humidified incubator at 5% CO2, 37°C. 
All cell culture materials used and protocols for maintaining COMPACT Consortium 
cell lines (HeLa, A549, bEND3) were as agreed by the COMPACT Consortium based 
on guidelines provided from GSK and Cardiff University.  This was to establish and 
maintain consistency across all partners of the COMPACT Consortium (Table 2.1). 
Each cell line used has also been sequence verified by GSK before provision. Non-
COMPACT Consortium cell lines utilised in this project are provided in Table 2.2. 
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Table 2.1 – COMPACT Consortium verified Cell Lines and Culture Guidelines  
 HeLa A549 bEnd.3 
Tissue Cervical, epithelial Lung epithelial Brain endothelial 
Species Human Human Mouse 
Growth Medium sensi-cell MEM Ham’s F-12 Nutrient DMEM 
Maximum Passage 20 (/10 weeks) 20 (/10 weeks) 20 (/10 weeks) 
Seeding Density (T75) 18.75 x104 37.5 x 104 75 x 104 
Passage Frequency 90% confluency 90% confluency 90% confluency 
Media Change 3 days 3 days 3 days 
Centrifugation 300g/4 min 300g/4 min 300g/4 min 
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Table 2.2 – Non-COMPACT Consortium Cell Lines and Culture Details. H1299eGFP were stably transfected to express eGFP (Cun et al., 2011) 
 
 
 AG02262 H1299eGFP H1299WT 
Supplier Coriell Institute Medical Research University of Copenhagen University of Copenhagen  
Cell type Human Primary Lung Fibroblasts Human Lung Carcinoma Human Lung Carcinoma 
Growth Medium DMEM F-12 (1:1 mix) RPMI 1640 RPMI 1640 
Max. Passage Received P7-8, Max. P10  20 20 
Split Ratio (T75) 1:2 1:6 1:6 
Passage Frequency 90% confluency 90% confluency 90% confluency 
Media Change 3 days 3 days 3 days 
Centrifugation 300g/4 min 300g/4 min 300g/4 min 
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2.2.2 Media 
HeLa cells were cultured in Minimum Essential Media (MEM) containing phenol red 
and supplemented without antibiotics but containing 10% FBS, 1% L-glutamine and 1% 
Non-Essential Amino Acids (NEAA). A549 cells were maintained in Ham’s F-12 Nutrient 
Media containing phenol red and supplemented with 10% FBS. Mouse-derived bEnd.3 
endothelial brain cells were grown in Dulbecco's Modified Eagle Medium (DMEM) with 
phenol red and 10% FBS.  
H1299eGFP (enhanced green fluorescent protein)/wildtype (WT) cells were grown in 
Roswell Park Memorial Institute Media 1640 (RPMI 1640) with phenol red and 
supplemented with 10% FBS, 1% L-glutamine and 0.4% Geneticin (H1299eGFP cells). 
AG02262 were cultured in DMEM F-12 (1:1 mix) supplemented with 1% L-glutamine 
and 10% exosome-depleted FBS. Exosome-depleted FBS was provided by the Clayton 
lab and was produced by centrifuging the FBS overnight (18 hours) at 100,000 x g.  The 
FBS was then filtered through a 0.22 µm vacufilter, followed by further filtration 
through a 0.1 µm vacufilter.   
2.2.3 Routine cell culture  maintenance 
All cells were maintained in a humidified incubator at 37°C with 5% CO2. Cells were 
passaged every 3-5 days via one phosphate buffered saline (PBS) wash and incubation 
with 2.5 µL 0.05% trypsin ethylenediaminetetraacetic acid (EDTA) for 3-5 min (37°C, 
5%CO2) to detach the cells. bEnd.3 cells were incubated for 10 min (37°C, 5% CO2). 
After trypsinisation the cells were collected in 8ml of culture media before 
centrifugation at 300 x g for 4 min. The supernatant was removed and the pellet re-
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suspended in a specified volume of media depending on split ratio and addition to a 
new T75 flask depending on the split ratio of the cell line and seeding density (see 
Tables 2.1 and 2.2). 
2.2.4 Cell counting for splitting and plating 
Following pellet resuspension, 10 µL cell suspension was added to 10 µL Trypan Blue 
Solution to allow visualisation of dead cells. The haemocytometer was assembled and 
10 µL cell-Trypan Blue mix was added before cells were counted. Cell concentration of 
the complete cell suspension was calculated based on this value and appropriate 
volume for correct cell density added to a new T75 flask for culture, or per well for 
experiments.  
2.3 siRNA Transfection 
The siRNAs provided in Table 2.3 were custom designed and provided by Eurofins 
MWG Operon (Ebesburg, Germany). siRNA targeting eGFP was used as a negative 
control due to the absence of this gene in the mammalian genome. 
2.3.1 Standard Single siRNA Transfection 
A day prior to transfection, HeLa and A549 cells were seeded at a density of 1.5x105 
per 35 mm well (6 well-plate for lysate collection, 35 mm MatTeK dish for live 
imaging). bEnd.3 cells were seeded at a density of 1.0x105 cells per 35 mm well three 
days prior to transfection. Per well: siRNA was diluted with Opti-MEM I to generate a 
volume of 185 μL, and mixed via inversion (siRNAs and working concentrations used 
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are listed in Table 2.3). Oligofectamine (2 μL per 13 µL Opti-MEM) was added to the 
siRNA, inverted, and incubated at room temperature (R/T) for 30 min. Following two 
Opti-MEM I washes to remove serum, 800 µL Opti-MEM I was added per well followed 
by the drop-wise addition of the transfection medium (200 μL). Cells were incubated 
for 4 hours (37°C, 5% CO2) before addition of 500 µL FBS (30%) in Opti-MEM I, followed 
by a 48 hour incubation (37°C, 5% CO2). All transfection protocols were followed as 
according to the Invitrogen transfection guidelines. Untransfected control cells were 
seeded and treated with Opti-MEM I in the same manner as transfected cells, omitting 
the addition of Oligofectamine and siRNA. Cells were then used for microscopy studies 
or the lysates collected for Western blot analysis (Section 2.12). 
2.3.2 Double siRNA Transfection  
HeLa and A549 cells were seeded at a density of 1.5x105 per 35 mm well (6 well-plate 
for lysate collection, 35 mm MatTeK dish for live imaging) a day prior to transfection. 
Transfection was performed as specified in Section 2.3.1 followed by a second identical 
siRNA transfection 48 hours following the initial transfection, followed by further 48 
hour incubation (37°C, 5% CO2).  
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Table 2.3 – siRNA Targets and Sequences  
Target Sequence Stock  Working  Reference 
AP2μ2 GUGGAUGCCUUUCGGGUCAdTdT 50 µg/mL 100 nM Custom designed 
Caveolin-1 AGACGAGCUGAGCGAGAAGdTdT 100 µg/mL 100 nM (Al Soraj et al., 2012) 
Cdc42 GACUCCUUUCUUGCUUGUUdTdT 100 µg/mL 100 nM Custom designed 
Flotillin-1 UGAGGCCAUGGUGGUCUCCdTdT 100 µg/mL 100 nM Custom designed 
PAK1 AUAACGGCCUAGACAUUCAdTdT 100 µg/mL 100 nM (Al Soraj et al., 2012) 
Protein Kinase C (PKC)δ GGCUGAGUUCUGGCUGGACdTdT 100 µg/mL 100 nM (Llado et al., 2004) 
GFP GGCUACGUCCAGGAGCGCAdTdT 100 µg/mL 100 nM (Al Soraj et al., 2012) 
eGFP/Cy5-eGFP UGCGCUCCUGGACGUAGCCdTdT 100 µg/mL 100 nM Custom designed 
Scrambled (Scram) eGFP GCACGGACCGCGUCUAGGAdTdT 100 µg/mL 100 nM Custom designed 
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2.3.3 Synchronous siRNA Transfection 
The siRNA and Oligofectamine transfection complexes were prepared as for forward 
siRNA transfection (Section 2.3.1). During complex formation, HeLa cells were 
trypsinised and seeded at a density of 2.0x105 per 35 mm well in 800 μL Opti-MEM I. 
siRNA complexes were added (200 μL) directly to the cell suspension, pipetted to mix, 
placed in 35 mm MatTek dishes and incubated for 4 hours (37°C, 5% CO2). Addition of 
500 µL FBS (30%) in Opti-MEM I and 72 hour incubation (37°C, 5% CO2) were then 
performed before the cells were used for confocal microscopy studies. 
2.3.4 siRNA targeted depletion of eGFP in H1299eGFP cells 
2.3.4.1 Oligofectamine 
Oligofectamine/siRNA complexes were prepared and cells transfected (as detailed in 
Section 2.3.1) but with 100 nM of either scrambled eGFP siRNA (+ Oligofectamine), 
Cy5-labelled eGFP siRNA (no Oligofectamine), Cy5-labelled eGFP siRNA (+ 
Oligofectamine) or unlabelled eGFP siRNA (+ Oligofectamine) for a period of 48 hours 
(37°C, 5% CO2). Cells were incubated with 1 µM Hoechst33342 for 5 min before 
imaging live on the confocal microscope (R/T). 
2.3.4.2 Exosomes 
Unlabelled exosomes (2 or 20 µg/ml) were incubated with 100 nM of Cy5-eGFP siRNA 
in Opti-MEM I media for 30 min (R/T). Cells (seeded in 35 mm dishes as described in 
Section 2.3.1) were washed three times with Opti-MEM I before the addition of 800 µL 
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fresh media. Exosome/siRNA mixtures, 20 µg/ml exosomes only, 100 nM Cy5-eGFP 
siRNA only, or 100 nM Cy5-eGFP siRNA with Oligofectamine (prepared as described in 
Section 2.3.4.1) (200 µL of each) were added to the cells and incubated for 4 hours 
(37°C, 5% CO2) before the addition of 500 µL FBS in Opti-MEM I (30%). Hoechst33342 
(1 µM) was added for 5 min before live confocal imaging (R/T). Untransfected control 
cells were treated as transfected cells, omitting the addition of siRNA or transfection 
reagent.  
2.4 Live Cell Endocytic Uptake Assays for siRNA transfection studies 
2.4.1 Alexa488/647-Transferrin (Tf488/647)  
Following transfection of cells in 35 mm MatTeK dishes (as described in Section 2.3.1-
3), cells were washed twice with pre-warmed serum-free imaging media (SFIM - 
phenol red-free DMEM, 0.1% Bovine Serum Albumin (BSA), 20 mM HEPES pH 7.4), 
before serum starvation for 30 min (37°C, 5% CO2). Cells were subjected to two further 
washes with SFIM before addition of Tf488/647 (at the concentrations specified in 
Table 2.4) and incubated for 10 min (37°C, 5% CO2). Cells were subjected to two 
further SFIM washes, followed by incubation with fresh SFIM supplemented with 1 µM 
Hoeschst33342 for 5 min (37°C, 5% CO2). Cells were then washed three times with 
SFIM and confocal imaging was carried out live at R/T in SFIM.  
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2.4.2 Fluorescent Dextrans  
Following transfection of cells in 35 mm MatTeK dishes (as described in Section 2.3.1-
2), cells were washed twice with pre-warmed serum-free imaging media. Dextran was 
added for a period of 60 min (37°C, 5% CO2), and the specific fluorescent dextran 
concentrations are specified in Table 2.4. Cells were washed once 55 min after the 
addition of dextran, followed by incubation with 1 µM Hoescht33342 for 5 min before 
confocal imaging live at R/T in SFIM. 
2.4.3 Alexa647-BSA (BSA647)  
Following transfection of cells in 35 mm MatTeK dishes (as described in Section 2.3.1), 
cells were washed twice with pre-warmed SFIM. BSA647 (50 µg/mL) was added for a 
period of either 30 or 60 min (37°C, 5% CO2). Cells were washed with SFIM 5 min 
before the incubation period was complete and 1 µM Hoescht33342 added for 5 min 
(37°C, 5% CO2) before cells were imaged live on the confocal at R/T in SFIM.  
2.4.4 BODIPY-Lactosylceramide (BODIPY-LacCer) 
Cells were washed twice following transfection of cells in 35 mm MatTek dishes (as 
described in Section 2.3.1) with pre-warmed SFIM. BODIPY-LacCer (1 µg/mL) was 
added for 15 min (37°C, 5% CO2) before three 5% non-fatty acid BSA in phosphate 
buffered saline (PBS) washes were performed. Hoechst33342 (1 µM) was added for 5 
min before live confocal imaging at R/T in SFIM.  
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Table 2.4 – Endocytic Probes Used   
Endocytic Probe Incubation Stock Conc  Working Conc 
   HeLa A549 bEND3 
Transferrin488/647 10 min pulse 
5 min chase 
5 mg/mL  5 μg/mL 5 μg/mL 1 μg/mL 
10kDa Dextran488 30, 60 min 10 mg/mL 100 μg/mL 100 μg/mL 100 μg/mL 
10kDa Dextran647 60 min 10 mg/mL - 100 μg/ml - 
2MDa FITC-Dextran 60 min 10 mg/mL 1 mg/mL - - 
BSA647 30, 60 min 10 mg/ml 50 μg/mL - - 
BODIPY-LacCer 15 min 0.1 mM 1 µg/mL 1 µg/mL - 
 
2.5 Treatment of Cells with Chemical Inhibitors of Endocytosis 
2.5.1 Cell Culture 
HeLa cells were seeded at a density of 2.75x105 and A549 cells at a density of 3.0x105 
per 35 mm MatTek dish in complete media and cultured in a humidified incubator until 
80-90% confluent. 
2.5.2 Inhibitor Treatment and Live cell Endocytic Probe Assays  
Cells were washed three times with SFIM before inhibitor pre-treatment for 30 min 
(37°C, 5% CO2) in fresh SFIM. Cells were then co-incubated with the specific inhibitor at 
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the specified concentration and endocytic probe (details in Table 2.5) for the period 
stated (37°C, 5% CO2) in SFIM. Cells were imaged live on the confocal microscope in 
SFIM following three washes. Hoescht33342 (1 µM) was added 5 min before live cell 
confocal imaging at R/T. All inhibitors were prepared in dimethyl sulfoxide (DMSO) and 
stored at the temperatures and concentrations detailed in Table 2.5. DMSO was used 
as a diluent control for all experiments. 
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Table 2.5 – Chemical Inhibitors of Endocytosis 
Inhibitor Target Incubation Period Storage Temperature Stock Concentration Working Concentration 
 Dextran/Exosomes Transferrin  
EIPA Macropinocytosis 
Na+/H+ Exchange 
90 min 45 min 4°C 100 mM  10, 25, 50, 100 μM 
Rottlerin Fluid-phase 
PKCδ? 
90 min 45 min 4°C 20 mM 5,10 μM 
IPA-3 PAK1 90 min 45 min -20°C 50mM 50 µM 
ML-7 Myosin II 90 min 45 min -20°C 20 mM 20 μM 
Dynasore Dynamin II 90 min 45 min -20°C 100 µM 80 nM 
139 
 
2.6 Fixed Cell Confocal Fluorescence Microscopy 
2.6.1 Cell Culture 
HeLa and A549 cells were seeded onto glass coverslips in 6-well plates at a density of 
2.5x105 per 35 mm well and grown in complete media in a humidified incubator (37°C, 
5% CO2) until 80-90% confluent. For siRNA transfection, cells were seeded in the same 
manner but at a density of 1.5x105 before transfection according to (Section 2.3.1). 
2.6.2 Epidermal Growth Factor (EGF) stimulation of HeLa and A549 cells 
HeLa cells were plated at a density of 2.5x105 per 35 mm well a day before the 
experiment was carried out. Cells were washed three times with DMEM (0.1% BSA) 
and serum-starved for one hour (37°C, 5% CO2) with DMEM (0.1% BSA) before the 
addition of 20 nM EGF and a further 10 min incubation (37°C, 5% CO2). Cells not 
subjected to EGF stimulation were treated identically to stimulated cells but with an 
equal aliquot of deionised water (dH2O, solvent used for EGF). Cells were then fixed 
using the protocol in Section 2.6.3. For HeLa and A549 cells transfected with siRNA, 
this protocol was carried out 48 hours following transfection. 
2.6.3 Fixation and permeabilisation with Paraformaldehyde and Triton X-100 
Cells were washed three times in PBS before fixation in 3% paraformaldehyde for 15 
min. Cells were again washed three times with PBS and 50 mM ammonium chloride 
added for 10 min to block free aldehyde groups. After three PBS washes, 0.2% Triton 
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X-100 was added for 5 min to permeabilise the cells before a further three PBS washes 
were performed. 
2.6.4 Rhodamine-Phalloidin and Hoescht33342 Labelling 
Following fixation actin filaments were labelled by incubation with 2 μg/mL 
Rhodamine-Phalloidin and the nucleus labelled by incubation with 1 µg/mL 
Hoechst33342 for 10 min at R/T. Both labels were diluted in PBS. Cells were washed 
twice with PBS before dipping coverslips once into fresh PBS and then once into dH2O. 
Coverslips were mounted onto glass slides using 10 µL DAKO mounting media, left at 
R/T for one hour before sealing with clear nail polish. Slides were stored at 4°C until 
fixed cell confocal imaging was performed. 
2.7 Extracellular vesicle isolation, purification and characterisation 
Using the methodology outlined in Appendix B, the isolation and subsequent analyses 
performed by the Clayton lab satisfy the criterion set by the International Society for 
Extracellular Vesicles (ISEV), for defining this specimen as exosomes (Lotvall et al., 
2014). 
2.8 Labelling of Du145 exosomes with Alexa488/633 
C5-maleimide-Alexa488 or C5-maleimide-Alexa633 (200 μg/mL - 2.5 µL) was added to a 
30 μL exosome aliquot containing 60 to 100 µg protein, and made up to 50 μL with PBS 
before incubation, with no agitation, for 60 min in the dark (R/T). During incubation 
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exosome spin columns (Invitrogen) were prepared according to manufacturer’s 
instructions and powdered resin was hydrated with 650 µL for 15-30 min at R/T. Spin 
columns placed in the collection tubes were centrifuged for 2 min (750 x g), in a swing-
out rotor. The collection tubes were discarded before the addition of the labelled EV 
aliquot to the resin. Columns were placed in 1.5 mL eppendorf tubes and centrifuged 
for 3 min (750 x g) to collect labelled exosomes. Non-incorporated, excess dye was 
retained by the resin, and controls involving dye but no exosomes were performed in 
parallel to confirm dye retention by the column. For microscopy analysis, labelled 
exosomes were gently mixed to 1000 μL in phenol red free DMEM, before filtration 
through a 0.22 μm filter (Millex), aliquoted and stored at -80°C until required. 
2.9 Live Alexa488/633-Exosome (Exo488/633) Endocytic Uptake Assay 
2.9.1 Standard endocytic uptake assay 
As for live cell endocytic probe uptake assay experiments, HeLa cells were seeded at 
2.5x105, primary human lung fibroblasts at 2.5x105 and H1299eGFP cells at 3.0x105 in 
35 mm MatTek imaging dishes in complete media before being cultured to reach 80-
90% confluency. Cells were washed three times with SFIM before the addition of 60 
µg/mL of either Exo488 (HeLa) or Exo633 (Fibroblasts/HeLa) in SFIM for 30-360 min 
(37°C, 5% CO2) before confocal imaging (R/T). For siRNA transfection and inhibitor 
experiments in HeLa, Exo488 were incubated for 60 min (37°C, 5% CO2). For uptake in 
H1299eGFP cells, Exo633 were incubated for 60 min at either 2 µg/ml or 20 µg/ml. 
Cells were incubated with 1 µM Hoechst33342 for 5 min (37°C, 5% CO2) before 
washing thrice with SFIM and imaging live (R/T). For time-lapse confocal imaging, HeLa 
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cells were incubated with 1 µM Hoechst33342 and Cell Mask Deep Red Plasma 
Membrane Stain (1:5000) and fibroblasts incubated with 1 µM Hoechst33342 for 5 min 
before washing with SFIM and time lapse confocal imaging (37°C). 
2.9.2 Endocytic Uptake in siRNA transfected cells 
Following transfection of HeLa cells (described in Section 2.3.1), cells were subjected to 
three SFIM washes before the addition of 60 µg/mL of Exo488 or Exo633 (Fibroblasts) 
in SFIM for 60 min (37°C, 5% CO2). Media was removed and Hoescht33342 (1 µM) 
added for the final 5 min of incubation before cells were washed thrice with SFIM and 
imaged live on the confocal microscope (R/T).  
2.9.3 Endocytic Uptake in cells treated with Chemical Inhibitors of Endocytosis 
Following inhibitor pre-treatment (detailed in Section 2.5.2), Exo488 (60 µg/mL) in 
SFIM were added to cells in the continued presence of the specified inhibitor for 60 
min (37°C, 5% CO2). Hoescht33342 (1 µM) was added for the final 5 min before live cell 
confocal imaging (R/T).   
2.10 Labelling of lysosomes with Dx647 
Cells were seeded in complete media at 2.0x105 in 35 mm MatTek dishes and cultured 
in a humidified chamber (37°C, 5% CO2) to be 50-60% confluent on the day of Dx647 
incubation. Dx647 (100 µg/mL) was incubated with cells for 2 hours (5% CO2, 37°C), 
before washing with PBS and re-addition of complete media. Cells were then 
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incubated for approximately 18 hours (37°C, 5% CO2) before incubating with 60 µg/mL 
Exo488 (as described in Section 2.9.1) for colocalisation analysis. 
2.11 Microscopy 
2.11.1 Live Cell Confocal Microscopy 
Fluorescent images were taken using a Leica SP5 Confocal Microscope system and 
LASAF software. Cells were imaged at R/T with either a 40x 1.25 NA or a 63x 1.4 NA Oil 
Objective. Hoechst33342 emission was collected after excitation at 405 nm; Alexa488 
and FITC fluorophores were excited by a 488 Argon laser rhodamine fluorescence was 
excited by a 543 Helium-Neon laser and Alexa633/647 and Cy5 fluorophores were 
excitation by a 633 Helium-Neon laser. Bi-directional, sequential scanning was applied 
to ensure spectral separation of fluorophores. Gain and offset settings were optimised 
for each fluorescent channel within an experiment. Images were collected using a line 
average of three and scanned at 200-400 Hz to reduce noise. Where Xyz projections 
are shown, images were taken beginning at the basal surface of the cell and at every 
0.5 µm within the z plane until the apical surface of the cell, to produce a z-stack of 
each field of view.  
2.11.2 Live Cell Time-Lapse Imaging 
This was performed to visualise the intracellular dynamics of Exo488/647 in 
HeLa/Fibroblasts, respectively.  Microscope settings used were as described in Section 
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2.11.1 but with cells maintained at 37°C. Images were scanned every 1-2 sec over a 
period of 5 min. 
2.11.3 Fixed Cell Confocal Microscopy 
This was performed to visualise rhodamine-phalloidin labelled actin filaments. 
Objectives and lasers used were as used for live cell microscopy, unless otherwise 
stated. Images were collected at 100Hz using uni-directional and sequential scanning. 
Images were taken every 0.2-0.5 µm within the z-plane.   
2.12 SDS PAGE and Western Blotting 
2.12.1 Lysate collection 
Following siRNA transfection (Section 2.3.1-2) cells, , were washed twice with ice-cold 
PBS before the addition of 100 µL of lysis buffer (150 mM NaCl, 50 mM Tris-base pH 
8.0, 10% Triton X-100, dH2O) with protease inhibitor per 35 mm well. One cOmplete 
Mini Protease Inhibitor Cocktail Tablet was dissolved per 10 mL of lysis buffer. Cells 
were incubated with the lysis buffer on a lateral, circular shaker (high speed setting) 
for 5 min (4°C). Cells were scraped using a sterilised cell scraper, suspension removed 
and centrifuged for 10 min at 4°C (13,000 x g). Supernatant was collected for further 
analysis and the pellet discarded. 
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2.12.2 Bicinchoninic (BCA) Assay for protein quantification 
A 200 µL aliquot of BCA working solution (49:1, Bicinchoninic Acid: Copper Sulphate 
Pentahydrate) was added per well of a 96-well plate. Cell lysates to be quantified were 
added to triplicate wells at 10 μL per well. BSA protein standards (0, 0.2, 0.4, 0.6, 0.8, 1 
mg/mL in Triton X-100 lysis buffer) were added to duplicate wells at 10 μL, in order to 
generate a protein standard curve. Samples were incubated for 30 min at 37°C before 
absorbance reading at 562 nm. Quantification of each lysate supernatant was 
calculated through analyses of the protein concentration standard curve generated 
based on the absorbance readings of the BSA standards. 
2.12.3 SDS-PAGE Electrophoresis 
Stock samples of each lysate were prepared at concentrations of 1 mg/mL in lysis 
buffer and stored at -20°C until required.  One part sample buffer (2% SDS, 10% 
glycerol, 0.02% Bromophenol Blue (0.8% w/v), 62.5 mM Tris-HCL, 400 mM 
Dithiothreitol (DTT), dH2O, pH 6.8) was added to three parts lysate before incubation 
at 95°C for 5 min to denature the sample protein. Samples were then centrifuged for 1 
min at 4°C (13,000 x g). Prepared samples were loaded onto pre-cast 10% or 12% 
resolving and stacking gels (Life Science BIO-RAD, Hertfordshire, UK) at between 18-24 
μg of protein per well. Dual Color molecular weight marker was loaded at 10 µL. 
Electrophoresis was carried out at 100 V for approximately 85 min (R/T) using a BIO-
RAD 300W PowerPac HC. 
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2.12.4 Wet Protein Transfer 
Protein was transferred from the resolving gel to Polyvinylidene difluoride (PVDF) 
membrane at 100 V for 1 hour (approximately 4°C). PVDF membrane was removed and 
washed once in dH2O, followed by incubation with PonceauS solution for 
approximately 5 min to allow protein visualisation. Relevant parts of the membrane 
were retained regarding relevant molecular weights before three 5 min PBS washes 
were performed to remove remaining PonceauS from the membrane. 
2.12.5 Semi-dry Protein Transfer 
Resolving gels were transferred to a 0.2 µm PVDF mini-gel transfer system (BIO-RAD) 
and protein transfer carried out at 1.3 A, 25 V for 7 min (2 gels) or 4 min (single gel) 
using a BIO-RAD Transblot TURBO. This setting is defined by BIO-RAD for the universal 
transfer of proteins with mixed molecular weights on the same gel. PVDF membrane 
was removed and treated with PonceauS solution as described in Section 2.12.4. 
2.12.6 Immunoblotting for protein detection 
PVDF membrane was blocked with 5% milk (Marvel in PBS-0.0025% Tween (PBST)) for 
1 hour on an oscillator (low speed setting) to prevent non-specific antibody binding. 
Primary antibody incubation was carried out on the oscillator (low speed setting) for 
either 1 hour at R/T, or overnight at 4°C. Membranes were subjected to three 5 min 
washes with PBS supplemented with 0.025% Tween (PBST) on a lateral, circular shaker 
(medium speed setting). Secondary species specific Horseradish Peroxidase (HRP) 
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conjugated antibody incubation for 1 hour (R/T) on the oscillator (low speed setting) 
was performed followed by three 5 min PBST washes. Primary and secondary 
antibodies and the dilution used are presented in Table 2.6. Incubations of membranes 
with mouse anti-β-tubulin-HRP conjugate were carried out in 5% milk for 1 hour (R/T) 
and required no secondary antibody incubation. 
Table 2.6 - Antibodies used for Immunoblotting 
Antibody Dilution Supplier 
Primary Antibodies   
Mouse Anti-AP50 1:200 BD Transduction Laboratories (Oxford, U.K.) 
Rabbit Anti-Caveolin 1 1:200 Cell Signalling Technologies (Hertfordshire, U.K.) 
Rabbit Anti-Cdc42 1:200 Sigma-Aldrich (Dorset, U.K.) 
Rabbit Anti-Flotillin1 1:500 BD Transduction Laboratories (Oxford, U.K.) 
Rabbit Anti-PAK1 1:500 Cell Signalling Technologies (Hertfordshire, U.K.) 
Rabbit Anti-PKCδ 1:200 Sigma-Aldrich (Dorset, U.K.) 
Rabbit Anti-GAPDH 1:1000 Cell Signalling Technologies (Hertfordshire, U.K.) 
Anti-δ-Tubulin-HRP 1:50000 Sigma-Aldrich (Dorset, U.K.) 
   
Secondary Antibodies   
Goat anti-mouse HRP 1:2000 (Thermo-Scientific Pierce, Loughborough, U.K.) 
Goat anti-rabbit HRP 1:2000 (Thermo-Scientific Pierce, Loughborough, U.K.) 
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2.12.7 HRP Detection  
Membranes were incubated with Clarity Western ECL Solution (BIO-RAD) for 5 min at 
R/T before imaging. AP50 and Cdc42 bands were imaged following 2.5 min incubation 
with SuperSignal West Femto ECL solution (Thermo Scientific-Pierce). The membrane 
was wrapped in cling film, placed in a developer cassette and imaged in an x-ray 
developer with ECL hyperfilm or excess ECL solution was shaken from the membrane 
before being imaged using a BioRad ChemiDoc system. 
2.13 Data Analysis 
2.13.1 Mean Fluorescence Intensity Quantification of Individual Cells 
Individual cells from Leica Application Suite Advanced Fluorescence (LAS AF) Software 
files were manually selected as regions of interest (ROIs) using ImageJ software 
(Schindelin, J. et al., 2012). Mean fluorescence intensity (MFI) of each was calculated, 
resulting in the quantification of approximately 150-160 cells per experimental sample 
from 8-10 fields of view. The geometric mean (GM) of each sample group was 
calculated to provide an average MFI for repeat experiments; the mean of the GM 
from three independent experiments was calculated and used for statistical 
calculations. Figure 2.1 demonstrates this protocol. 
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(A) 
(C) (D) 
(B) 
(E) 
Fig.  2.1. Method to calculate MFI (ImageJ software). (A) Brightfield (BF) channel, Hoechst33342 
channel and channel containing fluorescence intensity to be measured (shown as green) of one field 
of view were merged. Drawing tool was selected and the peripheries of individual cells identified 
and marked as shown for one cell. (B) ROI Manager was opened and (C) the selected cell added as a 
new ROI. (D) The periphery of all cells in the field of view were selected and added as ROIs to the ROI 
Manager. Only cells completely within the field of view were selected. (E) All ROIs were selected and 
measured using the ROI manager. This process was repeated for another field of view, the mean 
intensity of each cell collected and the GM of approximately 160 cells per sample calculated.    
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The data generated from this method can be presented in a variety of ways. Using the 
GM, as described above, the data could be presented in a bar graph. The GM has an 
advantage in that intensity values obtained from cells containing saturated pixels 
would not skew the resulting average value. 
2.13.2 Calculation of Colocalisation Coefficients from Confocal Microscopy 
To determine the proportion of exosomes (green fluorescence) associated with 
lysosomes (red fluorescence) in the cells treated as described in Section 2.10 the M1 
Mander’s coefficient (a metric used to calculate the ‘fraction of probe 1 in 
compartments containing probe 2’ (Dunn et al., 2011)) was calculated using the JaCop 
ImageJ plug-in and thresholded using the automated default algorithm. Six fields of 
view (approximately 60 cells) per time point were analysed and the mean M1 
coefficient of the six fields of view calculated to provide an average colocalisation 
value for each repeat. The mean of the average colocalisation value for three separate 
experiments was plotted.  
2.13.3 Statistical Analysis  
To compare control treated samples against experimental samples, a Student’s 
unpaired t-test was utilised using the geometric mean of each separate experiment. 
Significance was calculated for geometric means normalised to either the 
untransfected control (Utx) value for siRNA transfection uptake experiments or the 
DMSO Control value for inhibitor uptake experiments. Significance was specified as 
*p<0.05, **p<0.01, or ***p<0.001. 
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3 Developing and optimizing methodologies:  siRNA targeting 
methods for analysing endocytic pathways 
3.1 Introduction 
A variety of methodologies have previously been utilised by a number of groups to 
specifically inhibit different endocytic mechanisms. These most notably involve 
siRNA targeted depletion of a number of endocytic proteins, transfecting cells to 
overexpress mutant endocytic proteins and pharmacological inhibition (Dutta and 
Donaldson, 2012). Targeting known endocytic regulatory proteins using siRNA 
transfection in distinct model cell lines defined by the COMPACT Consortium was 
initially performed. 
This work began by using the in vitro barrier models provided by GSK as part of the 
COMPACT consortium, the details of which are presented in Table 3.1. 
Table 3.1 – Biological Barrier models of COMPACT Consortium Cell Lines  
Cell line Species Biological Barrier 
HeLa  cervical epithelial Human Cervical mucous membrane 
A549 alveolar epithelial  Human Deep Lung epithelia 
bEnd.3 brain endothelial Mouse Blood Brain barrier (BBB) 
Caco.2 colorectal epithelial  Human Gut epithelia 
Calu.3 lung epithelial  Human Upper Lung epithelia 
HaCaT keratinocyte Human Skin 
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HeLa, A549 and bEnd.3 cells were initially used for these studies due to their ease 
of culture and transfection. Other members of the lab have found that Caco.2 and 
Calu.3 cells form a thick mucal layer that is useful for their use as a barrier model to 
test drug delivery systems, but makes their culture difficult. This physical barrier 
also prevents efficient transfection, which rendered them unsuitable for the aims of 
this project, which included the use of siRNA transfection as a method of targeting 
endocytosis.  
3.2 Aims and Objectives 
- To explore protein targets and techniques for siRNA depletion in order to 
inhibit Clathrin-Mediated Endocytosis (CME) in the barrier model cell lines 
supplied by the COMPACT Consortium. 
- To use the same siRNA techniques in order to identify proteins which are 
involved in the regulation of fluid-phase endocytosis and macropinocytosis 
in these same cell lines. 
- To assess the effects on both cell structure and on the uptake of different 
endocytic probes following the depletion of the proteins targeted in Aim 1. 
and 2. 
- As an overall aim, to become comfortable and efficient in the basic 
laboratory techniques, cell culture, and confocal microscopy that will be 
essential for the completion of this project.   
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3.3 Results 
3.3.1 Exploration siRNA depletion methods to inhibit Clathrin-Mediated 
Endocytosis (CME) 
In this section the HeLa cell line was utilised as the laboratory has been developing 
in vitro endocytosis assays in this cell line (Al Soraj et al., 2012; Moody et al., 2015). 
By depleting the levels of AP2µ2, a subunit of the AP2 complex to which CME is 
dependent, it was postulated that internalisation of the CME marker, transferrin, 
would be prevented; an observation that has been previously demonstrated 
(Moody et al., 2015; Motley et al., 2003).  Cells were transfected with siRNA 
targeting this protein and then analysed for AP2µ2 expression and transferrin 
uptake. A single 48 hour AP2μ2 siRNA transfection demonstrated a significant 
decrease in AP2μ2 expression via Western blotting (Figure 3.1a). Indeed, a double 
band was evident at 50 kDa (AP2µ2), yet the higher weight band was reduced in 
cells transfected with siAP2µ2 indicating that expression of the protein was 
reduced.  Furthermore, many cells of the transfected population demonstrated 
membrane bound transferrin after 10 min (Figure 3.1b), suggesting an inability of 
these cells to carry out CME. To ensure that the depletion of AP2µ2 did not affect 
the internalisation capacity of other endocytic pathways, a dextran488 (Dx488) and 
albumin647 (BSA647) endocytosis assay was performed using the method 
described in Section 2.4.2-3, as these two probes do not enter the cell via CME. 
Dextran is a widely recognised fluid-phase endocytosis/macropinocytosis probe and 
BSA is believed to enter the cell via clathrin independent endocytosis (CIE). 
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Fluid-phase endocytosis and caveolin-mediated endocytosis are both proposed. 
Following a 30 min pulse of both probes, both Dx488 and BSA647 positive vesicles 
could be observed in cytoplasmic vesicular structures in control and AP2µ2 depleted 
cells to a similar extent. This thesis demonstrates an ability to quantify the 
fluorescence in cell populations as described in Section 2.13.3 and mean fluorescence 
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Fig.  3.1. AP2μ2 depletion via single 100nM siRNA transfection successfully inhibits Tf488 
endocytosis in HeLa cells. (A) Representative Western blot analysis demonstrates successful 
depletion of AP2μ2 following 100 nM siRNA transfection. Blots representative of two separate 
experiments. (B) Following a 48 h period of siRNA transfection, cells were serum starved for 30 min 
(37°C, 5% CO2). Tf488 (5 μg/ml) was pulsed for 10 min, washed and incubated with Hoeschst33342 
for 5 min before imaging live (R/T). Arrows indicate membrane bound Tf488. Scale bar: 20 µm. 
Images summarise of three separate experiments.  
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intensity (MFI) quantification of each population supports these findings, providing 
further evidence that AP2µ2 depletion via this method does not affect the endocytic 
ability of dextran and albumin (Figure 3.2) and the pathway(s) that are utilised by 
them. In both populations the appearance of large BSA647 aggregates was apparent, 
though the number was greater in cells depleted of AP2µ2. This could be for a number 
of reasons, but as this was a single experiment it may be an issue with the probe used 
or problem with the treatment.  
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Though the described 48 hour single transfection method successfully depleted the 
AP2 subunit, double transfection experiments were also investigated (as described in 
Section 2.3.2) having been utilised previously (Motley et al., 2003). Similar results were 
obtained following double transfection (Figure 3.3), with transferrin labelling punctate 
structures in control cells and largely contained on the plasma membrane of siAP2µ2 
cells. Cells subjected to this double transfection, however, were less confluent and had 
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Fig.  3.2. HeLa cells retain the ability to internalise Dextran488 and Albumin647 following depletion 
of AP2μ2 via siRNA transfection. (A) Following 48 h transfection, cells were subjected to a 30 min 
Dx488 (100 µg/ml) and Albumin647 (50 μg/ml) pulse (37°C, 5% CO2) before imaging live (R/T). Scale 
bar: 10 µm. (B) MFI quantified for both Dx488 and BSA647 in each cell population. Bars: Standard 
deviation of cell variability within population. 
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formed a greater number of stress fibres, suggesting that this technique may have 
detrimental effects on overall cell physiology. Secondary effects of depleting a target 
protein for extended periods must be considered regarding these assays, as results 
comparable to a ‘physiological norm’ will be the most reliable. For these reasons, all 
further transfections, where possible, were restricted to a single application for a 48 
hour period. Notably, such low expression levels of AP2μ2 from double transfections 
could indicate the occurrence of undesirable secondary effects due to the inability of 
successfully transfected cells to perform CME. 
Reverse transfection is primarily used in high-throughput analyses and involves 
simultaneous siRNA complex application and cell seeding (synchronous siRNA 
transfection), or the addition of cells to dry siRNA (Erfle et al., 2007; Fujita et al., 2010). 
By removing a day of culture and returning to a single application of siRNA it was 
hoped that cells would be subject to less physiological stress and therefore yield more 
reliable results. Tf488 uptake in cells subjected to synchronous siRNA transfection of 
AP2µ2 was non-uniform across the cell population (Figure 3.3). Although some cells 
had clearly internalised transferrin, others presented only membrane bound 
transferrin, indicating that AP2μ2 had been successfully depleted in these cells. In cells 
transfected (synchronous) with GFP siRNA, transferrin could be clearly observed at 
early endocytic compartments in the perinuclear region 15 min following addition of 
the probe (Figure 3.3). This indicated that the synchronous transfection protocol did 
not cause a consistent observable effect regarding the ability of the cell to internalise 
transferrin.  
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 These observations indicated that a single 48 hour siRNA transfection provided 
greater efficiency for the obstruction of transferrin endocytosis without causing effects 
such as elongation and greater production of intercellular stress fibres observed with 
double transfections. 
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Fig.  3.3. AP2μ2 depletion via synchronous and double siRNA transfection successfully inhibits Tf488 
endocytosis in HeLa cells.  Following either a 72 h synchronous transfection (A) or two 48 h periods of 
siRNA transfection (B), cells were serum starved for 30 min (37°C, 5% CO2). Tf488 (5 μg/ml) was 
pulsed for 10 min, washed and Hoechst33342 added  for 5 min (37°C, 5% CO2) before imaging live 
(R/T). Scale bar: 20 μm. n=1 
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The establishment of a specific endocytic model for CME inhibition in HeLa is 
demonstrated from these studies. The use of a single siRNA transfection targeting 
AP2µ2 as a specific inhibitory method, with the use of a transferrin pulse as a specific 
probe can now be applied at the high content level to assess CME as an entry route for 
specified drug delivery systems (DDSs) via microscopy. To compliment this data, 
forward siRNA transfection targeting AP2µ2 was carried out in A549 cells, a COMPACT 
Consortium barrier model for the deep lung epithelia. Initial analysis with A549 cells 
demonstrated the presence of punctate auto-fluorescence, which in some cells is 
particularly extensive (Figure 3.4). These structures can be observed from 405 and 
488nm excitation lasers set at low power settings, but not by the 633 laser. For these 
reasons, it was decided that markers conjugated to Alexa647 or those which fluoresce 
in the far-red would be used for further uptake studies in A549 cells.  
Western blot analysis indicates that AP2µ2 could be successfully depleted in these cells 
(Figure 3.5a). As expected control siRNA cells internalised transferrin647 (Tf647), which 
was visualised within the cell 15 min following addition (Figure 3.5b). In contrast, an 
extensive number of the cell population transfected with siRNA targeting AP2μ2 are 
unable to internalise transferrin, where it is confined to the plasma membrane.  
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The efficiency of synchronous transfection in this cell line was investigated, but unlike 
single transfection, transferrin uptake was largely unaffected and, as observed in 
control cells it was located in punctate cytoplasmic structures in a high percentage of 
the population (Figure 3.5b). These results provide evidence that the use of a single 
siRNA transfection as a depletion method in conjunction with a CME specific endocytic 
model can also be applied in A549 cells at a high content level. CME as an endocytic 
route for drug delivery systems, such as those provided by COMPACT Consortium 
partners, could then be evaluated in HeLa and A549 cells. 
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Fig.  3.4. Autofluorescent structures in A549 cells visualised by the 488 laser but not the 633 laser. 
Cells were incubated with Hoechst33342 for 5 min (37°C, 5% CO2) before imaging live (R/T). Scale bar: 
20 µm.  
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Fig. 3.5. Tf647 endocytosis is prevented following 48 h depletion of AP2μ2 via siRNA transfection in 
A549 cells. (A) Western blot analysis indicates that AP2µ2 is depleted 48 h following single 
transfection.  (B) Following a 48 h single transfection or 72 h synchronous transfection, cells were 
serum starved for 30 min (37°C, 5% CO2)  before being subjected to a 10 min Tf647 (5 μg/ml) pulse, 
washed and addition of Hoechst33342 (37°C, 5% CO2) for 5 min before imaging live (R/T). For single 
transfection images are representative of two separate experiments. Scale bar: 20 µm. 
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Lactosylceramide (LacCer) is a glycosphingolipid believed to preferentially reside in 
lipid-rafts, and is therefore used as a marker for Caveolin- and Flotillin-mediated 
endocytosis, or more generally CIE (Marks et al., 2005; Singh et al., 2007). Here, 
BODIPY-labelled LacCer was used to assess whether siRNA mediated depletion of 
AP2µ2 also affected the uptake of the probe. Uptake has been assessed through the 
use of chemical inhibitors of endocytosis (Vercauteren et al., 2010) but to our 
knowledge this was the first time that this experiment had been performed using 
siRNA depletion of endocytic proteins. In HeLa cells treated with control siRNA (GFP) 
and LacCer (as described in Section 2.4.4), the probe was strongly localised to the 
plasma membrane and was also observed within the intracellular region of the cell as 
punctate structures (Figure 3.6). LacCer positive punctate structures indicate 
internalisation via endosomes, possibly derived from caveolae. Association of BODIPY-
LacCer with endosomal membranes has indeed been previously observed in human 
fibroblasts (Marks et al., 2008). Dispersion throughout the cytosol may be lipid 
resultant from endosomal escape or direct translocation through the membrane. This 
pattern of uptake is replicated in control transfected A549 cells (Figure 3.6), indicating 
that LaCer has similar cellular interaction and mode of uptake between these two cell 
lines. Following depletion of AP2µ2, uptake of LacCer is unaffected, strongly labelling 
the plasma membrane and intracellular vesicles (Figure 3.6). These observations 
indicate that depletion of AP2µ2 via siRNA transfection does not affect the uptake of 
probes believed to internalise independent of CME, suggesting that other endocytic 
mechanisms are not affected by this method.  It also confirmed that robust in vitro 
assays for CME and CIE in these two cell lines were now available in the laboratory. 
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bEnd.3 cells are a mouse derived brain endothelial line, and a commonly used in vitro 
model for the BBB. Using a single siRNA transfection targeting mouse AP2µ2, the 
protein was successfully depleted after 48 hours (Figure 3.7a). Transferrin uptake was 
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Fig. 3.6. BODIPY-LacCer endocytosis is not affected in either HeLa or A549 cells following depletion 
of AP2μ2. Following 48 h transfection, cells were washed and subjected to a 15 min pulse of BODIPY-
LacCer (1 μg/ml) followed by 3x 5% non-fatty acid BSA in PBS (37°C, 5% CO2) washes. Hoechst33342 
was added 5 min before imaging live (R/T). Scale bar: 10 µm. 
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then assessed in these cells including an acid wash step to remove surface bound label. 
This was in an attempt to better differentiate surface from intracellular staining that 
was difficult to separate in these very thin cells (5-7 µm) that also, compared with HeLa 
and A549 had relatively low transferrin uptake. 
Uptake of both Tf488 and Tf647 in control transfected cells was observed in vesicular 
structures in control cells (Figure 3.7b). Following AP2µ2 transfection, cells appear to 
internalise Tf488 to the same extent as control cells (Figure 3.7b) but uptake of Tf647 
appeared to be compromised. MFI quantification to obtain quantifiable results was 
very difficult for this cell line due to low fluorescence and they also tended to stack on 
top of each other. For these reasons, it was difficult to assess whether the decrease in 
Tf647 uptake observed in siAP2µ2 transfected cells was significant using this method.  
The effect of siAP2µ2 targeting on fluid-phase uptake of dextran was then analysed in 
bEnd.3 cells. Dextran presented as punctate structures in control transfected cells after 
60 min of uptake (Figure 3.8) and there was no evidence that inhibition of CME 
affected uptake or distribution of this probe.  
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Fig.  3.7. Tf488 and Tf647 endocytosis is not prevented following depletion of AP2μ2 in bEnd.3 
cells. (A) Western blot analysis indicates that AP2µ2 is depleted 48 h following single transfection. 
(B) Following 48 h transfection, cells were serum starved before being subjected to a 10 min Tf647 
(5 μg/ml) pulse, wash and 5 min Hoechst33342 incubation. An ice cold 3 min acid wash (pH 4.5) was 
performed before imaging live (R/T). Scale bar: 10 µm.   
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These studies began to indicate which cell lines would be suitable to study the uptake 
of exosomes. Transfection and endocytic probe uptake efficiency of HeLa and A549 
cells, over bEnd.3 suggested that these would be the most appropriate choice at this 
stage of the project.  
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Fig.  3.8. Dx488 endocytosis is not prevented following depletion of AP2μ2 via siRNA transfection 
in bEnd.3 cells. Following a 48 h transfection, cells were subjected to a 60 min Dx488 (100 μg/ml) 
pulse. Hoechst33342 was added 5 min before imaging live (R/T). Images representative of three 
separate experiments. Scale bar: 10 µm. 
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3.3.2 Exploring the role of P21-associated kinase 1 (PAK1) in actin cytoskeletal 
dynamics and fluid-phase endocytosis/macropinocytosis in HeLa and A549 cells 
The involvement of PAK1 in actin regulation, through its interaction with small GTPases 
such as Cdc42 and Rac1, has been demonstrated in growth factor mediated 
macropinocytosis (Dharmawardhane et al., 2000; Edwards et al., 1999) and indeed 
other cellular processes that rely on actin (Ong et al., 2011; Tunduguru et al., 2014). 
However, it must be noted that the distinction between fluid-phase endocytosis, 
constitutive and growth factor induced macropinocytosis is still relatively undefined. 
PAK1 was further investigated in this thesis including the effects of its depletion on 
actin, which was visualised in cells using Rhodamine-Phalloidin. Unlike previous 
experiments performed in this chapter that were performed with live cells, labelling 
with this fluorophore required cell fixing using established methods.  
Western blot analysis indicated successful depletion of PAK1 protein in both HeLa and 
A549 cells subjected to a single 48 hour transfection with siRNA targeting PAK1 (Figure 
3.9). Epidermal growth factor (EGF) acting through the Epidermal growth factor 
receptor (EGFR) is a powerful stimulator of macropinocytosis that can be visualised by 
looking at actin causing membrane ruffling and also stimulating the internalisation of 
fluid as large gulps into macropinosomes (Buckley and King, 2017; Jones, 2007) is 
routine. HeLa have very low EGFR levels (Al Soraj et al., 2012) but A549 cells with 
higher EGFR levels have been used to demonstrate EGF effects on actin (Peter et al., 
2009); the extent of actin response following EGF treatment was then mostly explored 
in this cell line.  
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Introducing EGF to serum starved A549 cells, as described in Section 2.6.2 induced 
clear effects on the actin cytoskeleton, which manifest by classic signs of actin ruffling 
and filopodia formation (Figure 3.10). Growth factor induced macropinocytosis 
involves extensive ruffling of the plasma membrane and the formation of filopodia 
within 10 min of EGF stimulation. These protrusions are also observed in control cells 
but are much more prominent in stimulated cells (Figure 3.10). Here images were 
captured through the Z axis and then separated as Basal, Centre and Apical using 
methodology developed in the laboratory  (He et al., 2015). This allowed closer 
scrutiny of distinct locations of the cell in response to EGF and in PAK1 depleted cells. 
Following a 48 h depletion of PAK1 via siRNA transfection, the effect of EGF on the 
actin cytoskeleton was investigated in order to evaluate the necessity for PAK1 in 
filopodia formation and macropinocytosis. The cellular response to EGF stimulation in 
cells transfected with control siRNA was analogous to the response observed in 
untransfected cells (Figure 3.11), indicating that the ability of the cells to perform and 
respond to EGFR signalling is unaffected by the transfection process. With regards to 
GFP PAK1 
GAPDH 
PAK1 
siRNA: Utx 
- 68kDa 
- 37kDa 
GFP PAK1 
GAPDH 
PAK1 
siRNA: Utx 
- 68kDa 
- 37kDa 
HeLa A549 
Fig.  3.9. PAK1 is successfully depleted 48 h after siRNA transfection in HeLa and A549 cells. 
Following 48 h siRNA transfection, Western blot analysis confirms PAK1 depletion in HeLa and A549 
cells in comparison with the loading control GAPDH.   
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PAK1 depleted cells, no major differences in actin response to EGF stimulation was 
observed. There was little observable difference between these two populations with 
regards to actin dynamics. A difference between the control siRNA and PAK1 siRNA 
treated cells under non-EGF stimulated conditions would suggest a necessity for PAK1 
in constitutive actin dynamics, yet no distinguishable difference between these 
populations can be observed either (Figure 3.11). There are several reasons for these 
observations. PAK1 may not be directly and solely responsible for the events leading 
up to macropinocytosis; it may have a greater role in later events, such as cup 
formation and closure. As PAK1 activity has previously been linked with growth factor 
induced stimulation of dextran endocytosis the involvement of this kinase in fluid-
phase mechanisms cannot be ignored (Dharmawardhane et al., 2000). Further studies 
were performed in in PAK1 depleted cells.  
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Fig.  3.10. Actin demonstrates greater activity following EGF stimulation in untransfected A549 cells. Cells were serum starved for 1 h 
before 10 min incubation with either SFIM only or 20 ng/ml EGF (37°C, 5% CO2). PFA fixation was carried out before 10 min incubation with 
Rhodamine-Phalloidin (1:500) and Hoechst33342 (1 µM) at R/T before imaging. Empty arrows indicate membrane ruffling and solid arrows 
indicate extensive filopodia-like cell-cell connections.          
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Fig. 3.11.  Actin demonstrates no difference in activity following EGF stimulation 
in A549 cells with depleted PAK1 levels. Cells were transfected with either GFP or 
PAK1 siRNA for 48 h followed by serum starvation for 1 h. Incubation with either 
SFIM only or 20 ng/mL EGF for 10 min was performed (37°C, 5% CO2) before PFA 
fixation and 10 min incubation with Rhodamine-Phalloidin (1:500) and 
Hoechst33342 (1 µM) at R/T.          
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After a 48 h depletion of PAK1 in A549 cells, dextran was found to internalise to the 
same degree as in untransfected and control cells. MFI quantification confirmed the 
microscopy images, in that there was no significant difference in uptake (Figure 3.12). 
These observations indicate that depletion of PAK1 does not affect the fluid-phase in 
A549 cells. This was further explored in HeLa cells confirming the data in A549 (Figure 
3.13). Uptake of a larger dextran molecule (2 MDa) was also investigated to explore 
whether the fluid-phase uptake of larger molecules was affected by depletion of this 
protein. Control transfected cells were found to internalise 2 MDa dextran as 
intracellular punctate structures, not dissimilar to those resultant from 10 kDa dextran 
uptake (Figure 3.13). The effect of PAK1 depletion on the uptake of the CME probe 
transferrin was also explored in order to assess any effects on CME. Both control and 
siPAK1 cells internalised to a similar extent and this was confirmed using MFI 
measurements (Figure 3.14).  
Though there is strong data for the involvement of PAK1 in growth factor induced 
macropinocytosis (Dharmawardhane et al., 2000) and in organising cell shape (Figure 
3.11) the protein does not appear to be involved in constitutive fluid phase uptake. 
This led to studies investigating the role of another actin interacting protein named 
Cdc42. 
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Fig.  3.12. Dx647 endocytosis is reduced following depletion of PAK1 48 h following siRNA 
transfection in A549 cells. (A) Following 48 h transfection, cells were washed before being subjected 
to a 60 min Dx647 (100 μg/ml) pulse before imaging live (R/T). Hoechst33342 was added 5 min 
before imaging.  Scale bar: 20 µm. (B) MFI quantification of Dx647 for each cell population. Bars: 
Standard deviation. Graph summarises two separate experiments. 
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Fig.  3.13. Neither 10 kDa Dx488 nor 2 MDa Dex endocytosis is prevented following depletion of PAK1 via siRNA transfection in HeLa cells. Following 
48 h transfection, cells subjected to a 60 min 10 kDa Dex (100 µg/ml) or 2 MDa Dex  (1 mg/ml) pulse before washing and imaging live (R/T). Scale bars: 
20 µm and 10 µm respectively. 
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Fig.  3.14. Tf488 endocytosis is unaffected following depletion of PAK1 via siRNA transfection in 
HeLa cells. (A) Following 48 h transfection, cells were serum starved before being subjected to a 10 
min Tf488 (5 μg/ml) pulse and 5 min chase with Hoechst33342 before imaging live (R/T). Scale Bar: 
20 µm. (B) MFI quantification of Tf488 for each cell population in (A). Bars: Standard error. Graph 
summarises three separate experiments.   
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3.3.3 Exploring the role of Cdc42 in actin cytoskeletal dynamics and fluid-phase 
endocytosis /macropinocytosis in HeLa and A549 cells. 
Cdc42 is one of several RhoGTPases involved in the regulation of actin function and has 
been associated with fluid-phase uptake, growth factor induced macropinocytosis and 
phacocytosis (Beemiller et al., 2010; Cox et al., 1997). Notably, it acts upstream of 
PAK1.  Effects on endocytosis were investigated in cells depleted of this protein, 
initially focusing on constitutive fluid phase uptake of dextran in HeLa and A549 cells. 
Western blot analysis indicated that a 48 h siRNA transfection was sufficient for Cdc42 
depletion (Figure 3.15), thus permitting further endocytosis studies. 
HeLa                          A549
 
Quantification of microscopy images represented by Figures 4.16 and 4.17 
demonstrated that there was no significant effect on dextran uptake in either cell type 
when they were depleted of Cdc42.  Again, uptake of 2 MDa dextran was investigated 
in HeLa cells depleted of this protein, showing no major requirement for Cdc42 (Figure 
3.18). To assess whether Cdc42 regulates CME, HeLa cells were depleted of this 
Utx Cdc42 siRNA: GFP 
Tubulin 
Cdc42 - 21kDa 
- 55kDa 
Utx Cdc42 
Tubulin 
Cdc42 
siRNA: GFP 
- 21kDa 
- 55kDa 
Fig. 3.15. Cdc42 is successfully depleted following siRNA transfection in both HeLa and A549 cells. 
Western blot analysis indicates levels of Cdc42 are depleted 48 h following siRNA transfection in 
HeLa and A549 cells when compared with tubulin as a loading control.  
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protein and incubated with Tf488 as previously described (Section 2.4.1). The 
microscopy images clearly suggested that depleting this protein inhibited transferrin 
uptake and this was confirmed by MFI quantification ((p=0.01), Figure 3.19). This result 
was somewhat unexpected but suggested that this protein may be an unsuitable 
target for analysis of fluid phase endocytosis. 
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Fig. 3.16. Dx647 endocytosis is unaffected following depletion of Cdc42 via siRNA transfection in 
A549 cells. (A) Following 48 h transfection, cells were subjected to a 60 min Dx647 (100 μg/ml) pulse 
before washing. Hoechst33342 was added 5 min before imaging live (R/T). Scale Bar: 20  µm. (B) MFI 
quantification of Dx647 in each cell population. Bars: Standard error. Images and graph summarise 
three separate experiments.   
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Fig.  3.17. Dx647 endocytosis is not affected following depletion of Cdc42 via siRNA transfection in 
HeLa cells. (A) Following 48 h transfection, cells were subjected to a 60 min Dx647 (100 μg/ml) pulse 
before washing. Hoechst33342 was added 5 min before imaging live (R/T). Scale Bar: 20 µm (B) MFI 
quantification of Dx647 in each cell population. Bars: Standard error. Images and graph summarise 
three separate experiments.   
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Fig.  3.18. Neither 10 kDa Dex nor 2 MDa Dex endocytosis is affected following depletion of Cdc42 
via siRNA transfection in HeLa cells. Following 48 h transfection, cells were subjected to a 60 min 10 
kDa Dx488 (100 μg/ml) or a 2 MD FITC Dx (1 mg/ml) pulse before washing. Hoechst33342 was added 
5 min before imaging live (R/T). Scale Bar: 20 µm.  
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Fig.  3.19. Tf488 endocytosis is significantly reduced following depletion of Cdc42 via siRNA 
transfection in HeLa cells. (A) Following 48 h transfection, cells were serum starved for 30 min 
before being subjected to a 10 min Tf488 (5 μg/ml) pulse and 5 min chase with Hoechst33342 before 
imaging live (R/T). Scale Bar: 20 µm. (B) MFI quantification of Tf488 in each cell population. Bars: 
Standard error. Images and graph summarise three separate experiments. **p<0.01   
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There was a suggestion in Figure 3.11 that PAK1 depletion was affecting cell 
morphology without having noticeable effects on endocytosis. As PAK1 and Cdc42 are 
linked with respects to affecting actin function control and Cdc42 depleted A549 cells 
were labelled with the plasma membrane probe cell mark deep red. Figure 3.20 shows 
that Cdc42 depleted cells appear narrower and longer than control cells. 
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Fig.  3.20. Cdc42 depleted HeLa cells present with aberrant morphology. Following 48 h siRNA 
treatment (100 nM siRNA), cells were incubated with cell mask deep red (CMDR) (37°C, 5% CO2) 
before confocal imaging live (R/T). Scale bar: 20 μm.  
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3.4 Discussion 
Methods to inhibit specific endocytic pathways in vitro should provide reliable 
platforms for evaluating cellular entry of DDSs. Successful inhibition of CME in HeLa 
and A549 cells through siRNA targeted depletion of AP2μ2 expression was 
demonstrated in this chapter, providing two robust models for CME for future studies.  
Live cell confocal microscopy was chosen as a tool to provide both visual qualitative 
analysis of cell uptake, in this case transferrin, but methods were also adapted to 
quantify the fluorescent output from a fraction of the analysed cell population. 
Imaging cells live also allowed analysis of the live endocytic system, ruling out the 
possibility of artefacts produced during the fixing process.  Quantification of the 
intracellular fluorescence using these described methods avoided the need to perform 
further flow cytometry analysis on fixed cells and also provided further relatively high 
content information on possible more global effects that siRNA targeting of endocytic 
proteins or chemical inhibition may cause.  
PAK1 was targeted as a regulator of induced macropinocytosis due to its close 
association with actin dynamics (Dharmawardhane et al., 2000; Kalwat et al., 2013; 
Zhang et al., 2016). Inhibition of this kinase by siRNA transfection does not seem to 
have a great effect on the dynamics of actin following growth factor stimulation in 
A549 cells, yet results in some phenotypic effects. Previous studies in the laboratory 
indicated that targeting PAK1 did inhibit the uptake of cationic cell penetrating 
peptides (Al Soraj et al., 2012) but only affected stimulated dextran uptake in response 
to growth factor stimulation – i.e. the fraction of dextran internalised via induced 
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macropinocytosis rather than the constitutive fraction. Overall PAK1 was not a suitable 
target for fluid phase uptake or constitutive macropinocytosis in HeLa or A549 cells 
based on these results so other actin regulatory proteins were explored.  
The involvement of the small GTPase, Cdc42, was further investigated as a possible 
target for macropinocytic inhibition due also to its involvement in actin dynamics 
(Beemiller et al., 2010; Cox et al., 1997), most notably through its interaction with 
PAK1 (Kalwat et al., 2013), and suggested involvement in fluid-phase endocytosis 
(Cheng et al., 2010; Singh et al., 2013).  Cdc42 depletion through siRNA transfection 
however had no effect on the ability of HeLa or A549 to carry out fluid-phase 
endocytosis. Additionally, similar phenotypic effects of Cdc42 depletion as those 
observed in PAK1 depleted cells were apparent, consistent with previous reported 
observations (Monypenny et al., 2009). The significant decrease in transferrin uptake 
in HeLa cells depleted of Cdc42 supports this idea. This inhibition of CME is not 
surprising considering that the progression of CPP invagination involves active Cdc42 
(Shen et al., 2011) and that Cdc42 regulated actin dynamics are essential for endocytic 
trafficking from the membrane (Chi et al., 2013; Watson et al., 2014). There is further 
evidence that a Cdc42 binding kinase (Myotonic dystrophy kinase-related Cdc42-
binding kinase alpha-MRCKalpha) is important for internalisation of the transferrin 
receptor (Cmejla et al., 2010).   
Furthermore, cells undergoing migration or undertaking migratory preparation display 
F-actin ruffles solely at their leading edge (Yi and Coppolino, 2006). Via the 
introduction of EGF a migratory stimulus is provided, a common and well established 
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consequence of EGF signalling particularly in epithelial cells (Jiang et al., 2006; 
Zeineldin and Hudson, 2006). This knowledge was used to assess the effect of EGF 
stimulus on the actin cytoskeleton in this project. The involvement of Cdc42 and Rac1 
activity in dendritic dextran uptake has previously been shown, indicating that these 
proteins are involved in these processes (Tourkova et al., 2007); this cell line however 
is classically phagocytic unlike HeLa cells. Fluid-phase endocytosis may well have 
different dependencies on Cdc42 across the different cell-types, as the actin 
cytoskeleton in dendritic cells is more likely to be carrying out these processes at a 
much higher constitutive rate. Furthermore, it has been suggested that antigen 
presentation in dendritic cells requires macropinocytosis as regulated by Cdc42 and 
Rac1 (Garrett et al., 2000; Nobes and Marsh, 2000). Notably, the wide-ranging roles of 
Cdc42 and other factors give cause to question whether this is a suitable target for 
siRNA depletion. Cell cycle regulation is particularly dependent upon this RhoGTPase, a 
role that explains the slow growth exhibited by HeLa cells in which the protein has 
been depleted. 
This data presented in this chapter describes an efficient high content platform to 
assess the involvement of CME in the uptake of novel drug delivery systems. With 
regards to the inhibition of fluid-phase endocytosis and macropinocytosis the 
depletion of Rac1 may be a possible avenue to explore further, but the observations 
made following the PAK1 and Cdc42 studies suggest that siRNA depletion of proteins 
regulating actin dynamics may affect too many other cellular processes. For these 
reasons the use of pharmacological inhibitors to study fluid-phase endocytosis and 
macropinocytic uptake was decided upon.   
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4 Investigations on chemical inhibitors of fluid-phase endocytosis 
and macropinocytosis in HeLa and A549 cells 
4.1 Introduction 
Useful in vitro siRNA targeting models for CME and CIE were now available but 
there was still a requirement for models to study unstimulated and induced 
macropinocytosis. Inhibitors directly targeting the actin cytoskeleton, such as 
cytochalasin D, were avoided due to the extensive morphological effects of these 
agents that is likely to have global cellular effects (He et al., 2015). 
This work was performed using HeLa and A549 cells, rather than bEnd.3 cells, as the 
use of two cell lines in siRNA transfection and endocytic probe uptake had 
generated an efficient platform for the analysis of CME. Indeed, identification of a 
protein target for the siRNA inhibition of fluid-phase endocytosis/macropinocytosis 
had not been as successful, but these cell lines were again used to maintain 
consistency within the project.    
4.2 Aims and Objectives 
- To further explore inhibitory methods involving chemical inhibitors to target 
fluid-phase endocytosis and macropinocytosis, due to the lack of an efficient 
protein for siRNA targeted depletion. 
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- To assess the fluid-phase uptake of dextran in HeLa and A549 cells treated 
with the common inhibitors of fluid-phase endocytosis and 
macropinocytosis: EIPA, Rottlerin, IPA-3 and ML-7. 
- To identify the potential cell-wide effects caused by the treatment of these 
inhibitors at different concentrations on these cell lines. 
- To establish chemical inhibitor based in vitro models for the inhibition of 
fluid-phase endocytosis and macropinocytosis that can be used to evaluate 
the uptake of novel drug delivery systems via these mechanisms.     
4.3 Results 
4.3.1 Investigation of the chemical inhibitor of fluid-phase endocytosis and 
macropinocytosis 5-(N-ethyl-N-isopropyl)amiloride (EIPA) 
As previously discussed in Chapter 1, the Na+/H+ exchange inhibitor EIPA and the 
parent molecule amiloride have been widely employed in macropinocytic studies at 
low micromolar concentration (Al Soraj et al., 2012; Devadas et al., 2014).  
At 100 µM, the cells are more rounded and highly autofluorescent in the green 
channel when compared to control cells (Figure 4.1), indicating that this 
concentration of EIPA may affect the wider physiology of the cell. Hoechst33342 
staining is also uniform across the cell structure and not solely localised to the 
nucleus. Dextran uptake was noticeably reduced following treatment with 50 µM 
EIPA yet the Hoechst33342 staining was not confined to the nucleus but was 
uniform across the cell cytoplasm. The lower concentrations of 25 µM and 10 µM 
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were subsequently used in an attempt to prevent dextran uptake in HeLa and A549 
without visibly affecting Hoechst33342 staining or cell morphology. These 
concentrations have been utilised in previous studies to assess the macropinocytic 
uptake of various other entities (Weinberg et al., 2014). 
Firstly, the noted effects on cell morphology and Hoechst33342 staining at 25 µM and 
10 µM are not apparent in both cell types, indicating that these are adequate 
concentrations. Following a 60 min dextran pulse in HeLa, dextran positive vesicles can 
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Fig. 4.1. Dx488 uptake in HeLa cells treated with 100 µM and 50 µM EIPA. Cells were pre-treated 
with either DMSO (0.05%), 50 µM EIPA or 100 µM EIPA for 30 min before being subjected to a 60 
min Dx488 (100 μg/ml) pulse in the continued presence of the inhibitor. Hoechst33342 was added 5 
min before imaging live (R/T). Scale bar: 20 µm. 
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be observed within the cell (Figure 4.2). A small decrease in intracellular dextran 
fluorescence was apparent following 25 µM EIPA treatment as viewed via microscopy 
and MFI quantification (Figure 4.2), suggesting that a proportion of fluid-phase 
endocytosis has been obstructed. Statistically this was insignificant. Little difference in 
dextran uptake can be observed between untreated cells and 10 µM EIPA, indicating 
that an optimum concentration for the inhibition of dextran uptake without having 
effects on cell morphology is approximately 25 µM.  
Treatment with these concentrations also indicated little difference in cell morphology 
when compared with control treated cells, as demonstrated by Cell Mask deep red 
(CMDR) staining following treatment (Figure 4.3). Transferrin internalisation in EIPA 
cells was significantly reduced, indicating an effect on CME (Figure 4.4). Notably, 
differences in the localisation of transferrin loaded vesicles was apparent, agreeing 
with our previous studies that show effects on the subcellular localisation of early and 
late endosomes/lysosomes in cells treated with this drug (Fretz et al., 2006). 
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Fig. 4.2. Dx488 endocytosis in HeLa cells is not affected by 25 µM EIPA (A) Cells were pre-treated with 
either DMSO (0.05%), 25 µM EIPA or 10 µM EIPA for 30 min before being subjected to a 60 min Dx488 
(100 μg/ml) pulse in the continued presence of the inhibitor. Hoechst33342 was added 5 min before 
imaging live (R/T). Scale bar: 20 µm. (B) MFI quantification of Dx488 in each cell population. Error 
bars: Standard error. Images (25 µM) and graph summarise three separate experiments.  
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Fig. 4.3. Cell Mask Deep Red (CMDR) staining indicates little difference in cell morphology following 
EIPA treatment in HeLa cells. Cells were pre-treated with either DMSO (0.05%), 25 µM EIPA or 10 
µM EIPA for 30 min before being subjected to a 60 min Dx488 (100 μg/ml) pulse whilst in the 
continued presence of the inhibitor. Hoechst33342 and CMDR were added 5 min before imaging live 
(R/T). Scale bar: 20 µm. Images representative of three separate experiments. 
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Fig. 4.4. Tf488 internalisation following EIPA treatment in HeLa cells. (A) Cells were pre-treated with either DMSO (0.05%) or 25 µM EIPA for 30 min before 
being subjected to a 10 min Tf488 (5 μg/ml) pulse whilst in the continued presence of the inhibitor. Hoechst33342 was added 5 min before imaging live (R/T). 
Solid arrows indicate concentrated transferrin localisation/fluorescence at the cell periphery. White squares presented as zoomed images. Scale bar: 20 µm, 
10 µm in zoomed images. (B) Graph presents MFI quantification of Tf488 in each cell population. Error bars: Standard error. Images and graph summarise 
three separate experiments. **p<0.01 
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Identical experiments were carried out in A549 cells. Possible effects on cell 
morphology and therefore the wider physiology of the cell were more observable at 25 
µM and 10 µM in this cell line, whereby the production of the autofluorescent 
structures previously described are extensive (Figure 4.5). This suggests that both 
concentrations may have global effects in A549 cells. 
MFI quantification also indicated that there was little difference in the ability of cells to 
internalise dextran at both 10 µM and 25 µM EIPA in A549 cells (Figure 4.5b), signifying 
that fluid-phase endocytosis was not prevented at these concentrations. Transferrin 
uptake (Section 2.5.2) was assessed following EIPA treatment in A549 cells to observe 
the effects of this inhibitor treatment on different endocytic pathways, and because of 
the observations discussed previously.  
There was no difference in uptake or localisation of transferrin vesicles between EIPA 
treated cells and control treated cells (Figure 4.6), indicating that CME and trafficking 
are not visibly affected by this drug. MFI quantification supports these observations in 
that there was little difference in uptake intensity (Figure 4.6). Furthermore, a greater 
number of autofluorescent structures previously described in A549 cells can again be 
viewed in A549 cells, suggesting that the inhibitor may affect other physiological 
processes. For these reasons, EIPA may not be an efficient inhibitor for these studies in 
A549 cells, but its use in HeLa should not be disregarded.  
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Fig. 4.5. Dx647 endocytosis is not affected following EIPA treatment in A549 cells. (A) Cells were pre-
treated with either DMSO (0.05%), 25 µM or 10 µM EIPA for 30 min before being subjected to a 60 
min Dx488 (100 μg/ml) pulse in the continued presence of the inhibitor. Hoechst33342 was added 5 
min before imaging live (R/T). White arrows indicate autofluorescent punctate structures. Scale bar: 
20 µm. (B) MFI quantification of Dx488 in each cell population. Error bars: Standard error. Images and 
graph summarise three separate experiments. 
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Fig. 4.6. Tf647 endocytosis is not affected following EIPA treatment in A549 cells. (A) Cells were pre-
treated with either DMSO (0.05%) or 25 µM EIPA for 30 min before being subjected to a 10 min 
Tf647 (5 μg/ml) pulse and 5 min chase whilst in the continued presence of the inhibitor. 
Hoechst33342 was added 5 min before imaging live (R/T). Arrows indicate autofluorescent punctate 
structures. Scale bar: 20 µm. (B) MFI quantification of Tf647 in each cell population. Error bars: 
Standard error. Images and graphs summarise three separate experiments. 
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4.3.2 Investigation of the fluid-phase inhibitor Rottlerin and its potential target PKCδ 
This drug has been utilised to study fluid-phase endocytosis and macropinocytic events 
in different cell lines through its suggested capacity to inhibit PKCδ in the 5-10 µM 
range (Fenyvesi et al., 2014; Sarkar et al., 2005; Vercauteren et al., 2011).  For instance, 
10 µM Rottlerin was previously shown to reduce the uptake of dextran in ARPE-19 cells 
(Vercauteren et al., 2011) and the uptake of Lucifer yellow and cyclodextrin in Caco-2 
cells (Fenyvesi et al., 2014). Here, dextran was again utilised as a fluid phase probe for 
Rottlerin studies and after 60 min incubation in Hela there was evidence that uptake 
was inhibited at both 5 µm and 10 µM (Figure 4.7), but MFI scrutiny for a repeated 10 
µM concentration revealed that this was not significant. Localisation of dextran 
fluorescence did however appear to be more disperse through the cytoplasm/cytosol 
in cells treated with this inhibitor (Figure 4.7). This could suggest that Rottlerin may be 
affecting endosomes and possibly inducing endocytic escape. Despite this observation, 
there were no notable effects on cell morphology following Rottlerin treatment in 
comparison with control cells (Figure 4.7).  
Rottlerin treatment in A549 cells produced a significant decrease in dextran 
fluorescence (Figure 4.8), providing evidence that the target of Rottlerin may be a 
target for fluid-phase specific inhibition in this cell line. 
 
205 
 
 
DM
SO
 C
tr
l 
Ro
tt
le
rin
 5
 µ
M
 
Ro
tt
le
rin
 1
0 
µM
 
Dx488 Merge Xyz Projection CMDR 
0
0.5
1
1.5
DMSO Ctrl Rottlerin 10µM
M
FI
 D
x4
88
(A) 
(B) 
Fig. 4.7. Dx488 endocytosis and cell morphology are not affected following Rottlerin treatment in 
HeLa cells. (A) Cells were pre-treated with either DMSO (0.05%), 5 µM Rottlerin or 10 µM Rottlerin 
for 30 min before being subjected to a 60 min Dx488 (100 μg/ml) pulse whilst in the continued 
presence of the inhibitor. Hoechst33342 and CMDR were added 5 min before imaging live (R/T). 
Scale bar: 20 µm. (B) MFI quantification of Dx488 in each cell population. Error bars: Standard error. 
Images and graph summarise three separate experiments.  
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Fig. 4.8. Dx488 endocytosis is significantly reduced following Rottlerin treatment in A549 cells. (A) 
Cells were pre-treated with either DMSO (0.05%) or 10 µM Rottlerin for 30 min before being 
subjected to a 60 min Dx647 (100 μg/ml) pulse whilst in the continued presence of the inhibitor. 
Hoechst33342 was added 5 min before imaging live (R/T). Scale bar: 20 µm. (B) MFI quantification of 
Dx647 in each cell population. Error bars: Standard error. Images and graph summarise three 
separate experiments. **p<0.01 
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Fig. 4.9. Tf647 endocytosis following Rottlerin treatment in A549 cells. (A) Cells were pre-treated 
with either DMSO (0.05%) or 10 µM Rottlerin for 30 min before being subjected to a 10 min Tf647 (5 
μg/ml) pulse whilst in the continued presence of the inhibitor. Hoechst33342 was added 5 min before 
imaging live (R/T). Scale bar: 20 µm. (B) MFI quantification of Tf647 in each cell population. Error bars: 
Standard error. Images and graphs summarise three separate experiments. 
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To investigate whether Rottlerin is exclusively affecting fluid-phase uptake in A549 
cells, we also performed transferrin uptake assays to evaluate its potential effects on 
CME. Characteristic transferrin positive vesicles visualised within control cells were 
also observed in cells treated with Rottlerin, suggesting that the inhibitor has no effect 
on CME (Figure 4.9a). Quantification of transferrin MFI supports this observation 
(Figure 4.9b). The ability of Rottlerin to affect the fluid-phase in A549 cells indicates 
that one of its identified targets Protein Kinase Cδ (PKCδ) (Gschwendt et al., 1994) is 
involved in this process. siRNA sequences were then identified and purchased to test 
this hypothesis for macropinocytic studies (Sarkar et al., 2005). For this reason, PKCδ 
was identified as a possible target for inhibiting fluid-phase endocytosis and 
macropinocytosis. 
Following a 48 hour transfection with PKCδ siRNA, Western blot analysis demonstrated 
that the protein was successfully depleted in HeLa and A549 cells (Figure 4.10). A 
dextran uptake assay was then performed to ascertain the effects of PKCδ depletion 
on fluid-phase endocytosis. Uptake was initially performed in A549 cells, as Rottlerin 
induced a diminished ability of this cell line to internalise dextran. Data shown in 
Figure 4.11a however shows no clear difference in dextran uptake in siPKCδ cells 
compared with controls. MFI quantification supported this observation (Figure 4.11b). 
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Many of the PKC isoforms, including PKCδ, have been implicated in regulating actin 
function (Keenan and Kelleher, 1998; Larsson, 2006) so actin localisation was 
compared in both control cells and siPKCδ cells using rhodamine-phalloidin staining of 
fixed cells. PKCδ depletion did induce a minor but consistent change in the structure 
and organisation of the actin cytoskeleton. Cells depleted of the protein presented 
with more pronounced stress fibres compared with control cells and this was most 
pronounced in the basal and central portions of the cells’ Z-axis (Figure 4.12). 
Utx PKCδ 
Tubulin 
PKCδ 
siRNA: GFP 
- 78kDa 
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Utx PKCδ 
Tubulin 
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HeLa A549 
Fig.  4.10. PKCδ is successfully depleted following siRNA transfection in both HeLa and A549 cells. 
Western blot analysis indicates levels of PKCδ are depleted 48 h following siRNA transfection in HeLa 
and A549 cells when compared with tubulin as a loading control.  
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Fig. 4.11. Dex647 endocytosis is not affected following depletion of PKCδ via siRNA transfection in 
A549 cells. (A) Following 48 h transfection, cells were subjected to a 60 min Dx647 (100 μg/ml) pulse. 
Hoechst33342 was added 5 min before imaging live (R/T). Scale Bar: 20 µm. (B) MFI quantification of 
Dx647 in each cell population. Bars: Standard error. Images and graphs summarise three separate 
experiments. 
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Fig.  4.12. The actin cytoskeleton of A549 cells presents with a greater number of stress fibres following PKCδ depletion. Cells were transfected with PKCδ siRNA 
(100 nM) for 48 h. PFA fixation was carried out before 10 min incubation with Rhodamine-Phalloidin (1:500) and Hoechst33342 (1 µM) at R/T before imaging. 
Translucent arrows indicate greater actin activity, solid arrows indicate stress fibres. Scale bar: 10 µm.  
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4.3.3 Exploration of the PAK1 inhibitor IPA-3 to target fluid-phase endocytosis and 
macropinocytosis   
The PAK1 inhibitor IPA-3 has previously been used to propose macropinocytosis as a 
mechanism for viral cell entry (Krzyzaniak et al., 2013; Wen et al., 2013). The effects of 
this inhibitor on fluid-phase uptake of dextran were initially explored in HeLa cells. A 
prominent decrease in dextran uptake was observed (Figure 4.13a), supported by MFI 
quantification (p=0.033)(Figure 4.13b). These experiments were also performed in 
A549 cells and at 50 µM there was again evidence that dextran uptake was decreased 
but also some evidence of cell toxicity that manifested as cell loss (floating cells) and 
cell shrinkage (Figure 4.14). At 25 µM IPA-3 there was no evidence of a reduction in 
dextran uptake or loss of viability. Further studies on IPA-3 will be presented in the 
following results chapter.  
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Fig. 4.13. Dx488 endocytosis is significantly reduced following IPA-3 treatment in HeLa cells. (A) Cells 
were pre-treated with either DMSO (0.05%) or 50 µM IPA-3 for 30 min before being subjected to a 60 
min Dx488 (100 μg/mL) pulse whilst in the continued presence of the inhibitor. Hoechst33342 was 
added 5 min before imaging live (R/T). Scale bar: 20 µm. (B) MFI quantification of Dx488 in each cell 
population. Error bars: Standard error. Images and graphs summarise three separate experiments. 
*p<0.05. 
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Fig.  4.14. Dx647 endocytosis decreases following IPA-3 treatment in A549 cells. (A) Cells were pre-
treated with either DMSO (0.05%), 25 µM or 50 µM IPA-3 for 30 min before being subjected to a 60 
min Dx647 (100 μg/ml) pulse whilst in the continued presence of the inhibitor. Hoechst33342 was 
added 5 min before imaging live (R/T). Scale bar: 20 µm. (B) MFI quantification of Dx488 in each cell 
population. Error bars: Standard error. Images and graph summarise three separate experiments. 
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4.3.4 Investigation of the cellular effects of ML-7, a myosin light chain kinase inhibitor 
As a myosin light chain kinase inhibitor, ML-7 has been utilised in a small number of 
endocytic studies targeting fluid-phase, macropinocytosis and phagocytosis. Dextran 
uptake experiments were then performed in cells treated with this drug using the 
methodology outlined in Section 2.5.2. Control treated cells were observed to 
internalise dextran in a characteristic manner after 60 min of uptake (Figure 4.15). 
Dextran uptake in 10 µM ML-7 treated Hela cells appeared to be normal (Figure 4.15) 
but in cells treated with the higher drug concentration obvious morphological changes 
were apparent. These mostly manifested as cells rounding. These morphological 
effects were not observed when the same experiments were performed in A549 that 
showed visibly higher levels of dextran fluorescence when incubated with the drug 
(Figure 4.16).  
Indication that myosin II (which is indirectly targeted by ML-7) is required for the 
progression of CME (Chandrasekar et al., 2014) let to investigation as to whether the 
drug also inhibits CME. Data in Figure 4.17 strongly suggests this is the case but this 
was not followed by MFI quantification as the drug by this time, due to its multiple 
effects was discontinued as a possible selective marker for fluid-phase endocytosis. 
Some individuals within the HeLa population were also noted to contain very large 
dextran loaded vesicles or vacuoles (Figure 4.18). Punctate dextran structures were 
enlarged and correlated with 2-5 μm vesicles that could be visualised via differential 
interference contrast (DIC) microscropy (Figure 4.18). 
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Fig. 4.15. Dx488 endocytosis is reduced and cell morphology is affected following ML-7 treatment of increasing concentrations in HeLa cells. Cells were pre-
treated with either DMSO (0.05%), 10 µM or 20 µM ML-7 for 30 min before being subjected to a 60 min Dx488 (100 μg/ml) pulse whilst in the continued presence 
of the inhibitor. Hoechst33342 and CMDR were added 5 min before imaging live (R/T). Scale bar: 20 µm.  
 
217 
 
DM
SO
 C
tr
l 
M
L-
7 
 1
0 
µM
 
M
L-
7 
20
 µ
M
 
Dx647 Merge CMO Merge 
Fig. 4.16. Dx647 uptake and cell morphology of ML-7 treated A549 cells. Cells were pre-treated with either DMSO (0.05%), 10 µM or 20 µM ML-7 for 30 min 
before being subjected to a 60 min Dx647 (100 μg/ml) pulse whilst in the continued presence of the inhibitor. Hoechst33342 and Cell Mask Orange (CMO) were 
added 5 min before imaging live (R/T). Scale bar: 20 µm.  
 
218 
 
 
Tf
64
7 
M
er
ge
 
Xy
z P
ro
je
ct
io
n 
DMSO Ctrl ML-7 
Fig. 4.17. Tf647 endocytosis is reduced following ML-7 treatment in A549 cells. Cells were pre-
treated with either DMSO (0.05%) or 20 µM ML-7 for 30 min before being subjected to a 10 min Tf647 
(5 μg/ml) pulse and 5 min chase in the continued presence of the inhibitor. Hoechst33342 was added 
5 min before imaging live (R/T). Scale bar: 20 µm.  
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4.4 Discussion 
In this chapter, the search for an efficient technique to inhibit macropinocytosis 
using pharmacological inhibition was investigated.  EIPA resulted in changes in cell 
morphology as described in Section 3.3.1. These observations were apparent at 100 
µM, which is generally the concentration used for endocytic studies. Many of these 
studies however do not present microscopy images of the cells used for these 
studies and conclusions are based on analysis of flow cytometry data (Al Soraj et al., 
2012). Cell viability had been previously measured by other members of the lab 
indicating that the concentrations utilised do not affect viability (data not 
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Fig. 4.18. Vesicular Dx647 structures are larger following ML-7 treatment in A549 cells. Cells were 
pre-treated with either DMSO (0.05%) or 20 µM ML-7 for 30 min before being subjected to a 60 min 
Dx647 (100 μg/ml) pulse whilst in the continued presence of the inhibitor. Scale bar: 20 µm, zoomed 
image: 10 µm.  
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published). The incubation periods used for this project are generally too short for 
many commercial viability/cytotoxicity kits which require incubation for over 4 
hours. The shorter periods of incubation used for uptake studies are therefore less 
likely to cause quantifiable effects on viability. Viability does not necessarily 
correlate to changes in the endocytic network, and the morphology effects 
observed suggest that cellular homeostasis is altered at these higher concentrations 
of inhibitor treatment. Regardless of these observations, EIPA treatment had a 
small effect on the fluid-phase uptake of dextran, suggesting that a proportion of 
dextran uptake was affected. The obvious effects on trafficking of the CME probe 
transferrin suggests that EIPA may affect CME, which may account for this 
proportion of dextran. It is plausible that a number of dextran molecules are caught 
within internalising clathrin pits, and therefore enter the cell via the CME pathway.   
The ability of Rottlerin to prevent fluid-phase uptake of dextran, particularly in 
A549s suggests that its target is part of the fluid-phase machinery, and may be a 
possible target for siRNA depletion. PKCδ was investigated due to its original 
identity as a target of Rottlerin. Depletion of this protein however, did not affect 
dextran uptake in A549 cells, the line in which Rottlerin had an effect on dextran 
uptake suggesting that the protein is not the causal factor of Rottlerin’s effects in 
A549 cells.   
PKCδ was chosen as siRNA target in A549 cells due to the ability of Rottlerin to 
reduce dextran uptake. Depletion of this protein however has no effect on the 
uptake of dextran in either A549 or HeLa cells. This could be for several reasons. 
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The targets of Rottlerin may range wider than this particular kinase. Rottlerin has 
most notably been identified to uncouple mitochondria from oxidative 
phosphorylation (Soltoff, 2001; Soltoff, 2007), which could theoretically result in an 
indirect effect on PKCδ phosphorylation. It is possible that the other targets of 
Rottlerin may affect dextran uptake in a manner completely independent of PKCδ. 
For these reasons, PKCδ is not a suitable target for the inhibition of fluid-phase or 
macropinocytosis. 
In Chapter 3, depletion of the protein PAK1 by siRNA transfection did not 
significantly affect fluid-phase endocytosis of dextran. Treatment with IPA-3, which 
allosterically inhibits the activation site of the kinase (Deacon et al., 2008; Viaud 
and Peterson, 2009), caused a reduction in dextran uptake however. The use of IPA-
3 has been utilised to investigate the impact of PAK1 regulation on cell growth, in 
cancer studies for instance (Wang et al., 2016; Wong et al., 2013). Indeed these 
studies use concentrations were less than or within the same range as used here 
(10-50 µM), which could account for the apparent cell loss/shrinkage observed in 
the uptake studies performed here. Effects on the mechanisms of cell growth would 
explain this. IPA-3 also causes inhibition of actin polymerisation (Zhang et al., 2016), 
which as discussed previously, is an essential component of fluid-phase 
endocytosis, macropinocytosis and endocytic trafficking from the membrane, and 
this correlates with the observations presented here. Whether this is via the 
specific inhibition of PAK1 is a question that remains to be answered, as specific 
depletion of the protein did not have this effect on fluid-phase endocytosis.  
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These studies continue to work toward finding an efficient target for 
macropinocytic and fluid-phase inhibition, resulting in the establishment of a 
specific model for macropinocytic inhibition that can be applied on a high-content 
scale. From these studies however it is clear that specific models of inhibition will 
involve the utilisation of both siRNA transfection models and pharmacological 
inhibition. Preliminary use of such pathway specific models can be utilised to 
evaluate the entry mechanism of a model drug delivery system. 
To begin to test these techniques for intended purpose, the characteristics of 
prostate derived exosomes was explored in collaboration with the Velindre 
Hospital. The details of these studies are presented and further discussed within 
the following Chapter.  
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5 Exploration of the Cellular Uptake and Trafficking Characteristics 
of Fluorescently Labelled Prostate Cancer Exosomes 
5.1 Introduction 
The natural ability to functionally transfer a spectrum of macro-molecular cargo 
between cells raises opportunities for exploiting exosomes as vectors for drug 
delivery (Batrakova and Kim, 2015; Vader et al., 2016; van Dommelen et al., 2012). 
However little is known about the ways in which exosomes initially interact with the 
cell, gain intracellular access and are trafficked through the cell to their final 
destination. Even less is known about how intravesicular cargo is released and 
directed towards the intended target within the cytosol or other intracellular 
compartments. The capacity of exosomes to mediate these effects, possibly 
through endocytosis, requires further characterisation in order to fully understand 
their natural roles in disease pathogenesis and also unlock their potential for drug 
delivery.  
Exosome entry and cargo release has been proposed to occur via endocytosis 
(Escrevente et al., 2011) and/or through direct exosome-plasma membrane fusion 
(Montecalvo et al., 2012; Mulcahy et al., 2014). These studies labelled purified 
exosome preparations with fluorescent probes and then used either microscopy or 
flow cytometry to monitor cell interaction and uptake. As previously discussed in 
Chapter 1, labelling strategies include the use of lipophilic dyes such as PKH26 (Feng 
et al., 2010; Sagar et al., 2016) and the carbocyanine dyes (DiI, DiO) (Tian et al., 
2014; Wiklander et al., 2015), which embed within the membrane bilayer of the 
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exosome. Such dyes can however form dye aggregates or micelles, of similar 
proportions to exosomes, giving misleading information in uptake experiments. This 
was highlighted in Figure 1 in Roberts-Dalton et al 2017 via work performed by our 
collaborators at the Velindre Cancer Hospital (Appendix B). Exosome permeable 
compounds including CFSE and CFDA have also been used for this purpose 
(Escrevente et al., 2011; Temchura et al., 2008). Any structural modifications on 
exosomes following labelling with these dyes could alter their physical 
characteristics but may also affect their functional properties. For cell uptake 
analysis this functional impact is rarely considered.   
In this chapter, a simple and rapid method for fluorescently labelling purified Du145 
exosomes is used to provide high content microscopy analysis of the ways in which 
these exosomes interact with cells in vitro. This together with subsequent 
endocytosis experiments has now been accepted for publication (Roberts-Dalton et 
al. Nanoscale. 2017. Manuscript in Press.). The method takes advantage of thiol 
(sulph-hydryl) groups on the exosome surface and experiments were also 
performed by collaborators led by Professor Aled Clayton and Dr Jason Webber at 
the Velindre Cancer Hospital to assess whether they retain the documented 
capacity to induce fibroblast differentiation in vitro (Webber et al., 2010; Webber et 
al., 2015).  
The Du145 exosome preparations used were subjected to rigorous characterisation 
by members of the Clayton lab before labelling was performed and this is also 
presented in Figure 1 of Appendix B. Cryo-electron microscopy (Cryo-EM) indicated 
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the isolation of vesicular structures with a lipid bi-layer membrane that were mostly 
around 100 nm in diameter (Appendix B, Figure 1A), and this observation was 
supported by Nanoparticle Tracking Analysis (NTA) (Appendix B, Figure 1B). 
Furthermore, these vesicles were found to be enriched in tetraspanins such as CD9, 
CD81 and CD63, and exosome-related proteins including TGS101, Alix and MHC 
Class-I (Appendix B, Figure 1C). Using a combination of BCA-protein assay and 
NanoSight-concentration measurements, the particle to protein ratio for purified 
exosomes was also calculated. All preparations used had a particle:protein ratio of 
>2x1010 particles/μg protein, indicating specimen purity as previously described 
(Webber and Clayton, 2013). The isolation and subsequent analyses satisfy the 
criterion set by the International Society for Extracellular Vesicles for defining this 
specimen as exosomes (Lotvall et al., 2014).  
The exosome is an environment that is cysteine rich through, for example, the 
presence of tetraspanin webs (Martínez and Yáñez-Mó, 2014).  It was postulated 
that the thiols (-S-H groups) present on these structures would react with a 
maleimide functional group to form a stable, non-reversible, thio-ether linkage. 
Fluorophore conjugated maleimides are often used to fluorescently label bio-
molecules so C5-maleimide conjugated to Alexafluor488/633 was used. Other 
groups have exploited this labelling protocol in order to study micro-particle 
populations whereby whole blood samples were labelled with BODIPY-maleimide 
for analysis via flow cytometry (Enjeti et al., 2008; Headland et al., 2014).  However, 
BODIPY itself is used to label membranes, and is therefore likely to integrate onto 
the exosome bilayer. The capacity for C5-maleimide-Alexa488/633 to react with 
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exosome thiols was explored by previous members of the Clayton and Jones labs. 
This procedure involves the removal of non-bound dye from the exosome-
preparations and spin-columns (Invitrogen) that retain molecules of <3000 Da was 
used to do this. Initial experiments explored incubating a constant quantity of 
purified exosomes with varying fluorophore concentrations, showing saturating 
levels of labelling at ≥100 µg/ml after an incubation of 1 hour (R/T) (Appendix B, 
Figure 1D). At the saturating fluorophore concentration of 200 µg/ml a range of 
incubation times were investigated revealing that most of the fluorophore-exosome 
labelling occurred very rapidly within the first 5 min, and saturation was reached at 
1 to 2 hours (Appendix B, Figure 1E). Conditions of 200 µg/ml of fluorophore for 1 
hour were chosen for labelling the Du145 exosomes for further microscopy studies. 
To ascertain whether or not the fluorophore was actually forming a covalent bond 
through the thiol groups, or merely binding passively to the vesicle surface, a 
competitor that works by capping the available reactive thiol groups was used. Pre-
incubating exosomes with doses of N-acetyl-L-cysteine showed a potent (~80%) 
inhibition of labelling under these same conditions (Appendix B, Figure 1F).  
NTA revealed a similar size distribution profile following incubations with C5-
maleimide-Alexa488, suggesting a paucity of gross complexation due to maleimide-
vesicle cross-linking. Importantly, NTA in the presence of a low-pass 500 nm filter 
showed the majority (>90%) of vesicles were fluorescent. The stock C5-maleimide-
Alexa488 reagent was also analysed by NTA (Appendix B, Figure 1G). Unlike for 
some other fluorescent labels, particularly PKH26, there were negligible particles 
detected in scatter mode, and there were no particles seen with a fluorescent filter 
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in place. An example of nano-particulate PKH26 fluorescent aggregates in the 
absence of exosomes is shown in Appendix C, Figure 1. Particulate material 
spanning the size range of exosomes was present in the stock solution, and a high 
proportion (52%) of these were fluorescent. The Jones and Clayton labs therefore 
concluded that this method was a simple, rapid and highly effective modality for 
fluorescently labelling exosome preparations that were free of artefacts relating to 
insoluble dye nano-particulates. 
The functional impact of coating exosomes with this fluorescent label was also 
investigated by the labs; an aspect that is rarely considered in other studies. To do 
this, a well-established functional assay whereby prostate cancer exosomes trigger 
the differentiation of fibroblasts to myofibroblasts was used (Webber et al., 2010). 
This process required delivery of exosome-associated Transforming growth factor β 
(TGFβ) to fibroblasts, but was also likely to involve additional exosome-cargo as the 
myofibroblasts generated are distinct from those formed by soluble TGFβ-
stimulation in that secretion of Hepatocyte growth factor (HGF) is triggered 
(Webber et al., 2015). Stimulation of fibroblasts either with native or with C5-
maleimide-Alexa488 labelled exosomes successfully triggered the onset of stress 
fibres visualized via αSMA labelling; soluble TGFβ also did this as expected. When 
evaluating the secretion of HGF however, there was clear difference in levels of 
HGF whether stimulations were by exosomes or soluble TGFβ (Appendix B, Figure 
1H). The labelled or unlabelled exosomes were equally proficient at stimulating HGF 
secretion. In this assay, which represents a major and complex cell differentiation 
process, the C5-maleimide-Alexa488 labelling approach showed no signs of 
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attenuated exosome function. This method was used to fluorescently label Du145 
exosomes provided by the Clayton lab and explore their interaction and uptake 
with cells, using the endocytic models explored and described in Chapters 4 and 5 
of this thesis. 
5.2 Aims and Objectives 
- To provide a simpler and more efficient method of visualising the ways in 
which Du145 exosomes interact with the cell and possibly gain intracellular 
access in order to induce their phenotypic effect. As previously stated, this 
method made use of the free thiol-groups abundant on the surface of the 
exosome membrane.  
- To analyse cell binding and uptake of fluorescent Du145 exosomes in 
primary lung fibroblasts (AG02262-Coriell Institute of Medical Research), the 
cell line for which a phenotypic effect has been documented.  
- To perform high content analysis of the cellular interaction, uptake and 
traffic of fluorescently labelled Du145 exosomes using the in vitro 
techniques of endocytic inhibition explored in Chapter 4 and 5 of this thesis. 
HeLa cells were used for this analysis based on their well-characterised 
endocytic profile (Al Soraj et al., 2012; Moody et al., 2015; Nakase et al., 
2004) and ease of cell culture. 
- Based on their ability to induce a phenotypic effect, the possible drug 
delivery potential of Du145 exosomes was preliminary investigated in a 
human lung carcinoma line engineered to stably express eGFP (H1299eGFP).  
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5.3 Results 
5.3.1 Uptake of labelled Du145 exosomes in primary lung fibroblasts 
Du145 exosomes have been shown to induce primary lung fibroblasts to 
differentiate into myofibroblasts and secrete an increased level of HGF (Webber et 
al., 2010; Webber et al., 2015). This represents a major phenotypic change 
indicating that these exosomes had the capacity to interact with recipient cells and 
transfer functional cargo, a characteristic of a theoretical drug delivery vector. 
There is however the possibility that differentiation is induced at the level of the 
plasma membrane by a ligand on the exosome binding to a receptor on the host 
cell for example.  There is evidence from the Clayton laboratory that TGFβ on the 
exosome surface is critical for induction of differentiation (Webber et al., 2015), 
most probably via interaction with the TGFβ receptor (TGFβR). Interaction of this 
ligand and receptor is well documented to induce differentiation in a number of 
different cell lines (Grafe et al., 2017). Exosome-fibroblast differentiation could be 
further explored via high content microscopy analysis following fluorescent 
labelling. As described in Section 2.8, C5-maleimide-Alexa488/633 (200 µg/ml) was 
mixed with exosomes to form a covalent linkage between the fluorophore and the 
exosome, thereby providing a fluorescent preparation.  Preliminary experiments in 
the Clayton lab identified that exosomes at concentrations of 50-60 µg/ml could be 
easily visualised on cells using wide field microscopy and a concentration of 60 
µg/ml was used for the following studies. 
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Due to their documented effects in fibroblasts, we investigated the possibility of 
visualising the labelled exosomes following incubation in this cell line.  These cells 
had high background cellular autofluorescence after excitation at 488 nm (Figure 
5.1a), thus distinguishing between this autofluorescence and internalised C5-
maleimide-Alexa488-exosomes (Exo488) was not possible (Figure 5.1b). The 
purified exosomes were therefore labelled with C5-maleimide-Alexa633 using the 
same procedure for uptake in fibroblasts. Figure 5.2 demonstrates that these 
exosomes (Exo633) were internalised to label punctate structures indicative of 
endosomes. The movement of these endosomes over a period of 5 minutes (Video 
5.1) was also indicative of endocytic trafficking movements in the fibroblasts, 
further suggesting endocytosis as the mechanisms by which these exosomes gain 
intracellular access. It also showed that another fluorescent dye could be utilised to 
label exosomes to monitor their cellular uptake. These cells are however poorly 
characterised with respects to characterisation of endocytosis and it was decided 
that focus would be given to the HeLa cell line that from previous work in the Jones 
laboratory and work presented in this study is much better characterised with 
respects to endocytosis.  
Previous studies on exosome uptake have also been published using HeLa cells 
allowing for some comparative investigations (Nakase and Futaki, 2015; Nakase et 
al., 2015; Svensson et al., 2013).  
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Fig. 5.1. Primary lung fibroblasts contain punctate autofluorescent structures detected following excitation with the UV and 488 laser but not the 633 laser.  (A) 
Cells were either untreated (washed with SFIM) before imaging (R/T) or (B) pulsed with Exo488 (60 µg/ml) for 2 h (37°C, 5% CO2) before incubation with 
Hoechst33342 for 5 min and imaging live (R/T).  Scale bar: 20 µm.  
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5.3.2 Endocytic Uptake of C5-maleimide-Alexa labelled Du145 exosomes in HeLa cells  
HeLa cells incubated with Alexa633 labelled exosomes (Exo633) for 30 and 60 min 
demonstrated a scattered punctate distribution throughout the cell cytoplasm (Figure 
5.3). There was a noticeable time dependant increase in fluorescence intensity from 30 
min to 360 min (Figure 5.3) and at this later time point fluorescence was more 
polarised to the perinuclear regions. This uptake pattern was replicated using Alexa488 
labelled exosomes in HeLa cells, whereby distribution of punctate structures was 
initially scattered throughout the cytoplasm followed by a noticeable time dependant 
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Fig. 5.2. Alexa633 labelled exosomes seen as intracellular punctate structures after incubation with 
primary lung fibroblasts. Cells were pulsed with 60 µg/mL Exo633 for 60, 120 or 360 min (37°C, 5% 
CO2) before imaging prior to incubation with Hoechst33342 for 5 min before imaging live (R/T). Scale 
bar: 20 µm. Images representative of three separate experiments.  
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increase in increase in intensity from 30 to 240 min (Figure 5.4a). This increase was 
further supported by MFI quantification of Exo488 intensity (Figure 5.4b).  
 
Zoomed images of the cells in Figure 5.4a allow greater visualisation of the Exo488 
positive punctate structures indicative of endosomes (Figure 5.5). Time lapse imaging 
of Exo488 incubated with HeLa cells over a period of 3 min (after a 120 min pre-
incubation) shows these structures to be highly motile with little evidence of 
significant accumulation at the plasma membrane (Video 5.2). These experiments, 
clearly showing the localisation of endosomes in endolysosomal structures prompted 
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Fig. 5.3. Alexa633 labelled exosomes are internalised by HeLa cells and can be visualised as 
punctate structures. Cells were pulsed with 60 µg/mL Exo633 for 30, 60, 120 or 360 min (37°C, 5% 
CO2) before imaging. Cells were incubated with Hoechst33342 for 5 min before imaging live (R/T). 
Scale bar: 20 µm.  
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further analysis to investigate how they gain access to cells and whether this can be 
inhibited chemically or by depleting proteins regulating endocytosis. 
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Fig. 5.4. Time dependent cellular uptake of Exo488 in HeLa cells (A) Cells were pulsed with 60 µg/ml 
Exo488 for 30, 60, 120 or 360 min (37°C, 5% CO2) before imaging. Cells were incubated with 
Hoechst33342 for 5 min before imaging. Scale bar: 20 µm. (B) MFI quantification of each cell 
population in (A). Error bars represent Standard error. Images and graph summarise three separate 
experiments.  
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Fig. 5.5. Zoomed images of Exo488 internalisation in HeLa cells. Cells were pulsed with 60 µg/ml Exo488 for 30, 60, 120 or 360 min (37°C, 5% CO2) before 
imaging. Cells were incubated with Hoechst33342 for 5 min before imaging. Scale bar: 20 µm.  
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As these exosomes were internalising into endosomal like structures it was then 
important to learn more about their traffic and whether the final destination for these 
structures was the lysosome. We have previously used fluorescent dextran as a marker 
of fluid-phase endocytosis that is trafficked to lysosomes (Al-Taei et al., 2006; Moody 
et al., 2015). It can be pulsed into cells for approximately 2 hours and then following 
washing the cells can be further incubated in the absence of the probe to ‘chase’ the 
previously internalised fraction to lysosomes overnight (described in Section 2.10). 
Here, only lysosomes are labelled but via a simple 2 hour pulse, dextran can be used to 
label the entire endolysosomal pathway of fluid-phase endocytosis including early 
endosomes and lysosomes. For these reasons colocalisation of Exo488 with Dex647 
labelled lysosomes was investigated and performed using different pulse and pulse 
chase methods described in Section 2.10. Cells previously pulse chased with dextran 
were incubated with exosomes for 30-360 min and showed a gradual time dependant 
accumulation of exosome fluorescence in the perinuclear region that contained the 
labelled dextran in lysosomes (Figure 5.6a). Colocalisation between Exo488 and 647-
lysosomes was barely detected at 30 min and then increased over a period of six hours 
to the point that after 360 min approximately 60% of the identified exosomes were 
contained in labelled lysosomes (Figure 5.6b). Experiments by which dextran was 
similarly used to label lysosomes were then performed but following a two hour pulse 
of exosome endocytosis the cells were washed and the material already associated 
with the cells was chased for a further 4 hours. This revealed that over 60% of 
exosome associated labelling had reached and remained at the lysosomes by the end 
of this chase period (Figure 5.7). 
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Fig. 5.6. Colocalisation of 488-labelled exosomes with dextran-loaded lysosomes in HeLa cells. (A) 
Cells were incubated with Dx647 (100 µg/ml) for 2 h, washed with PBS and incubated for a further 18 
h in culture media. Cells were then incubated with Exo488 (60 µg/ml) for either 30, 60, 120 or 360 
min before treatment with Hoechst33342 for 5 min and imaging. Solid arrowheads indicate 
colocalisation between exosomes and lysosomes and transparent arrowheads indicate exosomes not 
colocalised with lysosomes. Scale bars: 20 µm and 10 µm in zoomed images. Images representative of 
three separate experiments. (B) Mander’s correlation coefficient analysis of the proportion of green 
fluorescence (exosomes) associated with far-red fluorescence (lysosomes) based on the experiments 
performed to generate images. Error bars: Standard error. n=3. 
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Fig. 5.7. Colocalisation of 488-labelled exosomes with dextran-loaded lysosomes in HeLa cells. Cells 
were incubated with Dx647 (100 µg/mL) for 2 h, washed with PBS and incubated for a further 18 h in 
culture media. Cells were then incubated with Exo488 (60 µg/mL) for 2 h with no chase or for 2 h 
followed by washing and a  4 h chase. Scale bars: 20 µm and 10 µm on zoomed images. Images 
representative of three separate experiments. 
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5.3.3 Endocytic Uptake of Exosomes in Clathrin-Mediated Endocytosis (CME) 
Compromised Cells 
CME has been extensively characterised in in vitro models including HeLa cells 
(McMahon and Boucrot, 2011; Robinson, 2015), and this process can be attenuated 
using a range of methods as described in Chapter 3 of this thesis and previous 
members of the Jones lab (Al Soraj et al., 2012; Vercauteren et al., 2011). These 
include siRNA depletion of a key member of the of the CME adaptor complex AP2, 
known as AP2µ2 or AP50. AP2 is essential for the anchorage of cargo at the plasma 
membrane and subsequent recruitment of clathrin and further regulatory proteins to 
allow the process of internalisation to proceed (Jackson et al., 2010). Members of the 
Jones lab and others have shown that siRNA depletion of AP2µ2 prevents the uptake 
of transferrin via the transferrin receptor (Moody et al., 2015; Motley et al., 2003). In 
this thesis these methods were employed to initially target CME and then other 
proteins known to regulate other endocytic pathways. As previously demonstrated in 
Chapter 3 of this thesis, endocytosis of the CME probe transferrin was significantly 
reduced in cells depleted of AP2µ2 (Figure 3.1). Cells were transfected with control 
siRNA (si-control) or siRNA targeting AP2µ2 depleted cells and then incubated with 
Exo488 for 60 min prior to analysing cell fluorescence. Figure 5.8a shows no noticeable 
difference in either the cell fluorescence or the distribution of vesicular labelling 
between these two conditions. This was further confirmed by quantification of the MFI 
from three separate analyses including cells that were not transfected (Figure 5.8b).  
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Exosome uptake was also evaluated in cells treated with a widely used dynamin II 
inhibitor, Dynasore, previously used in numerous studies to evaluate the uptake of 
different entities via dynamin-dependant endocytic processes, such as CME and 
caveolae (Macia et al., 2006). Cells were pre-incubated with Dynasore for 30 min prior 
to addition of Tf488 for 15 min both the confocal microscopy images and MFI data 
highlight the strong and significant inhibition (p<0.001) of Tf488 uptake by this drug 
(Figure 5.9).  
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Fig. 5.8. Uptake of Alexa488 labelled exosomes in HeLa cells depleted of the CME adaptor protein 
AP2µ2 (A) Following 48 h siRNA transfection cells were pulsed with 60 µg/ml Exo488 for 60 min (37°C, 
5% CO2). Cells were incubated with Hoechst33342 for 5 min before imaging live (R/T). Scale bar: 20 
µm. (B) MFI quantification of each cell population. Error bars: Standard error. Images and graph 
summarise three separate experiments.  
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Fig. 5.9. Uptake of Tf488 in HeLa cells treated with Dynasore is significantly reduced in comparison to uptake in control treated cells. (A) Following 30 min Dynasore 
(80 µm) pre-treatment, cells were pulsed with Tf488 (5 µg/mL) for 15 min whilst in the continued presence of the inhibitor (37°C, 5% CO2). Cells were incubated with 
Hoechst33342 for 5 min before imaging live (R/T). Scale bar: 20 µm. (B) MFI quantification of Tf488 of the cell populations in (A) Error bars: Standard error. Images 
and graphs summarise three separate experiments. ***p<0.001 
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Unlike the AP2µ2 phenotype showing strong Tf488 labelling on the plasma membrane, 
Dynasore treated cells (Section 2.5.2) were almost devoid of any labelling; the reason 
for this is currently unknown but suggests that transferrin is unable to access its 
receptor in Dynasore treated cells. This was highly unexpected and as the zoomed 
images indicate, transferrin fluorescence was observed to be more disperse 
throughout the cytoplasm of Dynasore treated cells, rather than within the distinct 
punctate structures of control treated cells (Figure 5.9b). The ability of Dynasore 
treated cells to internalise dextran via fluid-phase endocytosis was investigated to 
access the effects of dynaminII inhibition on this process, as the protein has reported 
involvement in this pathway (Cao et al., 2007). This is also important when 
investigating the effect of Dynasore treatment on other endocytic pathways in this cell 
model. Following 60 min uptake, Dx488 could be observed as characteristic punctate 
structures within control treated cells and Dynasore treated cells (Figure 5.10a). There 
was no decrease in fluorescence intensity of Dx488 between the two populations, 
further indicating that the inhibitor had no effect on the fluid-phase uptake of dextran 
(Figure 5.10b). With regards to the effects of this inhibitor on exosome internalisation, 
there was a much smaller yet significant decrease in exosome uptake in Dynasore 
treated cells (Figure 5.11). This observation shows that a proportion of exosomes are 
entering via a dynamin II-dependant mechanism that based on data in Figure 5.8 is not 
CME. Interestingly cells transfected with a dominant negative dynamin II mutant were 
also shown to have reduced exosome uptake in RAW 264.7 macrophages (Feng et al., 
2010). This observation of exosome uptake, by a Dynasore but not an AP2µ2 
dependent process, could be due to the fact dynamin II has been implicated in the 
regulation of other endocytic pathways such as fluid-phase uptake and caveolae (Cao 
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et al., 2007; Henley et al., 1998). Furthermore, it has recently been demonstrated that 
Dynasore elicits additional dynamin independent effects on the cholesterol 
organisation of plasma membrane lipid rafts (Preta et al., 2015). Alteration of the 
plasma membrane in this way could affect the wider endocytic network, thereby 
affecting the designated uptake route of these structures. These studies led to further 
investigations targeting other endocytic proteins and pathways. 
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Fig. 5.10. Endocytic Uptake of Dx488 in HeLa cells treated with Dynasore is not affected. (A) 
Following 30 min Dynasore (80 µM) pre-treatment, cells were pulsed with Dx488 (100 µg/mL) for 60 
min whilst in the continued presence of the inhibitor (37°C, 5% CO2). Cells were incubated with 
Hoechst33342 for 5 min before imaging live (R/T). Scale bar: 20 µm. (B) MFI quantification of Dx488 of 
the cell populations presented in (A). Error bars: Standard error. Images and graph summarise three 
separate experiments. 
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Fig. 5.11. Uptake of Exo488 in HeLa cells treated with Dynasore is significantly reduced. (A) Following 
30 min Dynasore (80 µM) pre-treatment, cells were pulsed with Exo488 (60 µg/mL) for 60 min whilst 
in the continued presence of the inhibitor (37°C, 5% CO2). Cells were incubated with Hoechst33342 for 
5 min before imaging live (R/T). Scale bar: 20 µm. (B) MFI quantification of each cell population 
presented in (A) Error bars: Standard error. Images and graph summarise three separate experiments. 
*p<0.05 
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5.3.4 Exosome Uptake in Caveolin-1 and Flotillin-1 depleted cells 
Using the same siRNA-based approach both Cav1 and Flot1 proteins were successfully 
depleted as indicated by Western blot analysis (Figure 5.12) but this did not 
significantly affect cellular uptake of the labelled exosomes (Figure 5.13). We and 
others have shown that endocytosis of LacCer and an anti-CD59 antibody have 
previously been shown to be reduced, respectively, in Cav1 and Flot1 depleted cells (Al 
Soraj et al., 2012; Vercauteren et al., 2011). These were not performed here due to: 1. 
the fact that the anti-CD59 antibodies that have been previously used by the Jones lab 
(Al Soraj et al., 2012) and the commercial variant used by Bitsikas et al (Bitsikas et al., 
2014) to demonstrate the existence of this pathway are no longer available, and 2. that 
analysing LacCer uptake is technically very difficult in that it involves multiple rounds of 
washes in fatty acid free BSA (Al Soraj et al., 2012). 
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Fig. 5.12. Western blot analysis indicates successful depletion of Cav1 and Flot1 expression 
following siRNA transfection in HeLa cells. Following a 48 h period of siRNA transfection (100 nM) 
with siRNA targeting either Cav1, Flot1 or GFP, cells were lysed and Western blotting performed on 
the lysates. Western blots indicate Cav1 and Flot1 protein levels in comparison to the loading controls 
Tubulin and GAPDH.  
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For these reasons the discovery of novel and more specific probes for the analysis of 
Cav1 and Flot1 mediated endocytosis is crucial for the continued analysis of this 
pathway. In this thesis both proteins were successfully depleted giving us confidence 
that we could then perform endocytic uptake assays in these cells.  It should also be 
noted that depletion of either of these proteins could have significant cellular effects 
beyond that of reducing endocytic processes as both have been implicated as 
important modulators of cell signalling and organisation of lipid rafts (Lajoie and Nabi, 
2010). Of interest was that the distribution of exosome labelling was more peripheral 
in siCav1 and siFlot1 cells compared with controls suggesting alterations in 
downstream endocytic traffic. Overall these observations strongly suggest that 
endocytic processes involving Cav1 and Flot1 are not the primary mode of exosome 
entry, but these proteins may be involved in their subsequent traffic. 
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Fig. 5.13. Uptake of Exo488 in HeLa cells depleted of Cav1 or Flot1 (A) Following 48 h siRNA 
transfection (100nM), cells were pulsed with Exo488 (60µg/ml) for 60 min (37°C, 5%CO2). Cells were 
incubated with Hoechst33342 for 5 min before imaging live (R/T). Arrows indicate surface localised 
exosomes. Scale bar: 20µm. (B) MFI quantification of Exo488 of the cell populations in (A). Error 
bars: Standard error. Images and graphs summarise three separate experiments. 
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5.3.5 Exosome uptake in cells depleted of proteins regulating actin dynamics, fluid-
phase endocytosis and macropinocytosis 
Macropinocytosis has been described as a mechanism that is activated upon growth 
factor stimulation and could be conceived as an activated form of fluid-phase 
endocytosis (Jones, 2007; Kerr and Teasdale, 2009; Lim and Gleeson, 2011; Swanson 
and Watts, 1995). It is still unknown whether macropinocytosis can be viewed as a 
constitutive process in cells.  Both fluid-phase endocytosis and macropinocytosis lack a 
specific master regulatory protein that could be targeted for siRNA depletion without 
affecting other processes. Macropinocytosis is highly reliant upon the organisation of 
actin, indicating that actin regulating proteins are candidate siRNA targets for 
inhibition of this process. Actin may also have involvement in constitutive fluid phase 
uptake (Shurety et al., 1998). PAK1 has been identified as an important regulatory 
factor in the events associated with actin dynamics and macropinocytosis 
(Dharmawardhane et al., 2000; Liberali et al., 2008). Cdc42 is also a regulator of actin 
dynamics, having also demonstrated an involvement in fluid-phase 
endocytosis/macropinocytosis (Yoshida et al., 2009). These proteins were therefore 
targeted with siRNA to investigate whether their depletion caused any effects on 
dextran endocytosis and the uptake of exosomes.  
 Cells were transfected with siRNA sequences targeting PAK1 and Cdc42 as performed 
in Chapter 4 of this thesis. Previous studies have indicated that PAK1 was involved in 
the cellular uptake of cationic cell penetrating peptides (CPPs) that may be inducing a 
form of macropinocytosis for cell entry (Al Soraj et al., 2012; Nakase et al., 2004). 
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Despite some visual evidence of a reduction of dextran uptake in PAK1 depleted cells, 
quantitative analysis showed that this was not significant and no effects were also 
noted for Cdc42 depletion (Chapter 3, Figure 3.17). Following a 60 min endocytic pulse 
in the cells depleted of either PAK1 or Cdc42, a small decrease (Figure 5.14) in 
exosome uptake was observed. Localisation of punctate exosome structures in Cdc42 
depleted cells was noticeably different from control cells. Exosome density was greater 
at the cell periphery (Figure 5.14), suggesting an inability of these structures to be 
trafficked beyond the plasma membrane region. As noted for Flot1 and Cav1 the 
effects of depleting these proteins extend beyond just endocytic processes but the 
data suggest that traffic of exosomes beyond the plasma membrane is regulated by 
Cdc42 and most probably actin. As discussed in Chapter 4, actin targeting agents such 
as Cytochalasin D, latrunculin B and jasplakinolide are routinely used to monitor the 
involvement of actin on endocytosis but they also cause gross morphological effects on 
cells (He et al. Manuscript in preparation) making data interpretation very difficult. 
These drugs were not used in this thesis. 
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Fig. 5.14. Uptake of Exo488 in HeLa cells depleted of Cdc42 or PAK1 (A) Following 48 h siRNA 
transfection (100 nM), cells were pulsed with Exo488 (60 µg/ml) for 60 min (37°C, 5% CO2). Cells were 
incubated with Hoechst33342 for 5 min before imaging live (R/T). Arrows indicate surface localised 
exosomes. Scale bar: 20 µm. (B) MFI quantification of Exo488 of each cell population in (A). Error bars: 
Standard error. Images and graphs summarise three separate experiments. 
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5.3.6 Exosome uptake in cells treated with fluid-phase endocytosis/macropinocytosis 
inhibitors 
Endocytosis inhibitors can be used in conjunction with siRNA transfection studies to 
provide a more comprehensive analysis of the endocytic uptake of different probes 
(Vercauteren et al., 2011). Following PAK1 and Cdc42 siRNA studies the inhibitors 
characterised in Chapter 5 targeting fluid-phase endocytosis and macropinocytosis 
were utilised to further explore the involvement of these pathways in exosome 
uptake. 
EIPA is a commonly utilised Na+/H+ exchange inhibitor, and most probably prevents 
macropinocytosis by lowering the submembranous pH of the macropinocytic cup 
(Koivusalo et al., 2010), as discussed in Chapters 1 and 4. Although EIPA did not affect 
fluid-phase uptake of dextran in this cell line, it caused a small observable decrease in 
exosome uptake (Figure 5.15). Although endocytosis measures as fluorescence 
intensity was unaffected, exosome localisation in EIPA treated cells was more confined 
to the periphery of the cell (Figure 5.15a), further indicating the role of actin-
dependant processes on the downstream traffic of these exosomes.   Previous studies 
in PC12 cells incubated with PC12 exosomes have shown by flow cytometry that EIPA 
significantly reduces uptake of DiD labelled PC12 exosomes (Tian et al., 2014).  
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Fig. 5.15. Reduced uptake and membrane localisation of Exo488 in HeLa cells treated with EIPA  (A) Following 30 min EIPA (25 µM) pre-treatment, cells were pulsed 
with Exo488 (60  µg/mL) for 60 min whilst in the continued presence of the inhibitor (37°C, 5%  CO2). Cells were incubated with Hoechst33342 for 5 min before 
imaging live (R/T). Scale bar: 20 µm. (B) MFI quantification of Exo488 of the cell populations in (A). Error bars: Standard error. Images and graphs summarise three 
separate experiments. 
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Rottlerin is an inhibitor primarily utilised to target fluid-phase endocytosis rather than 
macropinocytosis (Hufnagel et al., 2009). Exosome uptake was significantly decreased 
in Rottlerin treated cells (Figure 5.16), further suggesting that some of these entities 
are simply entering with the fluid.  
The PAK1 inhibitor IPA-3 (Deacon et al., 2008), has previously been used to suggest 
macropinocytosis as a mechanism for viral cell entry  (Krzyzaniak et al., 2013; Wen et 
al., 2013). This drug induced a significant decrease in dextran uptake indicating a 
disruption of fluid-phase endocytosis in these cells (Chapter 4, Figure 4.13). Exosome 
uptake was also significantly reduced in cells treated with IPA-3 (Figure 5.17) further 
suggesting that a fraction of these exosomes are gaining intracellular access via the 
fluid-phase. Collectively observations with these inhibitors suggest that a major 
fraction of exosomes enter these cells by fluid phase endocytosis rather than 
macropinocytosis. 
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Fig.  5.16. Significant inhibition of Exo488 in Rottlerin treated HeLa cells. (A) Following 30 min 
Rottlerin (10 µm) pre-treatment, cells were pulsed with Exo488 (60 µg/mL) for 60 min whilst in the 
continued presence of the inhibitor (37°C, 5% CO2). Cells were incubated with Hoechst33342 for 5 min 
before imaging live (R/T). Scale bar: 20 µm. (B) MFI quantification of Exo488 of the cell populations in 
(A). Error bars: Standard error. Images and graphs summarise three separate experiments. *p<0.05 
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Fig. 5.17. Significant inhibition of Exo488 uptake in IPA-3 treated HeLa cells. (A) Following 30 min 
IPA-3 (10 µm) pre-treatment, cells were pulsed with Exo488 (60 µg/mL) for 60 min whilst in the 
continued presence of the inhibitor (37°C, 5% CO2). Cells were incubated with Hoechst33342 for 5 
min before imaging live (R/T). Scale bar: 20 µm. (B) MFI quantification of Exo488 of the cell 
populations in (A). Error bars: Standard error. Images and graphs summarise three separate 
experiments. *p<0.05 
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5.3.7 Establishment of an in vitro cell model to analyse the siRNA delivery potential of 
exosomes 
Several different formulations have been investigated, based a library of different 
delivery vectors, to transport nucleotides to the inside of cells. Vectors include lipids as 
lipoplexes, polymers as polyplexes, combinations of these and other systems based on 
CPPs. As preliminary studies and to establish an in vitro model for siRNA delivery this 
thesis also investigated the capacity of the prostate derived exosomes to deliver siRNA. 
This was via provision the non-small lung cancer cell line (H1299) that stably expresses 
eGFP (kind gift from Professor Camila Foged at the University of Copenhagen).  
Initial experiments were performed to ensure eGFP could be depleted in these cells 
using Oligofectamine, the transfection reagent that is routinely used in the Jones 
laboratory to deliver siRNA. Using our established protocols (Section 2.3), 
Oligofectamine was complexed with siRNA targeting eGFP that was either unlabelled, 
or labelled with the fluorophore Cy5, before the complexes were incubated with cells 
for 48 hours in this cell line (H1299eGFP). Cells transfected with both Cy5 and 
unlabelled siRNA demonstrated reduced expression of eGFP that was uniform across 
all cells of the population indicating that this protocol was sufficient for delivering 
siRNA into the cytosol of these cells (Figure 5.18). Cy5-labelled siRNA was observed 
within cells as punctate vesicular structures with and without Oligofectamine 
complexation, suggesting that the siRNA alone can gain intracellular access but not as 
an active entity in the cytosol. Wildtype H1299 cells (H1299WT) were utilised to 
provide an observable baseline fluorescence to compare eGFP depletion against. These 
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control studies provided a useful tool to further investigate the drug delivery potential 
of Du145 exosomes. 
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Fig. 5.18. Reduction of eGFP expression in H1299eGFP cells transfected with Oligofectamine and siRNA (Cy5-labelled and unlabelled) targeting eGFP. Cells were 
transfected with 100  nM of either scrambled siRNA (+Oligo), Cy5siRNA (no Oligo), Cy5siRNA (+Oligo) or unlabelled siRNA (+Oligo) for a period of 48 h. Cells were 
incubated with Hoechst33342 for 5 min before imaging live (R/T). Scale bar: 20 µm. Images representative of three separate experiments.  
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The ability of Du145 exosomes to deliver siRNA to the cell interior was explored in the 
H1299eGFP cells, using the same transfection techniques applied here. Exosomes 
labelled with Alexa633, at either 2 µg/ml or 20 µg/ml, were shown to be internalised 
by this cell line and could be visualised as punctate structures after a period of 4 hours 
(Figure 5.19). Confident that these exosomes could gain access to the cell interior, 
their ability to complex with and carry eGFP siRNA into the cell was then investigated.    
Exosomes were incubated with both labelled and unlabelled siRNA for a period of 30 
min at R/T in a manner similar to Oligofectamine/siRNA complexation. Following a 48 
hour transfection, depletion in eGFP expression was not observed in cells treated with 
exosome ‘complexed’ siRNA unlike cells treated with Oligofectamine complexed siRNA, 
which displayed a reduced expression of eGFP (Figure 5.19).  
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Fig. 5.19. Uptake of Exo633 in H1299eGFP cells. Cells were pulsed with either 2 µg/ml or 20 µg/ml 
Exo633 for 4 h (37°C, 5% CO2). Cells were incubated with Hoechst33342 for 5 min before imaging live 
(R/T). Scale bar: 20 µm.  
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Fig. 5.20. eGFP expression in H1299eGFP cells transfected with Oligofectamine, exosomes and siRNA (Cy5-labelled and unlabelled) targeting eGFP. Cells were 
transfected with either 20 µg/ml exosomes alone, exosomes (2 µg/ml or 20 µg/ml) and Cy5siRNA (100  nM), Cy5siRNA (100  nM) only or unlabelled siRNA (100 nM) 
and Oligofectamine, for a period of 48 h. Cells were incubated with Hoechst33342 for 5 min before imaging live (R/T). Scale bar: 20 µm.  Images representative of 
three separate experiments.  
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Cy5siRNA could be observed as punctate structures within the perinuclear region of: 
exosome complexed siRNA, Oligofectamine complexed siRNA and siRNA only treated 
cells (Figure 5.20), indicating that exosomes do not interfere with the ability of siRNA 
to reach the cell interior. No visible differences in the localisation of siRNA could be 
observed between siRNA alone and exosome ‘complexed’ siRNA further indicating that 
exosomes have no effects on the uptake and trafficking of siRNA within the cell, 
although they do not aid transfection. Indeed, it is likely that the exosomes did not 
complex with siRNA, causing inefficient transfection. Due to time limitations and the 
need for methods to load exosomes with siRNA these studies were not continued. 
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5.4 Discussion 
In this chapter an efficient and novel method to fluorescently label exosomes for 
subsequent high content microscopy analysis of their interactions with cells and in 
endocytic traffic has been explored. Unlike other current labelling methods, this 
technique provides flexibility with regards to choice of fluorophore used and also 
provides the ability to easily label exosomes from different cell types. In the case of 
prostate cancer Du145 derived exosomes the labelling procedure did not affect their 
capacity to induce complex cellular responses such as fibroblast to myofibroblast 
differentiation and induction of HGF secretion. It however remains to be determined 
whether this labelling method influences the other numerous functional effects 
documented for exosomes.  
These studies strongly suggest that these exosomes enter cells as components of the 
extracellular fluid in both primary lung fibroblasts and HeLa cells, and like dextran are 
mostly trafficked to lysosomes in HeLa. The localisation and dynamic activity of 
exosome positive vesicles suggest cellular entry via endocytosis rather than plasma 
membrane-exosome membrane fusion, as has been previously demonstrated in 
ovarian cancer cells (Escrevente et al., 2011) and discussed in a review from the 
Society of Extracellular Vesicles (Mulcahy et al., 2014).  Approximately 60% of 
exosomes were fated for the lysosome, and if a longer chase were performed it may 
be that a greater percentage of exosomes would be found within these regions. The 
interference of endocytic pathways with inhibitors and siRNA depletion of endocytosis 
mediators together provided greater knowledge of the ways in which exosomes are 
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gaining access to the cell interior. Depletion of the CME moderator AP2µ2 indicated 
that this pathway is not primarily involved in exosome uptake. The Dynasore studies 
however suggest that a dynamin II dependent mechanism may be involved. Indeed, 
Dynasore treatment may have a global effect on the cell, as a variety of cellular 
processes require the function of this scission protein, meaning that the effects on 
exosome uptake could be due to secondary effects of the inhibitor treatment. The 
effects of dynasore of transferrin uptake was highly unexpected as it was expected 
that a dynamin II inhibitor would not prevent binding of the ligand to its receptor but 
only its uptake into the cells. This support previous warnings regarding the selectivity 
of this inhibitor to dynamin II effects (Preta et al., 2015). It also highlights how 
microscopy can give additional information to FACS studies that here would have given 
the ‘expected’ decrease in transferrin fluorescence. 
Caveolin-1 and Flotillin-1 depletion did not affect exosome uptake with regards to 
internalisation intensity however localisation of exosome positive vesicles was altered. 
Accumulation at the plasma membrane indicates that these proteins may be required 
for downstream trafficking of these entities. It should also be noted that a reduced 
expression of Cav1 and Flot1 does not necessarily mean that their associate pathways 
are no longer active within the cell. Previous members have indeed indicated a 
reduction in the probes LacCer and anti-CD59 (Cav1-dependent and Flot1-dependent, 
respectively) through FACS analysis (Al Soraj et al., 2012). It could be proposed that a 
reduced expression of these proteins is sufficient to affect trafficking, so should follow 
and also affect endocytosis, in which instance it can be stated that Cav1 and Flot1 
dependant pathways are not primarily involved in the uptake of these exosomes. 
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Indeed, the involvement of lipid-raft dependant endocytosis in exosome uptake has 
been previously demonstrated through siRNA depletion of Cav1. Here, uptake of 
exosomes increased following depletion of Cav1 suggesting that the protein can 
negatively regulate uptake (Svensson et al., 2013).  
From the observations presented here, the most likely route utilised by these 
exosomes to gain intracellular access is via a fluid-phase endocytic or 
macropinocytosis-like mechanism. Depletion of Cdc42 and PAK1, proteins highly 
involved in actin dynamics (as discussed in Chapter 1), caused a small but insignificant 
decrease in exosome uptake. The most likely reason for this lack of significance is the 
large variability in uptake intensity between cells in the same population. Successful 
transfection does not often occur in every cell of a treated population, meaning that 
some cells will therefore retain the capacity to perform the pathways targeted. Cdc42 
depletion has been shown in Chapter 3 to cause a decrease in transferrin uptake, 
indicating that pathways generally involving actin rearrangement such as CME are also 
affected. PAK1 depletion however did not demonstrate these effects on the uptake of 
other endocytic probes indicating that the reduction in exosome uptake is likely due to 
a reduction in a fluid-phase or macropinocytosis-like mechanism. Exosome uptake in 
cells treated with the chemical inhibitors of fluid-phase endocytosis and PAK1, 
Rottlerin and IPA-3, however was significantly reduced. Unlike siRNA transfection, 
chemical inhibition affects all cells in the population resulting in a smaller variability in 
uptake between cells.  The small but not significant decrease in EIPA treated cells also 
alludes to the fact that exosomes are gaining access primarily through a fluid-phase 
endocytic/macropinocytosis like mechanism. Previous exosome studies have indicated 
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this also through the use of EIPA and other chemical inhibitors of fluid-phase 
endocytosis/macropinocytosis including Nystatin and MβCD (Tian et al., 2014). For the 
reasons discussed in Chapter 1, the latter inhibitors were not utilised in this thesis, but 
the use of EIPA demonstrated a similar decrease in uptake as observed in this thesis. 
Macropinocytosis has previously been designated as an exosome uptake route in 
microglial cells, where they are also found to localise to late endosomes/lysosomes 
(Fitzner et al., 2011). Pharmacological inhibitors of these processes were also used 
here, with amiloride and dynasore again indicating a reduction in exosome uptake. At 
this point it is interesting to suppose that exosomes are acting on the plasma 
membrane in a manner similar to a growth factor, thereby activating the actin ruffles 
associated with macropinocytosis. For instance, activation of the EGFR has previously 
been shown to increase the uptake of exosomes and this activation is accompanied by 
the hallmarks of macropinocytosis: actin reorganisation and ruffling (Nakase et al., 
2015). As previously discussed in Chapter 1, in this instance however the EGF used 
originates from exosomes that have already been internalised and it is proposed that 
the growth factor is trafficked back to the cell surface in order to induce these effects. 
It is unlikely that such an engineered system would occur naturally.  
The ability to successfully package or load exosomes with macromolecular or indeed 
small molecule therapeutics is essential to their potential use as drug delivery vectors, 
but methods to do this are lacking. Most current techniques utilise electroporation, 
which involves passing an electric current through the preparation to create pores in 
the membrane bilayer of the exosome (Alvarez-Erviti et al., 2011; Kooijmans et al., 
2013), but other methods include sonification, transfection reagents and liposomal 
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techniques (Lee et al., 2016; Lu et al., 2017). Furthermore, such techniques have 
induced more efficient loading of porphyrins into exosomes when compared to 
lysosomes, another potential drug delivery vector (Fuhrmann et al., 2015). Optimising 
these loading techniques to improve the intracellular delivery of a range of 
therapeutics would indeed unlock the drug delivery potential of exosomes and other 
extracellular vesicles. Their use would greatly benefit the treatment of a multitude of 
diseases, particularly those in which biological barriers impair efficient treatment due 
to the natural passage of exosomes across them. For instance, exosomes are able to 
cross the BBB to carry therapeutics to tissues in which access to most entities is 
prevented by this structure (Rufino-Ramos et al., 2017).    
From the results presented here it is likely that Du145 exosomes are primarily gaining 
access to the cell interior through a fluid-phase endocytosis/macropinocytosis-like 
mechanism that is dependent on dynamin II and actin dynamics, whereby the majority 
are trafficked to the lysosome. The techniques established and used here are now 
being utilised for the endocytic analysis of these exosomes in the primary lung 
fibroblasts in which they induce a phenotypic effect. A PhD student in the Clayton lab, 
Alex Cocks, is now optimising these techniques for use in this cell line, studies that will 
aid the overall aim of finding how Du145 exosomes interact with the cell to transfer 
functional cargo. The implications of these endocytic characteristics for the use of 
exosomes as drug delivery vectors remain to be determined but their trafficking 
profiles may be beneficially exploited if they can be packaged with small molecule 
drugs for lysosomal release into the cytosol.  
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6 General Discussion 
A higher level of understanding of the ways in which drug delivery systems, 
incorporating macromolecular therapeutics, interact with cells could greatly improve 
their capacity to cross important biological barriers such as the BBB and the gut 
epithelium. Incorporating such therapeutics with a variety of vectors is absolutely 
required to improve their capacity for intracellular access and targeting across a range 
of cell types (Ke et al., 2009; Midoux et al., 2009; Regberg et al., 2016; Srimanee et al., 
2016).  Exosomes and other types of extracellular vesicles represent natural vectors 
that are now gaining increasing attention as potential delivery vectors (El Andaloussi et 
al., 2013; Jiang and Gao, 2017; Vlassov et al., 2012). Wanting are robust in vitro models 
that allow the true mechanisms of cell entry of drug delivery to be determined. 
Establishment of platforms to analyse in detail (high-content) the endocytic uptake of 
various drug delivery systems would benefit from greater knowledge of the proteins 
involved in regulating the different pathways that have now been described. Also 
needed are inhibitors that are truly specific for inhibiting defined pathways. Most of 
the described endocytic pathways have, however, only been partially characterised. 
The work carried out in this project aimed to address this issue and was initially 
successful in providing a robust in vitro model for clathrin-mediated endocytosis (CME) 
in more than one cell line. CME has been extensively studied and benefits form the 
fact that to date is the only pathway that allows uptake of transferrin. The 
establishment of a model to study fluid-phase endocytosis and macropinocytosis was 
more difficult due to lack of specific probes and identification of proteins that only 
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regulate these processes over other pathways and other cellular processes. This 
overall problem was partially addressed through the use of chemical inhibitors of these 
pathways together with siRNA depletion of key proteins. The techniques established 
were eventually successfully utilised to provide important information on the uptake 
characteristics of exosomes that were the main focus of these studies.  
High capacity endocytic screening of drug delivery systems provided by collaborators, 
across a range of cell lines, was the initial goal of the project. This in part was achieved 
through the work of Dr Edd Sayers in the lab. This project ran in parallel with the work 
of Dr Sayers to provide higher content analysis and focused primarily on improving our 
capacity to study individual pathways using endocytic probes and then moving on to 
test these systems using labelled exosomes and model drug delivery vectors. All the 
analysis here was performed using live cell confocal microscopy rather than fixed cell 
analysis. This eliminated one potential source of error in data interpretation and also 
allowed concomitant analysis of the subcellular distribution and quantification of 
probes and exosomes. This can also not be achieved using flow cytometry.    
Initially, only qualitative analysis of the differences in uptake of various entities 
(whether endocytic probes or exosomes) between cell samples was provided via 
confocal microscopy, and largely the images failed to provide a reliable indication of 
levels representative of cell populations as a whole. For this reason, quantitative 
methods of evaluating uptake was explored and developed. The optimised technique 
involved the quantification of mean fluorescence intensity of individual cells using the 
method described in Section 2.13.1. This method allowed the calculation of statistically 
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significant differences between the intracellular fluorescence values of different cell 
populations. Performing this analysis is however time-consuming due to the 
requirement of having to manually identify the outline of hundreds of cells per sample. 
Automation of this process, such as that provided by platforms such as Cell Profiler, 
would be extremely beneficial for this process and is currently being explored in the 
lab. Systems that perform this automation have been described via the composition of 
macros working through software such as MetaMorph (Araki et al., 2014). This study 
involved the automatic quantification of wide-field microscopy images, but this 
process is distinct from setting up a system to automatically quantify confocal images. 
With regards to endocytosis, this idea has been applied further to quantify the extent 
of macropinocytosis occurring in a cell population in a cell population (Wang et al., 
2014). Using this method it was found that following starvation, EGF stimulation was 
efficient in the activation of macropinocytosis in HEK239 cells, a process that was also 
reduced following EIPA treatment. 
Techniques such as flow cytometry provide quantitative data on thousands of cells per 
sample and experimental time point, negating the need for such a rigorous process. 
Important qualitative data is, however, missed using such methods. Employing the 
technique used and developed in this project produces quantitative data relating 
directly to the qualitative data provided by the microscopy images. FACS analysis also 
requires several wash steps and detachment of the cells, potentially altering the 
cellular system being analysed.             
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The work surrounding CME benefitted greatly from the huge amount of information 
relating to its molecular organisation in numerous cell types (Godlee and Kaksonen, 
2013; McMahon and Boucrot, 2011; Robinson, 2015; Xing et al., 2010). AP2µ2 
depletion provided an efficient method of inhibiting CME without noticeably, to our 
knowledge, affecting other processes. Cells depleted of AP2µ2 in this project did not 
present with differences in cell morphology and the uptake of the CIE probes dextran 
and albumin was not affected, indicating that the extended endocytic network was not 
affected. Further analysis investigation metabolic viability/cell division of cells depleted 
of AP2µ2 may well reveal that depleting this protein may have other non-endocytic 
effects. This needs further investigation. 
The use of Dynasore as a CME inhibitor is extensive in the literature but its effects on 
other cellular processes has now been reviewed (Preta et al., 2015). Furthermore, its 
target dynamin II is involved in endocytic processes other than CME (Cao et al., 2007; 
Henley et al., 1998; Kokotos and Low, 2015) and also in processes distinct from 
endocytosis (Menon and Schafer, 2013). This was exemplified by the uptake of 
transferrin in Dynasore treated cells, where transferrin was not observed, as expected, 
to label the plasma membrane only due to the fact that the GTPase activity of Dynamin 
is required to pinch the clathrin coated vesicle from the membrane to allow 
internalisation. Reasons for this could include the inefficient recycling of the transferrin 
receptor to the plasma membrane, leaving nothing for extracellular transferrin to bind 
to. Alternatively the drug may affect the capacity of the transferrin to bind to its 
receptor. Future studies may benefit from the use of other chemical inhibitors related 
to Dynasore, such as the Dyngo molecules (McCluskey et al., 2013).  Studies in this 
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thesis clearly highlighted how this anomaly would have been missed had we relied 
entirely on flow cytometry analysis. 
The distinction between fluid-phase endocytosis and macropinocytosis generally 
identifies macropinocytosis as a growth factor activated process (Kerr and Teasdale, 
2009) rather than constitutive like fluid-phase endocytosis. Both are independent of 
the requirement for clathrin (Stromhaug et al., 1997; Synnes et al., 1999). This project 
highlighted many of the issues that influence our ability to study these pathways, 
including choice of probe, cell line being studied and in general, the cell-wide 
reorganisation of the cytoskeleton involved in this processes, particularly 
macropinocytosis. It could be expected that the constitutive nature of fluid-phase 
endocytosis means that fluid-phase probes, such as dextran, can be internalised by 
most cell lines. Macropinocytosis however requires the ability of the cell to respond to 
growth factor stimulation, a reaction that depends upon expression of the growth 
factor receptor by a particular cell line. For instance, the actin cytoskeleton of HeLa 
cells did not respond to EGF stimulation to the extent that A549 cells do, suggesting 
that the latter cell line expresses more EGFR or has a greater capacity to respond to 
EGFR activation. Although described in the literature, western blot analysis of EGFR 
levels would further confirm this. Notably, analysis of dextran uptake in EGF stimulated 
cells (classical depiction of macropinocytosis) was not performed in this project, mainly 
because of time constraints. Furthermore, studies analysing EGF mediated promotion 
of micropinocytosis involve, in some cases, long periods of serum starvation. To the 
best of our ability we avoided this kind of cell manipulation to allow better correlation 
regarding what happens in vitro to what may happen in vivo.  
288 
 
Following the establishment of these inhibitory methods, the project moved on to 
using them to characterise the uptake of interesting molecules that were known to 
influence cell physiology and were of interest in the COMPACT consortium as potential 
drug delivery vectors. These were exosomes and an existing collaboration was in place 
with Dr Clayton and colleagues at the Velindre Hospital who had published work on 
the differentiation capacity of prostate cancer derived Du145 exosomes. Working with 
members of the Jones lab that had identified a novel technique to fluorescently label 
these structures.  
Exosomes have been shown to internalise into cells using a variety of mechanisms, 
including via CME and macropinocytosis (Tian et al., 2014), but this presented thesis 
indicated that CME was not primarily utilised by these Du145 exosomes in HeLa cells. It 
is likely that a macropinocytosis-like pathway with a dependence on dynamin is used; 
noting the earlier discussion on issues relating to the specificity of dynasore.  Using 
colocalisation analysis it would appear that lysosomes are major depots for these 
exosomes raising interesting questions regarding their usefulness for delivering 
therapeutics to these hydrolytic organelles and how they are able to naturally release 
cargo such as miRNA into the cytosol before degradation.  
The uptake mechanism used by any extracellular vesicle is likely to depend on a variety 
of factors including the recipient cell line. Another issue to consider is the 
identity/profile of the vesicles present in the isolate. The distinction between 
exosomes and other extracellular vesicles in the isolation of vesicle preparations is 
much debated. It is difficult to state that an isolate contains exclusively exosomes, with 
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a collection of different types of extracellular vesicle much more likely. The Clayton 
group performs rigorous tests to define an isolate as mainly exosomes (Webber and 
Clayton, 2013), (as described in Appendix B and C), so this work describes all 
extracellular vesicles used as exosomes, though it may be possible that other types of 
vesicles are present. 
Delineating the uptake mechanism(s) of Du145 exosomes, fluorescently labelled using 
this novel technique was used in conjunction with an innovative way of quantifying 
fluorescence as a measure of exosome uptake. The ways in which this developed high 
content endocytic platform, can be used to explore endocytosis of a potential drug 
delivery vector was demonstrated.  These platforms are now currently being used by 
members of the Clayton lab to study the uptake of Du145 exosomes in primary lung 
fibroblasts, and also by members of the Jones lab to aid their individual project aims. 
The work performed in this project to establish these models highlighted the need for 
a collection of different methods, comprising both siRNA depletion methods and 
chemical inhibitors to study different pathways, as these processes have both 
strengths and weaknesses that can almost be counterbalanced when used in 
conjunction with each other.   There is however a need for better inhibitors and a 
higher level of understanding of endocytic pathways. 
Preliminary experiments were also performed to assess whether simple mixing of 
siRNA with exosomes would result in protein depletion following addition to the cells. 
These experiments in H1299eGFP cells were not successful, which is not unexpected 
due to the fact that optimisation studies were lacking. It is clear that loading exosomes 
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with cargo represents a major challenge and considered also should be the possibility 
that these entities, like Du145 exosomes, may have other effects. These effects such as 
the differentiation mentioned here could be detrimental or could be exploited for 
therapeutic gain. The preliminary deliver studies presented here in H1299eGFP cells 
now provide a suitable platform to study the siRNA delivery potential within the Jones 
group and with collaborators sharing new drug delivery formulations.  
It is also worthwhile considering how exosomes and other extracellular vesicles could 
be produced industrially if found to be utilised as a successful drug delivery vector. The 
processes required to collect and isolate exosomes in the small amounts used for this 
project are currently extremely rigorous; escalating these would be expensive, time-
consuming, and require high levels of industrial cell culture. If efficient loading of 
exosomes were to be optimised and targeting to different tissues was successful, the 
use of exosomes as novel drug delivery vectors for packaging macromolecular 
therapeutics is an exciting prospect for the future of drug delivery.  
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Fig. 6.1 
Courtesy of Edd Sayers 
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Appendices 
Appendix A – List of Products and Suppliers 
Biorad (Hemel Hempstead, UK):  
- Precision plus protein dual colour standards (#161-0374)  
- Clarity, Western ECL substrate (#170-5060) 
- 10% Mini-PROTEAN TGX Precast Gel (#456-1033) 
 
DAKO (Ely, UK):  
- Fluorescence mounting medium “Dako oil” / (#S3023)  
 
Fisher Scientific (Loughborough, UK):  
- Coverslips No. 1 circle 16mm diameter (#12313138)  
- PVDF membrane (#10344661)  
- SuperSignal West Femto Chemiluminescent Substrate (#34094)  
 
Life Technologies (Paisley, UK):  
- DMEM (#21885) 
- DMEM (Phenol red free + 20mM HEPES) (#21063-029)  
- RPMI 1640 (#21875)  
- DMEM/F12 (#11330) 
- Sensicell MEM (#A15156-01) 
- Ham’s F-12K (#21127-022)  
- FBS (#16000-044) 
- Opti-MEM (#31985-047) 
- NEAA (#11140050) 
- Sodium Pyruvate (#11530396)  
- 0.05% Trypsin EDTA (#25300062)  
- Hoechst 33342 (#H3570) 
- Cell Mask deep red (#C10046) 
- Cell Mask orange (#C10045)  
- Rhodamine Phalloidin (#R415)  
- Transferrin Alexa 488 (#T13342)  
- Transferrin Alexa 647 (#T23366) 
- 10kDa Dextran Alexa 488 (#D22910) 
- 10kDa Dextran Alexa 647 (#D22914) 
- C5-maleimide Alexa 488 (#A10254) 
- C5-maleimide Alexa 633 (#A20342) 
- BODIPY – LacCer (#B34402) 
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- BSA Alexa 647 (#A34785) 
- Oligofectamine transfection reagent (#12252-011)  
- Exosome Elution Columns (MW3000) (#4484449) 
 
Roche Diagnostics (Burgess Hill, UK):  
- cOmplete Protease Inhibitor Cocktail Tablets (#11836153001)  
 
Sigma Aldrich (Poole, UK):  
- EGF (#E9644)  
- EIPA (#A3085)   
- Rottlerin (#R5648)   
- IPA-3 (#I2285) 
- ML-7 (#I2764)   
- Triton X-100 (#X100)  
- BSA (#A7906)  
- Bicinchoninic Acid solution (#B9643)  
- Copper (II) Sulphate solution (#C2284)  
- TEMED (#T9281)  
- Ponceau S solution (#P7170)  
- Tween 20 (#P1379)  
- Trypan Blue (#T8154)   
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Fluorescence labelling of extracellular vesicles
using a novel thiol-based strategy for quantitative
analysis of cellular delivery and intracellular
traﬃc†
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P. Watson,d A. Clayton*b and A. T. Jones *a
Extracellular vesicles, including exosomes, are naturally derived nanovesicles generated in and released by
numerous cell types. As extracellular entities they have the capacity to interact with neighbouring cells
and distant tissues and aﬀect physiological processes as well as being implicated in numerous diseases
including tumorigenesis and neurodegeneration. They are also under intense investigation as delivery
vectors for biotherapeutics. The ways in which EVs interact with recipient cells to inﬂuence cell physiology
and deliver a macromolecular payload are at the early stages of exploration. A signiﬁcant challenge within
these studies is the ability to label EVs directly or indirectly with ﬂuorescent probes to allow visualization
without compromising functionality. Here, we present a thiol-based ﬂuorescence labelling method allow-
ing comprehensive analysis of the cellular uptake of prostate cancer derived EVs in live cells using con-
focal microscopy. Labelling of the EVs in this way did not inﬂuence their size and had no eﬀect on their
ability to induce diﬀerentiation of lung ﬁbroblasts to myoﬁbroblasts. For endocytosis analyses, depletion
of key endocytic proteins and the use of chemical inhibitors (Dynasore, EIPA, Rottlerin and IPA-3) indi-
cated that ﬂuid-phase endocytosis and/or macropinocytosis was involved in EV internalisation. Over a
period of six hours EVs were observed to increasingly co-localise with lysosomes, indicating a possible
termination point following internalisation. Overall this method provides new opportunities for analysing
the cellular dynamics of EVs as biological entities aﬀecting cell and whole body physiology as well as
investigating their potential as drug delivery vectors.
1 Introduction
Exosomes, a subpopulation of extracellular vesicles (EVs), are
secreted 30–150 nm sized vesicles manufactured within multi-
vesicular endosomes and traﬃcked to the extracellular space
through Rab-GTPase dependent mechanisms.1,2 These struc-
tures comprise a phospholipid bilayer that is particularly
enriched in membrane proteins such as tetraspanins, MHC
Class-I proteins, integrins and many others.3,4 The vesicle
lumen also encompasses complex entities derived from the
cell of origin, including cytosolic proteins and a subset of cel-
lular RNAs.5,6 Exosomes naturally serve as a means of shuttling
this cargo intercellularly as a mode of communication, which
can modulate important physiological and pathological pro-
cesses such as cancer, cardiovascular diseases, and neurode-
generation, as well as in transfer of pathogenic virulence
factors.6
This natural ability to functionally transfer a spectrum of
macro-molecular cargo between cells raises opportunities for
exploiting exosomes as vectors for drug delivery.7,8 However,
little is known about the ways in which exosomes initially
interact with the cell, gain intracellular access and are
traﬃcked through the cell to their final destination. Even less
is known about how intravesicular cargo is released and
directed towards the intended target within the cytosol or
other intracellular compartments. The capacity of exosomes to
mediate these eﬀects, possibly through endocytosis, requires
further characterisation in order to fully understand their
natural roles in disease pathogenesis and also unlock their
potential for drug delivery.
†Electronic supplementary information (ESI) available. See DOI: 10.1039/
c7nr04128d
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Endocytosis involves the envelopment of materials from the
exterior region of the cell by the plasma membrane. Several
endocytic pathways have now been described, each utilising
proteins that regulate single and multiple uptake routes.9,10
Clathrin-mediated endocytosis is by far the most well-defined
mechanism, characterised by the formation of a clathrin
coated pit that eventually buds into the cytoplasm to form a
clathrin coated vesicle that is uncoated before fusing with an
early or sorting endosome.9–11 Endocytosis mediating from
distinct platforms of the plasma membrane termed lipid rafts
has also been described, with these processes demonstrating
involvement of Caveolin-19,12 or Flotillin-1.9,13 Other pathways
include fluid-phase endocytosis and macropinocytosis, which
are defined as cargo non-specific mechanisms, with the latter
process demonstrating a reliance on extensive plasma mem-
brane reorganisation by the actin cytoskeleton. This is often in
response to growth factor stimulation.14–16 Distinguishing
between macropinocytosis and fluid phase uptake as constitu-
tive processes is very diﬃcult as they may share similar protein
mediators. Proteins that have been implicated in the organis-
ation of macropinocytosis include PAK-1 and Cdc42 that func-
tion as actin regulators.17–19
Exosome entry and cargo release has been proposed to
occur via endocytosis20 and/or through direct exosome-plasma
membrane fusion;21 reviewed in ref. 22. These studies labelled
purified exosome preparations with fluorescent probes and
then used either microscopy or flow cytometry to monitor cell
interaction and uptake. Labelling strategies include the use of
lipophilic dyes such as PKH2623,24 and the carbocyanine dyes
(DiI, DiO),25,26 which embed non-covalently within the mem-
brane bilayer of the exosome. Such dyes can however form dye
aggregates or micelles in aqueous solutions, of similar pro-
portions to exosomes, potentially giving misleading infor-
mation in uptake experiments.27 Exosome permeable com-
pounds including carboxyfluorescein succinimidyl ester
(CFSE) and 5(6) carboxyfluorescein succinimidyl diacetate
(CFDA) have also been used for this purpose.20,28 Any struc-
tural modifications on exosomes following labelling with these
dyes will alter their physical characteristics but may also aﬀect
their functional properties. For cell uptake analysis this func-
tional impact is rarely considered. Other labelling methods
include the use of stable cell lines that fuse Green Fluorescent
protein (GFP), or variants of, on to a protein enriched in exo-
somes, such as the tetraspanin CD63. This consequently pro-
duces a sub-population of exosomes, of uncertain proportion,
that are GFP-tagged.29,30 This approach also produces cells
overexpressing tetraspanins; proteins that are known to be
important in the biogenesis and function of these vesicles,31
and this is therefore a major modification of the composition
of the vesicles being produced. Furthermore, tetraspanins are
also present on linear membrane fragments, various forms of
cellular debris and larger plasma-membrane derived vesicles,
and hence does not entirely alleviate the need for rigorous
exosome-purifications.
In this report, we have developed a simple and rapid
method for covalent fluorescent labelling of purified EVs. The
method takes advantage of thiol (sulph-hydryl) groups on the
EV surface and our labelling approach does not alter their
documented capacity to induce fibroblast diﬀerentiation
in vitro;32,33 suggesting they retain at least a fraction of their
biological eﬀects. We thereafter investigated the potential
pathways involved in EV uptake, using the well characterised
endocytic HeLa cell model. This was performed with chemical
inhibitors of endocytic pathways or siRNA-based depletion of
specific endocytosis regulating proteins, and thus pathways.34
Our findings show that EV uptake is clathrin-independent,
with an endocytic profile indicative of macropinocytosis with
eventual delivery to lysosomes.
2 Materials and methods
2.1 Reagents
Transferrin Alexa488 (Tf488), Alexa488/647 10 kDa dextran
(Dx488/647), C5-maleimide-Alexa488/633, Cell Mask Deep Red
Plasma Membrane Stain, Dulbecco’s Modified Eagle Medium
(DMEM), Oligofectamine, Opti-MEM I reduced serum medium
were purchased from Invitrogen (Paisley, UK). Bovine serum
albumin (BSA), Dynasore, 5-(N-ethyl-N-isopropyl) amiloride
(EIPA), 1,1′-disulfanediyldinaphthalen-2-ol (IPA-3) and
Rottlerin were obtained from Sigma-Aldrich (Dorset, UK).
Complete mini-protease inhibitor cocktail tablets were pur-
chased from Roche Diagnostics (Sussex, UK). Single sequence
(21–23 residues) siRNAs listed in Table 1 were purchased from
Eurofins MWG Operon (Ebesburg, Germany). Sucrose and D2O
for EV isolations were from Sigma-Aldrich and Optiseal™
ultracentrifugation tubes from Beckman Coulter.
2.2 Cell culture
All culture materials were purchased from Invitrogen (Paisley,
UK). DU145 prostate cancer cells (ATCC) were maintained in
Integra Bioreactors (CellLine 1000AD) as described35 with the
outer chamber housing RPMI and 5% foetal calf serum (FCS),
with the inner cell-containing chamber holding RPMI with 5%
FCS that has previously been made devoid of bovine EVs by
overnight ultracentrifugation and filtration. All were cultured
in a humidified incubator at 5% CO2, 37 °C. Primary lung
fibroblasts (AG02262, Coriell Institute of Medical Research)
were cultured as sub-confluent monolayers in DMEM F-12
(1 : 1 mix) supplemented with 10% EV-depleted FCS. HeLa cer-
vical cancer cells (CCL-2; ATCC, Teddington, UK) were main-
Table 1 siRNA sequences used to deplete key endocytic proteins
siRNA target Sequence Ref.
AP2μ2 GUGGAUGCCUUUCGGGUCAdTdT Custom designed
Cav-1 AGACGAGCUGAGCGAGAAGdTdT 34
Cdc42 GACUCCUUUCUUGCUUGUUdTdT Custom designed
Flot-1 UGAGGCCAUGGUGGUCUCCdTdT Custom designed
PAK1 AUAACGGCCUAGACAUUCAdTdT 34
GFP GGCUACGUCCAGGAGCGCAdTdT 34
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tained in sensi-cell MEM medium supplemented with 10%
FCS, as a sub-confluent monolayer.
2.3 Antibodies
Listed antibodies were from the following manufacturers:
AP50 (AP2µ2) and flotillin-1 BD Transduction Laboratories
(Oxford, UK); Caveolin-1, GAPDH, PAK-1 Cell Signalling
Technologies (Hertfordshire, UK); Anti-TSG101, Alix, Calnexin
(Santa Cruz Biotechnology, Dallas, TX, USA); anti MHC Class-I
(eBioscience, ThermoFisher Scientific, Paisley, UK). Anti-Cdc42
and horseradish peroxidase (HRP) -anti-δ-tubulin (Sigma-
Aldrich, Dorset, UK); secondary HRP conjugated goat anti-
mouse/anti-rabbit (Thermo-Scientific Pierce, Loughborough,
UK).
2.4 Extracellular vesicle isolation, purification and
characterisation
Using the methodology outlined in ESI,† the isolation and sub-
sequent analyses satisfy the criterion set by the International
Society for Extracellular Vesicles (ISEV), for defining this speci-
men as exosomes.36 However, as discussion continues within
the field on isolation and characterisation of exosomes as pure
entities we refer here on in to our purified particles as EVs.
2.5 Labelling of extracellular vesicles with Alexa488/633
C5-Maleimide-Alexa488 or C5-maleimide-Alexa633 (200
μg ml−1–2.5 µl) was added to a 30 μl EV aliquot containing 60
to 100 µg protein, and made up to 50 μl with PBS before incu-
bation, with no agitation, for 60 min in the dark at room temp-
erature (R/T). During incubation exosome spin columns
(Invitrogen) were prepared according to manufacturer’s
instructions and powdered resin was hydrated for 15–30 min
at R/T. Spin columns placed in the collection tubes were centri-
fuged for 2 min (750g), in a swing-out rotor. The collection
tubes were discarded before the addition of the labelled EV
aliquot to the resin. Columns were placed in 1.5 ml eppendorf
tubes and centrifuged for 3 min (750g) to collect labelled EVs.
Non-incorporated, excess dye was retained by the resin, and
controls involving dye but no EVs were performed in parallel
to confirm dye retention by the column. For microscopy ana-
lysis, labelled EVs (referred to as EV488 or EV633) were gently
mixed to 1000 μl in phenol red free DMEM, before filtration
through a 0.22 μm filter (Millex), aliquoted and stored at
−80 °C until required.
2.6 Fibroblast diﬀerentiation assay
To test the impact of labelling on EV function, we used a well-
established fibroblast diﬀerentiation assay as described.33
Briefly, 80% confluent primary lung fibroblasts (Coriell
Institute for Medical Research) were serum deprived for 72 h
prior to stimulation with native or fluorescently labelled
DU145 EVs (at 200 µg ml−1). This dose provides vesicle-associ-
ated TGFβ equivalent to a dose of 1.5 ng ml−1 of soluble
TGFβ.32 As a positive control, soluble rhTGFβ (Promocell) was
used at 1.5 ng ml−1. After 72 h, ice cold acetone: methanol
(1 : 1 ratio) was added as fixative for 5 min. Following solvent
evaporation in air, cells were blocked in 1% BSA/PBS for 1 h.
Monoclonal antibody against alpha-smooth muscle actin
(αSMA) (Santa Cruz Biotechnology, Dallas, TX, USA) followed
by secondary goat anti-mouse IgG Fab’-Alexa594 conjugate
(ThermoFisher Scientific) was used to visualise onset of αSMA
stress-fibres. This is a hallmark of the myofibroblastic pheno-
type visualised by fluorescence microscopy (Zeiss Observer,
Cambridge, UK). Fibroblast secretion of Hepatocyte Growth
Factor (HGF) was assessed by DuoSet ELISA (R&D Systems),
performed on fibroblast conditioned medium 72 h post-treat-
ment, following manufacturers protocol.
2.7 Cell internalisation of Alexa488 labelled extracellular
vesicles in HeLa and primary lung fibroblasts
Cells were seeded in 35 mm MatTek imaging dishes (MatTek
Corporation, MA, USA) and cultured for 24 h to reach 80–90%
confluency. On the day of the experiment, EVs in imaging
medium (phenol-red free DMEM, 20 mM HEPES) containing
0.05% w/v BSA were added to cells at 50–60 µg ml−1 for
30–360 min before live cell confocal microscopy was per-
formed. Cells were incubated with the nuclear label Hoechst
for 5 min before washing with imaging medium followed by
imaging. For time-lapse imaging, cells were incubated with
Hoechst and Cell Mask Deep Red Plasma Membrane Stain
(1 : 5000) for 5 min before washing with imaging medium and
time lapse confocal microscopy.
2.8 Labelling of lysosomes with dextran-Alexa647
Cells were seeded to be 50–60% confluent on the day of
dextran incubation. Dextran647 (Dx647, 100 µg ml−1) was incu-
bated with cells for 2 h (5% CO2, 37 °C), before washing with
PBS and re-addition of complete cell culture media. Cells were
then incubated for 18 h (5% CO2, 37 °C) before incubating
with 50–60 µg ml−1 EV488 for colocalisation analysis.
2.9 Incubation of cells with endocytosis inhibitors
All inhibitors were diluted from DMSO stocks to working solu-
tions in imaging medium containing 0.05% BSA. Cells were
seeded in 35 mm MatTek dishes 24 h before the day of the
experiment to be 80–90% confluent. They were then washed
three times with imaging medium containing 0.05% BSA and
subjected to 30 min inhibitor pre-incubation with either
Dynasore (80 µM), EIPA (25 µM), IPA-3 (50 µM) or Rottlerin
(10 µM). Cells were then incubated with the stated concen-
tration of experimental probe (Dx488/647, Tf488, EV488) for
the specified time period in the continued presence of the
inhibitor. They were then washed with imaging medium prior
to performing live cell confocal microscopy.
2.10 siRNA depletion of proteins regulating endocytosis
Performed as described in ESI.†
2.11 Internalisation of Tf488, Dx488/647 into cells
Cells were seeded in 35 mm MatTek dishes and cultured for
24 h to be 80–90% confluent on the day of the experiment. For
transferrin uptake analysis, cells were washed three times and
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incubated with imaging medium supplemented with 0.05%
BSA for 30 min before the addition of Tf488 (5 µg ml−1) for
15 min. For dextran uptake, 100 µg ml−1 of Dx488/647 in
imaging medium supplemented with 0.05% BSA was added to
cells for 60 min without 30 min pre-incubation. Cells were
incubated with Hoechst in imaging medium for 5 min before
washing with fresh imaging medium followed by performing
live cell confocal microscopy.
2.12 SDS PAGE and Western blotting for siRNA depletion
Performed as detailed in ESI.†
2.13 Fluorescence microscopy
2.13.1 Live-cell imaging confocal microscopy. Fluorescent
images were taken using a Leica SP5 Confocal Microscope
system and captured using LAS AF software. Cells were imaged
at R/T with either a 40× 1.25 NA or a 63× 1.4 NA oil objective.
Alexa488 was excited by a 488 Argon laser (20% intensity), and
Alexa633/647 excited by a 633 helium–neon laser (20% inten-
sity). Bi-directional, sequential scanning was applied to ensure
spectral separation of fluorophores. The presented movie was
acquired using the same microscopy settings but with cells
maintained at 37 °C.
2.13.2 Calculation of colocalisation coeﬃcients. To deter-
mine the proportion of EVs (green fluorescence) associated
with lysosomes (red fluorescence) the M1 Mander’s coeﬃcient
was calculated using the JaCop ImageJ plug-in and thre-
sholded using the automated default algorithm. Six fields of
view (approximately 60 cells) per time point were analysed and
the mean calculated to provide an average colocalisation value
for each repeat. The mean of the average colocalisation value
for three separate experiments was plotted.
2.13.3 Mean fluorescence intensity (MFI) quantification.
Individual cells from LAS AF files were manually selected as
regions of interest (ROIs) using ImageJ software. Mean fluo-
rescence intensity (MFI) of each was calculated, resulting in
the quantification of approximately 150–160 cells per experi-
mental sample. The geometric mean of each sample group
was calculated to provide an average MFI for repeat experi-
ments; the mean of the geometric mean from three indepen-
dent experiments was calculated and used for statistical
calculations.
2.14 Statistical analysis
To compare control treated samples against experimental
samples, a Student’s unpaired t-test was utilised using the geo-
metric mean of each separate experiment. Significance was
specified as *p < 0.05, **p < 0.01, or ***p < 0.001.
3 Results and discussion
3.1 Characterisation and labelling of purified extracellular
vesicles
Cells produce a variety of debris and diﬀerent types of vesicle,
we therefore utilised our established approach for the specific
isolation of EVs.37 Following the clearance of gross debris from
cell-conditioned medium, by centrifugation (2000g), the
medium were filtered (0.22 µm) to remove the majority of
larger microvesicles. The medium was thereafter ultracentri-
fuged, capturing vesicles floating in an isotonic cushion of
sucrose, preventing vesicles of classical densities 1.1–1.2
g ml−1 from pelleting.
Cryo-electron microscopy was performed on EVs purified by
this method, revealing the presence of genuine vesicle struc-
tures, with a lipid-bilayer boundary (Fig. 1A). There was some
heterogeneity in sizes, and the structures are typical for EVs
analysed by Cryo-EM as reported.38 Nanoparticle tracking ana-
lysis (NTA) using the NanoSight™ platform, revealed particu-
lates with a modal hydrodynamic diameter of ∼100 nm, and a
low proportion of larger particulates (Fig. 1B), comparable to
sizes seen by Cryo-EM. We also examined the preparation for
the presence of proteins typically enriched in EVs. EV-prep-
arations immobilised on microtitre plates were stained with
antibodies specific for CD9, CD81, CD63 and respective
isotype-matched controls.
This highlighted strong, specific signals for these tetra-
spanins (Fig. 1C), which is a particular trait of exosomes.39
In addition, by comparing the parent DU145 cancer cells
with EV preparations by western blotting, we also reveal an
enrichment of some classical EV-associated proteins such as
TGS101, Alix and MHC Class-I (Fig. 1C, inset). In contrast,
the endoplasmic reticulum marker, Calnexin, was not
detectable in these preparations, yet abundant in cell
lysates, demonstrating the paucity of cellular contamination
of these EV preparations. Furthermore, using a combination
of BCA-protein assay and NanoSight™-concentration
measurements, the particle to protein ratio for purified EVs
was calculated. This gives an indication of specimen purity
as we describe40 and for all preparations used in the study a
particle : protein ratio of >2 × 1010 particles per μg protein
was achieved.
The EV is an environment that is cysteine rich, through, for
example, the presence of tetraspanin webs.39 We therefore pos-
tulated that the thiol (–S–H groups) present on these structures
would react with a maleimide functional group, to form a
stable, non-reversible, thio-ether linkage. Fluorophore conju-
gated maleimides are often used to fluorescently label bio-
molecules and here we used C5-maleimide conjugated to
Alexafluor488. Other groups have exploited this labelling pro-
tocol in order to study micro-particle populations whereby
whole blood samples were labelled with BODIPY-maleimide
for analysis via flow cytometry.41,42 However, BODIPY itself is
used to label membranes, and is therefore likely to integrate
onto the EV bilayer.
We examined the capacity for maleimide-Alexa488 to react
with EV thiols. Part of this procedure however, involves the
removal of non-bound dye from the EV-preparations. Initial
experiments used ultracentrifugation washes to achieve this,
but the method was refined thereafter by using a spin-column
(Invitrogen), that retains molecules of <3000 Da. Initial experi-
ments explored incubating a constant quantity of purified EVs
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with varying fluorophore concentrations (Fig. 1D), showing
saturating levels of labelling at ≥100 µg ml−1 after an incu-
bation of 1 h. At the saturating fluorophore concentration
200 µg ml−1, we also examined various incubation times
revealing most of the fluorophore-EV labelling occurs very
rapidly within the first 5 min, and saturation was reached at
1 to 2 h (Fig. 1E, circles). A control for fluorophore-only (no EVs)
to assess its possible retention by the spin column is also
shown, revealing negligible signal (Fig. 1E). We chose labelling
conditions of 200 µg ml−1 for 1 h for the remainder of the
study. To ascertain whether or not the fluorophore was actually
forming a covalent bond through the thiol groups, or merely
binding passively to the vesicle surface, we added a competitor
that works by capping the available reactive thiol groups. Pre-
incubating EVs with doses of N-acetyl-L-cysteine showed a
potent (∼80%) inhibition of labelling under these same con-
ditions (Fig. 1F).
Nanoparticle tracking analysis revealed a similar size distri-
bution profile following incubations with maleimide-Alexa488,
suggesting a paucity of gross complexation due to maleimide-
vesicle cross-linking (Fig. 1G, left). Importantly, NTA-analysis
in the presence of a low-pass 500 nm filter showed the
majority (>90%) of vesicles were fluorescent (Fig. 1G, middle).
The capacity to monitor fluorescent nanovesicles by this
method is a challenge, and successful tracking here points to
strong fluorescence output from each vesicle. We also analysed
the stock maleimide-Alexa488 reagent, by NTA. Unlike for
some other fluorescent labels, particularly PKH26, there were
negligible particles detected in scatter mode, and there were
no particles seen with a fluorescent filter in place (Fig. 1G,
right graph). An example of nanoparticulate PKH26 fluorescent
aggregates in the absence of EVs are shown (Fig. S1†).
Particulate material spanning the size range of exosomes was
present in the stock solution, and a high proportion (52%) of
Fig. 1 Labelling of EVs with malemide-Alexa488. (a) Cryo-electron microscopy of a typical preparation of DU145 EVs, with examples of small vesi-
cular structures. Higher magniﬁcation micrographs highlight some heterogeneity in sizes. (b) Nanoparticle tracking analysis of DU145 EV size distri-
bution. (c) Plate-immobilised EVs with surface staining for tetraspanin proteins, as indicated. (c, inset) Western blot panel with cell lysates compared
to EV lysates (each with 20 µg protein per lane), stained for exosomal or cellular markers as indicated. (d) Malemide-Alexa488 (5–200 µg ml−1) was
incubated with EVs for 1 h prior to separation of free dye and analysis by ﬂuorometry. (e) EVs were labelled with malemide-Alexa488 at 200 µg ml−1
up to 3 h (circles) and retention of free dye by the column (squares). (f ) EVs were pre-incubated with N-acetyl-cysteine up to 1 mM for 30 min prior
to labelling with malemide-488 (200 µg ml−1 for 1 h). (g) Malemide-Alexa488 labelled EVs analysed by NTA, (left) shows a similar size distribution
proﬁle measured in light scatter mode or measured with ﬂuorescence ﬁlter revealing high proportion of ﬂuorescent vesicles (middle); absence of
ﬂuorescent dye-particles in the absence of EVs (right). (h) Growth arrested ﬁbroblasts were stimulated with treatments as indicated, and 72 h later
ﬁxed and stained for detection of α-smooth muscle actin (red, scale bar: 50 µm). (h, bars) Medium harvested from stimulated ﬁbroblasts after 72 h,
were assessed for levels of HGF by ELISA, showing mean ± standard deviation of triplicates. N/S: not signiﬁcantly diﬀerent, n = 3. (i) Primary lung
ﬁbroblasts were incubated with maleimide-633 labelled EVs (60 µg ml−1) for 1 h before live cell confocal microscopy was performed. Cells were
incubated with Hoechst for 5 min before imaging to label the nucleus. Scale bar: 20 µm.
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these are fluorescent. We conclude this method is a simple,
rapid and highly eﬀective modality for EV labelling, and is free
of artefacts related to insoluble dye nanoparticulate.
We next investigated the functional impact of coating EVs
with our fluorescent label; an aspect that is rarely considered
in previous studies. To do this, we relied on a well-established
functional assay whereby prostate cancer exosomes trigger the
diﬀerentiation of fibroblasts to myofibroblasts.32 This process
requires delivery of exosome-associated TGFβ to fibroblasts,
but also is likely to involve additional exosome-cargo as the
myofibroblasts generated are distinct from those formed by
soluble TGFβ-stimulation in that secretion of hepatocyte
growth factor (HGF) is triggered.33 Stimulation of fibroblasts
either with native or with maleimide-Alexa488 labelled EVs
successfully triggered the onset of stress fibres visualized via
αSMA labelling; soluble TGFβ also did this as expected
(Fig. 1H). When evaluating the secretion of HGF however,
there was clear diﬀerence in levels of HGF whether stimu-
lations were by EVs or soluble TGFβ (Fig. 1H, bars), as we have
previously observed.33 The labelled or unlabelled EVs were
equally proficient at stimulating HGF secretion.
In this assay, which represents a major and complex cell
diﬀerentiation process, our maleimide-Alexa488 labelling
approach shows no signs of attenuating EV function.
3.2 Endocytic analysis of Alexa488 extracellular vesicles in
cells
We investigated the possibility of visualising the labelled EVs
following incubation with the fibroblasts. These cells had high
background cellular autofluorescence at 488 nm excitation
(data not shown) and the purified EVs were therefore labelled
with Alexa633 using the same procedure. Fig. 1I demonstrates
these EVs were internalised to label punctate structures indica-
tive of endosomes. These cells are however poorly character-
ised with respects to characterisation of endocytosis. We and
others have performed detailed studies of the involvement of
individual endocytic pathways in HeLa cells as model for
uptake of drug delivery vectors.34 Previous studies on exosome
and EV uptake have also been published using HeLa
cells.30,43,44 We therefore decided to focus our subsequent
experiments on the well characterised HeLa cell line.
HeLa cells incubated with Alexa488 labelled EVs (EV488) for
30 and 60 min demonstrated a scattered punctate distribution
throughout the cell cytoplasm (Fig. 2A). Time lapse imaging of
EV488 incubated with HeLa cells over a period of 3 min (after
a 120 min pre-incubation) shows these structures to be highly
motile with little evidence of extensive accumulation at the
plasma membrane (Video S1†). There was a noticeable time
dependant increase in fluorescence intensity from 30 min to
240 min (Fig. 2B) and at this later time point fluorescence was
more polarised to the perinuclear regions. This confirmed that
these labelled EVs also have endocytic capacity in this cell line,
allowing further analysis of cell entry mechanisms.
3.3 Traﬃc of Alexa488 extracellular vesicles to lysosomes
Cells incubated with EVs for >60 min showed the accumu-
lations of fluorescence in the perinuclear region suggesting a
fraction were being traﬃcked to lysosomes that are also promi-
nent in this region in HeLa cells (Fig. 2).45 EV traﬃc from the
plasma membrane was then studied at diﬀerent time points in
cells containing labelled lysosomes via a pulse-chase incu-
bation. Colocalisation between 488-EVs and 647-lysosomes was
Fig. 2 Time dependent EV endocytosis in HeLa cells. (a) Cells were incubated with EV488 (60 µg ml−1) for 30, 60, 120 or 240 min and incubated
with Hoechst for 5 min before live cell confocal imaging. Scale bars: 20 µm. Images representative of three separate experiments. (b) MFI quantiﬁ-
cation of the experiments presented. Error bars: standard error. Representative of three separate experiments.
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barely detected at 30 min and then increased over a period of
six hours to the point that after 360 min ∼60% of detected EVs
were contained in labelled lysosomes (Fig. 3). This method
measures the location of EVs in early and late endocytic com-
partments including lysosomes. We then performed experi-
ments by which dextran was similarly used to label lysosomes
but following a two hour pulse of EV endocytosis the cells were
washed and the material already associated with the cells was
chased for a further 4 hours revealing that over 60% of EV
associated labelling had reached and remained at the lyso-
somes by the end of this chase period (Fig. S2†).
3.4 Endocytic uptake of extracellular vesicles in clathrin-
mediated endocytosis (CME) compromised cells
CME has been extensively characterised in in vitro models
including HeLa cells,10,11 and this process can be attenuated
using a range of methods.34 These include siRNA depletion of
a key member of the of the CME adaptor complex AP2, known
as AP2µ2 or AP50. This subunit is essential for the anchorage
of cargo at the plasma membrane and subsequent recruitment
of clathrin and further regulatory proteins to allow the process
of internalisation to proceed.46 We and others have shown that
siRNA depletion of AP2µ2 prevents the uptake of transferrin
via the transferrin receptor.45,47 Following a 48 hours transfec-
tion with siRNA the AP2µ2 protein (50 kDa) was eﬀectively
depleted versus a control siRNA (Fig. 4A). A second siAP2µ2
insensitive lower molecular weight band was identified with
this antibody that was insensitive to siRNA AP2µ2, this has
previously been shown but not explained.48 In these siAP2µ2
treated cells incubated with Tf488 for 15 min, the probe was
mainly sequestered at the plasma membrane compared to
internalised punctate structures in control cells (Fig. 4B). si-
Control and AP2µ2 depleted cells were also incubated with
EV488 for 60 min prior to analysing cell fluorescence. Fig. 4C
shows no noticeable diﬀerence in either the cell fluorescence
or the distribution of vesicular labelling between these two
conditions. This was further confirmed by quantification of
the mean fluorescence intensity (MFI) from three separate ana-
lyses including cells that were not transfected (Fig. 4D).
Extracellular vesicle uptake was also evaluated in cells
treated with a widely used dynamin II inhibitor, Dynasore, pre-
viously used in numerous studies to evaluate the uptake of
diﬀerent entities via dynamin-dependant endocytic processes,
such as CME and caveolae.49 Cells were pre-incubated with
Fig. 3 Co-localisation of 488-labelled EVs with dextran-loaded lysosomes in HeLa cells. (a) Cells were incubated with Dx647 (100 µg ml−1) for 2 h,
washed with PBS and incubated for a further 18 h in culture media. Cells were then incubated with EV488 (60 µg ml−1) for either 30, 60, 120 or
360 min before treatment with Hoechst for 5 min and live cell confocal imaging. Solid arrowheads indicate colocalisation between EVs and lyso-
somes and transparent arrowheads indicate EVs not colocalised with lysosomes. Scale bars: 20 µm and 10 µm in zoomed images. Images represen-
tative of three separate experiments. (b) Mander’s correlation coeﬃcient analysis of the proportion of green ﬂuorescence (EVs) associated with far-
red ﬂuorescence (lysosomes) based on the experiments performed to generate Fig. 3(A). Error bars: standard error. Representative of three separate
experiments.
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Dynasore for 30 min prior to addition of Tf488 for 15 min or
EV488 for 60 min. Both the confocal microscopy images and
MFI data highlight the strong inhibition of Tf488 uptake by
this drug (Fig. 4E and F). Unlike the AP2µ2 phenotype showing
strong Tf488 labelling on the plasma membrane, Dynasore
treated cells were almost devoid of any labelling; the reason
for this is currently unknown but suggests that Tf is unable to
access its receptor in Dynasore treated cells. There was a much
smaller but significant decrease in EV uptake in Dynasore
treated cells (Fig. 4E and F). This observation shows that a sig-
nificant proportion of EVs are entering via a dynamin II-
dependant mechanism that based on data in Fig. 4C is not
CME. Interestingly cells transfected with a dominant negative
dynamin II mutant were also shown to have reduced exosome
uptake in RAW 264.7 macrophages.23 Our observation of EV
uptake, by a Dynasore but not an AP2µ2 dependent process,
could be due to the fact dynamin II has been implicated in the
regulation of other endocytic pathways such as fluid-phase
uptake and caveolae.50,51 Furthermore, it has recently been
demonstrated that Dynasore elicits additional dynamin inde-
pendent eﬀects on the cholesterol organisation of plasma
membrane lipid rafts.52 Alteration of the plasma membrane in
Fig. 4 Internalisation of EVs in CME compromised HeLa cells. (a) Western blot analysis of AP2µ2 protein levels 48 h following siRNA transfection in
comparison with loading GAPDH loading control. (b) Cells were depleted of either AP2µ2 via siRNA transfection for 48 h before incubation with
either (b) Tf488 (5 µg ml−1) for 15 min or (c) EV488 (50 µg ml−1) for 60 min. White arrowheads indicate surface bound Tf488. (e) Cells were pre-incu-
bated with Dynasore (80 µM) for 30 min before incubation with either Tf488 (5 µg ml−1) for 15 min or EV488 (50 µg ml−1) for 60 min. All were incu-
bated with Hoechst for 5 min before live cell imaging. Scale bars: 20 µm. Images representative of three separate experiments. (d), (f ) MFI quantiﬁ-
cation of the experiments presented in (c), (e), respectively. Utx: untransfected. Error bars represent standard error. *p < 0.05, ***p < 0.001, n/s: no
signiﬁcance. Representative of three separate experiments.
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this way could aﬀect the wider endocytic network, thereby
aﬀecting the designated uptake route of these structures.
These studies led to further investigations targeting other
endocytic proteins and pathways.
3.5 Extracellular vesicle uptake in Caveolin-1 and Flotillin-1
depleted cells
Using the same siRNA-based approach, both Caveolin-1 and
Flotillin-1 proteins were successfully depleted but the loss of
these proteins, and the endocytosis that they organise, did not
significantly aﬀect cellular uptake of the labelled EVs (Fig. 5).
Although not performed for the studies presented here, we
and others have however shown that endocytosis of lactosyl-
ceramide and an anti-CD59 antibody have previously been
shown to be reduced, respectively, in Caveolin-1 and Flotillin-1
depleted cells.34,53 It should be noted that depletion of either
of these proteins could have significant cellular eﬀects beyond
that of reducing endocytic processes as both have been impli-
cated as important modulators of cell signalling and organis-
ation of lipid rafts.54 Of interest is that the distribution of EV
labelling was more peripheral in siRNA Flotillin-1 cells com-
pared with controls suggesting alterations in downstream
endocytic traﬃc. Overall these observations strongly suggest
that endocytic processes involving Caveolin-1 and Flotillin-1
are not the primary mode of EV entry.
3.6 Extracellular vesicle uptake in cells depleted of proteins
regulating actin dynamics, fluid-phase endocytosis and
macropinocytosis
Fluid-phase endocytosis could be viewed as a process of consti-
tutive plasma membrane turnover performed important for
functions such as nutrient gathering and sampling of the
extracellular environment. Macropinocytosis has been
described as a mechanism that is activated upon growth factor
stimulation and could be conceived as an activated form of
fluid-phase endocytosis.14,15,55,56 Both lack a specific master
regulatory protein that could be targeted for siRNA depletion
without aﬀecting other processes. Macropinocytosis is highly
reliant upon the organisation of actin, thus actin regulating
proteins are candidate siRNA targets for inhibition of this
process. Actin may also have involvement in constitutive fluid
phase uptake.57 The p21-activated kinases (PAKs) regulate
numerous modifications of the cytoskeleton, particularly
through their interactions with the Rho GTPases, Cdc42 and
Rac1.58,59 PAK-1 has been identified as an important regulatory
factor in the events associated with macropinocytosis.18,19
Cells were successfully transfected with siRNA sequences tar-
geting PAK-1 and Cdc42 (Fig. 6A) to investigate the roles of
these proteins on initially the uptake of dextran that represents
in the absence of growth factor activation, a constitutive fluid
phase probe.60,61 Our previous studies indicated that PAK-1
was involved in the cellular uptake of cationic cell penetrating
peptides that may be inducing a form of macropinocytosis for
cell entry.34,62 Despite some visual evidence of a reduction of
dextran uptake in PAK-1 depleted cells (Fig. 6B), quantitative
analysis showed that this was not significant and no eﬀects
were also noted for Cdc42 depletion (Fig. 6C). Following a
60 min endocytic pulse in the cells depleted of either PAK-1 or
Cdc42 (Fig. 6D), a small but insignificant decrease (Fig. 6E) in
EV uptake was observed. Localisation of punctate EV structures
in Cdc42 depleted cells was noticeably diﬀerent from control
cells, being much more apparent at the cell periphery
suggesting an inability of these structures to be traﬃcked
beyond the plasma membrane region (Fig. 6D). These obser-
vations are further represented in the additional fields of view
presented in Fig. S3.† As noted for Flotillin-1 and Caveolin-1
the eﬀects of depleting these proteins scope wider than endo-
cytosis but the data suggest that traﬃc of EVs beyond the
plasma membrane is regulated by Cdc42 and most probably
actin. Actin regulating agents such as Cytochalasin D are routi-
nely used to monitor the involvement of actin on endocytosis
but they also cause gross morphological eﬀects on cells (data
not shown) making data interpretation very diﬃcult.
Fig. 5 Internalisation of EVs in HeLa cells depleted of Cav-1 and Flot-1.
(a) Western blot analysis of Cav-1 and Flot-1 protein levels in HeLa cells
48 h following siRNA transfection in comparison with loading proteins
Tubulin or GAPDH. (b) Cells were depleted of either Cav-1 or Flot-1 via
siRNA transfection for 48 h before 60 min incubation with EV488 (50
µg ml−1). Cells were incubated with Hoechst for 5 min before live cell
imaging. Scale bar: 20 µm. Images representative of three separate
experiments. Arrowheads in B represent peripheral EVs (c) MFI quantiﬁ-
cation of the experiments presented in (b). Utx: untransfected. Error bars
represent standard error. n/s: no signiﬁcance. Representative of three
separate experiments.
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3.7 Extracellular vesicle uptake in cells treated with fluid-
phase/macropinocytosis inhibitors
Endocytosis inhibitors can be used in conjunction with siRNA
transfection studies to provide a more comprehensive analysis
of the endocytic uptake of diﬀerent probes.53 Following our
observations in siPAK-1 and siCdc42 cells, inhibitors targeting
fluid-phase endocytosis and macropinocytosis were utilised to
further explore the involvement of these pathways in EV
uptake.
5-(N-Ethyl-N-isopropyl) amiloride (EIPA) is a commonly uti-
lised Na+/H+ exchange inhibitor, and most probably prevents
macropinocytosis by lowering the submembranous pH of the
macropinocytic cup.63 A small but insignificant (p = 0.61)
decrease in dextran uptake was observed in EIPA treated cells
(Fig. 7A and B), suggesting that it has little eﬀect on fluid-
phase endocytosis. Transferrin internalisation in these cells in
comparison with control treated cells was significantly
reduced, indicating that EIPA aﬀects CME to a certain degree
(Fig. S4†). Notably, diﬀerences in the localisation of transferrin
loaded vesicles was apparent, agreeing with our previous
studies showing eﬀects on the subcellular localisation of early
and late endosomes/lysosomes in cells treated with this
drug.64 Previous studies in PC12 cells incubated with self-
Fig. 6 Internalisation of EVs in HeLa cells depleted of ﬂuid-phase/macropinocytosis related proteins. (a) Western blot analysis of Cdc42 and PAK-1
protein levels in cells 48 h following siRNA transfection in comparison with loading proteins Tubulin or GAPDH. (b) Cells were depleted of either
Cdc42 or PAK-1 via siRNA transfection for 48 h before 60 min incubation with either (b) Dx488 (100 µg ml−1) or (d) EV488 (50 µg ml−1). Cells were
incubated with Hoechst for 5 min before live cell imaging. Arrowheads in D represent peripheral EVs. Utx: untransfected. Scale bar: 20 µm. Images
representative of three separate experiments, respectively. (c), (e) MFI quantiﬁcation of the experiments presented in (b), (d), respectively. Error bars
represent standard error. n/s: no signiﬁcance. Representative of three separate experiments, respectively.
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derived exosomes have shown by flow cytometry that EIPA sig-
nificantly reduces uptake of DiD labelled PC12 exosomes.26 In
our study EIPA cells caused a small but insignificant decrease
in EV uptake (Fig. 7C and D). Rottlerin is an inhibitor primar-
ily utilised to target fluid-phase endocytosis rather than macro-
pinocytosis.61 Its eﬀects have previously been connected with
inhibition of PKCδ activity,65 though other Rottlerin targets
have been identified.66,67 Rottlerin did not aﬀect the uptake of
dextran but was a significant inhibitor of Tf and EV uptake in
these cells (44% and 51% respectively) (Fig. 7 and S4†). The
PAK-1 inhibitor IPA-3,68 has previously been used to propose
macropinocytosis as a mechanism for viral cell entry.69,70 This
drug induced a significant decrease in dextran uptake (60%)
and EVs (50%, Fig. 7) with Tf488 showing a slight, non-signifi-
cant decrease. However, Tf488 localisation was more scattered
in treated cells (Fig. S4†) with a concomitant loss of juxta-
Fig. 7 Internalisation of EVs in HeLa cells treated with ﬂuid-phase/macropinocytosis inhibitors. (a, c) Cells were pre-incubated with EIPA (25 µM),
Rottlerin (10 µM), IPA-3 (50 µM), or 0.05% DMSO as ‘Pos Ctrl’ for 30 min before 60 min incubation with either (a) Dx488 (100 µg ml−1) or (c) EV488
(50 µg ml−1). Cells were incubated with Hoechst for 5 min before live cell imaging. Scale bar: 20 µm. Images representative of three separate experi-
ments. (b), (d) MFI quantiﬁcation of the experiments presented in (a), (c), respectively. Error bars represent standard error. *p < 0.05. n/s: no signiﬁ-
cance. Representative of three separate experiments.
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nuclear polarisation that is indicative of the localisation of
Tf recycling compartments in this cell line. Collectively
observations with these inhibitors suggest that a major
fraction of EVs enter cells by fluid phase endocytosis rather
than macropinocytosis.
4 Conclusions
Here we describe an eﬃcient and novel method to fluores-
cently label EVs characterised as exosomes for subsequent
high content microscopy analysis of their interactions with
cells and endocytic traﬃc. Unlike other current labelling
methods, this technique provides flexibility with regards to
choice of fluorophore used and also provides the ability to
easily label EVs from diﬀerent cell types. In the case of prostate
cancer DU145 derived EVs the labelling procedure did not
aﬀect their capacity to induce complex cellular responses such
as fibroblast to myofibroblast diﬀerentiation and induction of
HGF secretion. It however remains to be determined whether
this labelling method influences the other numerous func-
tional eﬀects documented for EVs. It will also be interesting to
compare our data with exosomes labelled using the same pro-
cedure but with diﬀerent fluorophores, noting that they have
unique characteristics that could aﬀect cell uptake71 and
diﬀerentiation. Interference of endocytic pathways with inhibi-
tors and siRNA depletion of endocytosis mediators together
with endocytic traﬃcking studies strongly suggest our EVs
enter cells as components of the extracellular fluid and like
dextran are mostly traﬃcked to lysosomes. Approximately 40%
of endocytosed EVs however are not fated for lysosomes, at
least within the time-frame that we have explored. The impli-
cations of these endocytosis characteristics for the use of EVs
as drug delivery vectors remain to be determined but their
traﬃcking profiles may be beneficially exploited if they can be
packaged with small molecule drugs for lysosomal release into
the cytosol.
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Supplementary Materials 
 
Supplementary Materials and Methods 
 
1. Exosome isolation, purification and characterisation 
Exosomes were purified from 7-day cell conditioned media, pre-cleared of cell debris 
and microvesicles by differential centrifugation followed by filtration through a 0.22 
µm filter (Millipore).  Exosome vesicles were purified based on their density by 
ultracentrifugation at 100,000 x g on a 30% sucrose/D2O cushion as described 
1. 
Purified exosomes were resuspended in around 100 µl PBS, aliquoted, before 
storage at -80°C. Total protein was quantified by microBCA protein assay 
(ThermoFisher Scientific, Paisley, UK). The number, and size distribution of nano-
particles was assessed by nanoparticle tracking analysis (Nanosight; Malvern 
Instruments, Worcestershire, UK). As a measure of exosome purity, protein and 
nanoparticle concentrations were used to calculate a ratio of particle to protein. All 
preparations had a particle to protein ratio of >2x1010 particles per μg of protein, as 
described 2. The presence of tetraspanins at the outer exosome surface was 
determined using a plate-immobilisation of purified exosomes, and indirect staining 
with antibodies against CD9 (R&D Systems, Abingdon, UK), CD81 or CD63 (BioRad, 
Hertfordshire, UK), a secondary anti-Mouse IgG-biotin conjugate (PerkinElmer) and 
streptavidin-Europium detection. Primary antibodies against relevant isotypes, IgG1 
and IgG2b (eBioscience, ThermoFisher Scientific), were used as a control. Time 
resolved fluorometry was performed on a Pherastar FS instrument (BMGlabtech, 
Germany) as described 3. Whole cell lysates, prepared using RIPA-buffer (Santa Cruz 
Biotechnology) were compared to exosome lysates, prepared by boiling in SDS-
sample buffer containing 20 mM DTT, by western blotting running 10 µg protein per 
lane. After transfer to PVDF membranes (GE Healthcare), and blocking with 5% non-
fat powdered milk with 0.1% Tween-20 in PBS for 1 hr, primary monoclonal antibody 
at a concentration of 1-4 µg/ml was added at 4°C overnight. Antibodies for expected 
exosome proteins TSG101, Alix, LAMP1 (Santa Cruz Biotechnology), MHC Class I 
(eBioscience, ThermoFisher Scientific) were used, and to assess cellular 
contaminants, blots were also probed for calnexin expression (Santa Cruz). After 
washes in 0.1% Tween-20/PBS bands were detected using an anti-mouse IgG-
horseradish peroxidase conjugated antibody (Santa Cruz) and chemiluminescence 
substrate (PicoWest, ThermoFisher Scientific). Images of membranes were collected 
using the C-DiGit Chemiluminescence Blot Scanner (LI-COR Biotechnology, 
Cambridge, UK). 
 
2. Exosome analysis by Nano particle Tracking Analysis (NanoSight™) 
Freshly prepared exosomes, or those following fluorescent labelling were diluted in 
particle free water (Fresenius Kabi, Runcorn, UK) to concentrations up to 2x109 
particles/ml, which is within the linear range of the NanoSight instrument. Analysis 
was performed on a NanoSight™ NS300 system configured with a temperature 
controlled LM14 laser module with a 488 nm laser and a high sensitivity sCMOS 
camera system and a syringe-pump system (Malvern Instruments, Malvern, UK). 
Three videos of 30-60 s were taken under controlled fluid flow with a pump speed 
set to 80, and temperature set to 25°C. Videos were taken in light scatter mode. On 
some occasions, videos were also taken following application of a long-pass 
fluorescence filter, so that only particles emitting light at >500 nm were visible.  This 
required corrections for focusing, and an adjustment to the camera settings to 
maximise chances of visualising, and tracking fluorescent nano-particles. Videos 
were analysed using the batch analysis tool of NTA 2.3 software (version 2.3 build 
2.3.5.0033.7-Beta7), where minimum particle size, track length and blur were set at 
“automatic”. The area under the histogram for each triplicate measurement was 
averaged and used as a particle concentration measurement. 
 
3. Cryo-electron microscopy of purified exosomes 
Exosome preparations were adsorbed onto glow-discharging holey carbon 200-mesh 
copper grids (Quantifoil Micro Tools GmbH). Grids were vitrified with the aid of a 
Vitrobot (Maastricht Instruments BV). Vitrified samples were imaged at liquid 
nitrogen temperature using a JEM-2200FS/CR transmission cryo-electron microscope 
(JEOL) equipped with a field emission gun and operated at an acceleration voltage of 
200 kV. 
 
4. siRNA transfection 
In a 6 well plate (or 35 mm imaging dish) 100 pmols siRNA was diluted in 185 µl Opti-
MEM while in a separate container 2 µl Oligofectamine was diluted with 13 µl 
OptiMEM. The two solutions were gently mixed and incubated at room temperature 
for 30 min. The cells were washed with Opti-MEM and 800 µl of Opti-MEM was 
added before dropwise addition of the siRNA complex mixture. Cells were returned 
to the incubator for 4 h before addition of 500 µl Opti-MEM containing 30% FCS and 
incubated for 44 h. 
 
5. SDS PAGE and Western blotting 
5.1. Following siRNA depletion 
Following 48 h transfection, cells were washed with PBS followed by incubation on 
ice for 5 min in 100 µl ice-cold lysis buffer - 150 mM NaCl, 50 mM Tris-base pH 8.0, 
1% Triton X-100 containing protease inhibitor cocktail. Cells were scraped from the 
plastic surface, placed in eppendorf tubes and then centrifuged for 10 min (13000 x 
g) at 4°C. The protein concentration of each sample was calculated via BCA assay and 
18 µg protein per sample was mixed with 3x SDS PAGE sample buffer, heated to 95°C 
and loaded on to 8%, 10% or 12% SDS-PAGE gels. Following gel electrophoresis, 
proteins were transferred to PVDF membranes before blocking (5% w/v dried milk in 
PBS 0.0025% v/v Tween 20 (PBSTM)) and incubation with primary antibodies 
recognising AP2µ2, Caveolin-1 (Cav-1), Cdc42, Flotillin-1 (Flot-1), p21-activated 
kinase-1 (PAK-1), or GAPDH in 2% PBSTM. Secondary antibody incubation with goat 
anti-rabbit HRP conjugate, goat anti-mouse HRP conjugate or HRP conjugated anti-δ-
tubulin was then performed and chemiluminescence was detected on a ChemiDoc 
imager using ImageLab software (Bio-Rad).   
 
6. Optimisation and characterization of exosome labelling 
C5-maleimide-Alexa488 (5-200 μg/ml) was added to a 30 μl exosome aliquot 
containing 60 to 100 µg protein, and made up to a final volume of 50 μl with PBS.  
Incubations, with no agitation, for 60 min in the dark at room temperature (R/T), 
were followed by removal of unbound dye using exosome spin columns (Invitrogen) 
according to manufacturer’s instructions. Collected labelled exosomes were added 
to black-walled 96-well plates and the average fluorescence of triplicate wells 
measured on a PHERAstar FS plate reader (BMG Labtech, Ortenberg, Germany). 
Similarly, at a fixed dose of 200 µg dye, incubations for up to 3 h were performed 
before assessing intensity of labelling. In parallel, dye in the absence of exosomes 
were included in these experiments, to assess the efficacy of free-dye capture by the 
exosome spin columns. For some experiments, the free sulph-hydryl bonds at the 
exosome surface were capped by pre incubations with N-acytyl-L-cysteine (up to 1 
mM) for 30 min prior to dye labelling (200 µg/ml, 1 h) and fluorescence assessment; 
revealing approximately 80% inhibition of labelling at maximal N-acetyl-L-cysteine 
dose. 
 
 
 
 
 
 
 
Supplementary Figures 
 
Supplementary Figure. 1. PKH26 
dye was diluted 1 in 1000 in the 
provided dilution buffer, and 
analysed by NTA. The analysis was 
performed in light scatter mode 
(grey), and then following 
application of fluorescence filter 
where only fluorescing particles 
are visible (black, dashed line). We 
conclude that small particulate 
material spanning the size range 
of exosomes is present in the 
stock solution, and a proportion 
(52%) of these are fluorescent. 
  
Supplementary Figure. 2. Colocalisation of 488-labelled exosomes with dextran-loaded 
lysosomes in HeLa cells. Cells were incubated with Dx647 (100 µg/ml) for 2 h, washed with 
PBS and incubated for a further 18 h in culture media. Cells were then incubated with 
Exo488 (60 µg/ml) for 2h with no chase or for 2 h followed by washing and a 4 hr chase. 
Scale bars: 20 µm and 10 µm on zoomed images. Images representative of three separate 
experiments. 
 Supplementary Figure. 3. Additional fields of view showing internalisation of exosomes in 
HeLa cells depleted of fluid-phase/macropinocytosis related proteins. Cells were 
depleted of either Cdc42 or PAK-1 via siRNA transfection for 48 h before 60 min 
incubation with Exo488 (50 µg/ml). Cells were incubated with Hoechst for 5 min before 
live cell imaging. Utx: Untransfected. Scale bar: 20 µm. Images representative of three 
separate experiments. 
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Supplementary Figure. 4. Transferrin internalisation in HeLa cell models of fluid-
phase/macropinocytosis inhibition. (a) Cells were depleted of either Cdc42 or PAK1 via 
siRNA transfection for 48 h, or (c) pre-incubated with either EIPA (25 µM), Rottlerin (10 
µM), IPA-3 (50 µM), or 0.05% DMSO as ‘Pos Ctrl’ for 30 min before 15 min incubation 
with Tf488 (5 µg/ml). Cells were incubated with Hoechst for 5 min before live cell 
imaging. Scale bar: 20 µm. Images representative of three separate experiments. (b) and 
(d) MFI quantification of the experiments presented in (a) and (c), respectively. Error bars 
represent Standard error. *p<0.05, **p<0.01. Representative of three separate 
experiments. 
Supplementary Video.1. Time lapse images of Exo488 uptake in HeLa cells. Exo488 (60 
µg/ml) were added for a period of either 120 min before confocal time lapse imaging. 
Hoechst and cell mask deep red were added for the final 5 min before imaging. Imaging 
was continuously performed for a period of 2 min. 
